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Preface 
 
This dissertation is comprised of six chapters that describe my Ph.D. studies aimed at 
understanding and overcoming the antibiotic resistance conferred by acetyltransferases. 
Chapter one focuses on properties of aminoglycosides (AGs) as antibacterials, the 
challenges facing their use and development, as well as background on the other 
antibiotics discussed in this thesis; this chapter was adapted in-part from a review article 
(Houghton, J. L.; Green, K. D.; Chen, W.; Garneau-Tsodikova, S. ChemBioChem 2010, 
11, 880). Chapter two describes the characterization of Eis from Mycobacterium 
tuberculosis (Mtb) including NMR and TLC studies of the order and positions modified 
on various AGs (Houghton, J. L.; Chen, W.; Garneau-Tsodikova, S.). Chapter three 
reports the acetylation of capreomycin (CAP), a cyclic peptide antibiotic used as second-
line treatment for tuberculosis (TB), by Eis (Houghton, J. L.; Green, K. D.; Mayhoub, A. 
S.; Garneau-Tsodikova, S.). Chapter four focuses on the synthesis and testing of novel 
AGs aimed at overcoming antibacterial resistance (Houghton, J. L.; Green, K. D.; 
Garneau-Tsodikova, S.). In chapter five, crystal structures of chloramphenicol 
acetyltransferase I (CATI) in the unbound (apo) form and a chloramphenicol (CAM)-
bound complex are reported and compared to CATI-fusidic acid (FA) and CATIII-CAM 
structures to provide insight into the broader substrate preference of CATI  (Biswas, T.; 
Houghton, J. L.; Tsodikov, O. V.; Garneau-Tsodikova, S. Protein Science 2012, 4, 520.) 
Chapter six discusses future directions of the projects, with a focus on further synthesis of 
novel AGs to combat resistance and progression of methodology to study the kinetics of 
acetylation by Eis by NMR spectroscopy. 
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Aminoglycoside (AG) antibiotics have been widely applied to the treatment of bacterial 
infections since the discovery of streptomycin, the first drug successfully applied to 
treatment of tuberculosis (TB). The bactericidal properties of these carbohydrate natural 
products are attributed to their ability to bind to the prokaryotic ribosome at the decoding 
A-site of the 16S rRNA, in a fashion that disrupts the cells ability to properly produce 
proteins and eventually leads to the death of the affected cell. Having enjoyed over 60 
years of clinical success, AGs have encountered problems with bacterial resistance, as is 
eventually the case with all antibiotics. While there are several mechanisms by which 
bacteria may evade the activity of AGs, the covalent chemical modification of the AG 
structure by AG-modifying enzymes (AMEs) is the most common and poses the largest 
threat to the future use of AGs as antibacterial agents. Chloramphenicol (CAM), another 
natural product with excellent antibacterial properties, suffers from a similar resistance 
problem. The modification of CAM by CAM-modifying enzymes such as 
chloramphenicol acetyltransferase (CAT), reduces its affinity for the prokaryotic 50S 
ribosome, its cellular target, rendering it inactive. This dissertation focuses on the 
acetyltransferases that confer resistance to antibiotics, discussing progress towards 
understanding and overcoming a major hurdle in our ability to combat bacterial infections.  
 
Our laboratory recently reported the unusual regio-versatility of the AG N-
acetyltransferase (AAC), Eis, from Mycobacterium tuberculosis (Mtb). We used NMR 
spectroscopy to determine the order, number, and regio-specificity of the acetylations 
carried out by Eis. We found that Eis not only acetylates multiple positions, but that the 
order and positions of the acetyltations vary based on the particular AG scaffold studied. 
Furthermore, Eis is capable of acetylating amines that have never been reported with any 
other AAC. Those results caused us to investigate other anti-TB drugs in order to 
determine if it was possible that Eis could cause resistance across drug classes. We found 
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that capreomycin (CAP), a cyclic peptide antibacterial agent used as a second-line 
treatment for TB infections, could also be acetylated by Eis. 
 
Using our knowledge of AMEs, we sought to develop novel AGs with 
improved/maintained activity and the ability to avoid modification by AMEs. A series of 
molecules that incorporated 6'-N- and 1-N-glycinyl/AHB groups was synthesized and 
tested against a number of bacterial strains. These synthetic studies and the knowledge 
gained regarding Eis will serve as a guide to the development of novel AGs targeting Mtb 
and other pathogens, which are difficult to treat with known antibiotics. 
 
Additionally, we determined the first X-ray crystal structure of CATI with its natural 
substrate, CAM, bound in the active site, along with a structure of the unbound form of 
CATI. Comparison to a structure with fusidic acid (FA) bound in the active site and the 
previously well-characterized CATIII with CAM bound allowed for a deeper 
understanding of the broader substrate preference of CATI. Though CAM is seldom used 
in many developed countries due to problems with toxicity, the need for effective 
antibiotics may soon outweigh the risks, and we hope that the insights provided in our 
studies may one day aid in the development of novel CAM analogs that overcome the 







Introduction: aminoglycosides (AGs), chloramphenicol (CAM), tuberculosis (TB), 
and bacterial resistance 
  
1.1. Introduction to AGs 
1.1.1. AGs 
Since the discovery of penicillin in 1928, a variety of antibiotics including 
aminoglycosides (AGs), chloramphenicol (CAM), β-lactams, fluoroquinolones, among 
many others, have been discovered and applied clinically towards the treatment of one of 
the many growing number of bacterial infections. AGs (Fig. 1.1) in particular are being 
extensively studied in order to find new molecules or derivatives of existing scaffolds 
that may overcome the current resistant pathogens as well as prevent or slow the 
development of novel resistant pathogens. 
 
AGs were first established as antibiotics in the 1940s with the discovery of streptomycin 
(STR), the first drug successfully applied to the treatment of tuberculosis (TB). Since 
then, AGs have enjoyed widespread application as chemotherapeutic agents in the 
treatments of many types of bacterial infections, including those associated with both 
Gram-positive and Gram-negative pathogens.1 Additionally, kanamycin A (KAN) and 
amikacin (AMK) are both second-line drugs currently used to treat TB and multidrug-
resistant TB (MRD-TB), although STR, the first therapy used against TB infections, is no 
longer used. In addition to being used for antibacterial purposes, the application of AG-
based compounds in the treatment of HIV has been the focus of many research efforts in 
recent years due to their affinity for RNA.2-10 Yet another potential use for AGs is in the 
treatment of genetic diseases caused by premature termination codons (PTCs), which 
have been linked to over 1800 genetic disorders.11-18 However, no AGs are currently 




Fig. 1.1. The chemical structures of common AGs. 
 
AGs, and most other antibiotics isolated from bacterial species, arose in response to 
selective pressure from, presumably, another bacterial species. As such, the antibacterial 
agents of this class were designed by Nature as very potent RNA binding agents, which 
leads to some toxicity in mammals, and, consequently, apprehensive use in many places 
around the world. In addition, as with many other classes of antibiotics, heavy use in the 
treatment of bacterial infections has caused many strains of bacteria to become resistant 
to normal doses of AGs. This resistance often occurs via the production of AG-modifying 
enzymes (AMEs), though other mechanisms exist. In order to circumvent the issue of 
antibiotic resistance as it applies to AGs, many scientists have taken on the intricate task 
of synthesizing AG derivatives, including synthetically modified AGs, AG dimers, and 
AG-biomolecule conjugates. Efforts aiming to create better AGs have utilized several 
new strategies including chemoenzymatic modification, selective modification of amine 
or hydroxyl groups, as well as the coupling of antibiotics, both AGs as well as other 
classes of drugs, by synthetic or semi-synthetic methods. The scientific community’s 
understanding of these compounds and their effect on biological systems is increasing 
























































































































































































































































1.1.2. AGs’ antibacterial modes of action 
After decades of study, the modes of action 
of AGs have been well characterized. It 
was discovered in the late 1980s that their 
molecular target is the 16S rRNA subunit 
of the 30S bacterial ribosome.19 While 
alternative modes of binding have been 
seen with various AG derivatives,20 as 
determined by biochemical21-24 and 
structural25-28 (X-ray and modelling) 
studies, in general, the interactions of AGs 
with three unpaired adenine residues in the 
decoding loop displace non-complementary 
adenines and lock them into a so-called 
‘flipped-out’ orientation similar to that 
observed during mRNA decoding. 
Additionally, some AGs interfere with 
translocation via stabilization of the 70S 
subunit, by strengthening the interactions 
between the 50S and 30S subunits. These 
interactions stabilize the 70S complex, 
leading to faulty translocation of tRNAs, which may arise from the AGs’ ability to 
interact with specific sites of the 16S rRNA.29 The interactions of AGs with the 
eukaryotic ribosome serve to reduce the fidelity of translational processes by reducing the 
ability of the ribosome to discriminate between the proper mRNA•tRNA complexes, 
leading to the accumulation of truncated or non-functional proteins in the bacterial cells 
and eventually cell death. 
 
Two types of interactions have been shown to facilitate binding of AGs to their targets: 
(1) the electrostatic interactions that occur between the positively-charged amino groups 
of the AG and the negatively-charged phosphate backbones of the RNA target, which are 
 
Fig. 1.2. The structures of A. TOB, B. GTC, and 
C. AMK bound to 16S oligonucleotides 
mimicking the bacterial decoding A-site. Also 
shown is D. the crystal structure of PAR docked 
into a bacterial A-site oligonucleotide. These 
images illustrate the ‘flipped-out’ conformation of 




the most important,30 and (2) the hydrogen bonds that are formed between the amino and 
hydroxyl groups of both the RNA bases and AGs. Both types of interactions combine to 
form an intricate network of contacts between the RNA and AGs that results in very 
tightly bound complexes that are prone to decreased translational fidelity.31-34  
 
1.1.3. Problems associated with AGs 
1.1.3.1. Toxicity 
One of the primary obstacles preventing more widespread use of AGs as long-term 
treatment for genetic, viral, or microbial issues is the inherent toxicity associated with 
non-specific binding to RNA. The primary risk factors for AG-induced toxicity include 
the duration, dosage, and frequency of therapy, the patient’s age, the patient’s liver and 
kidney health, and drug-drug interactions with other potential nephrotoxic agents.35,36 
Toxicity and selectivity are two intertwining issues associated with targeting RNA, due to 
the fact that RNA is important in all forms of life.24,33,37-41 In general, AGs with fewer 
amino groups on the scaffold will show less toxicity, and the same is true of AGs with 
lower relative basicity of their existing amino groups, notably the 2'-amine.42,43 
 
Nephrotoxicity, from drug compounds damaging the kidneys is generally reversible upon 
halting therapy in the case of AGs. Ototoxicity, in contrast to nephrotoxicity, is mostly 
irreversible. There are two types of ototoxicity: vestibular toxicity and cochlear toxicity. 
AGs toxicity may lead to a temporary vestibular hypofunction or permanent high-
frequency hearing loss.44 The permanence of AGs ototoxicity, which is the result of 
degeneration of hair cells and neurons in the cochlea, remains one of the primary 
obstacles in AG based therapies.44-54 Very recently, Böttger and co-workers discovered 
that the AG apramycin (APR) is not ototoxic.55 
 
1.1.3.2. Resistance 
There are three mechanisms of bacterial resistance to AGs and more than one of the 
above mechanisms may be simultaneously active, leading to complex resistance 
problems. One mechanism of bacterial resistance to AGs is the reduction of the 
intracellular concentration of AGs due to alteration of the bacterial outer membrane (Fig. 
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1.3), decreasing drug transport into the cell and/or increasing the activity of active efflux 
systems. It is thought that three steps are involved in the uptake of AGs into bacterial 
cells. The first step is the adsorption of the poly-cationic AG to the surface of bacteria by 
electrostatic interactions with the negatively charged portions of biomolecules found on 
the outer cell membranes of bacteria.56-59 In numerous cases, changes in membrane 
components involved in interactions with AGs are associated with increased levels of 
resistance.57-66 The two subsequent absorption steps are oxygen dependent. For this 
reason anaerobic bacteria are intrinsically resistant to AGs,67 and mutations in ATP 
synthases involved in these processes can cause decreased susceptibility to AGs.68 
 
 
Fig. 1.3. Illustration of the various mechanisms of AG resistance. 
 
Another resistance mechanism involves the alteration of the 16S RNA of bacterial 30S 
ribosomal subunit by mutation or methylation of the AG binding site (Fig. 1.3). Many 
AG-producing organisms are capable of expressing rRNA methylases, which are able to 
methylate the 16S rRNA.69,70,71,72 Resistance to AGs resulting from a mutation of the 
ribosomal target has also been found in clinical isolates of Mycobacterium tuberculosis 











conserved regions, resulting in decreased affinity of the AG for its oligonucleotide 
partner such that the compounds are no longer effective.24 
 
1.1.3.2.1. Covalent modification of AGs 
Although AGs often target the 16S rRNA, the most common cause of AG resistance is 
not conferred by alteration of this target, owing to the highly preserved function of the 
rRNA across genera. Rather, the most common mechanism for bacterial resistance arises 
from the covalent modification of AGs by AMEs expressed by resistant strains (Fig. 1.3), 
which evolved from enzymes involved in normal cellular metabolism. Most 
modifications take place at the 1-, 3-, 2'-, and 6'-amino groups and the 3'-, 4'-, and 2"-
hydroxyl groups.74 There are three classes of AMEs: ATP-dependent AG 
nucleotidyltransferases (ANTs), ATP (and/or GTP)-dependent AG phosphotransferases 
(APHs), and AcCoA-dependent AG acetyltransferases (AACs) (Fig. 1.4), which are 
grouped according to the positions of the AG they modify. There are four ANTs, seven 
APHs, and four AACs (AAC(1), AAC(3), AAC(2'), and AAC(6')). An additional AAC, 
the enhanced intracellular survival (Eis) protein, has been shown to confer AG resistance 
in Mtb.75  
 
 






















































































There are also many bi-functional enzymes including AAC(6')/APH(2"),74,76,77 ANT(3")-
Ii/AAC(6')-IId,78 AAC(3)-Ib/AAC(6')-Ib',79 and AAC(6')-30/AAC(6')-Ib'80 that are 
capable of modifying numerous positions, and in some cases are capable of two types of 
modification. The various sites of modification demonstrated with kanamycin B are 
shown in Fig. 1.5. 
 
1.1.3.2.2. AG acetyltransferases (AACs) 
Over 50 members of the AAC family have been 
identified. These enzymes catalyze the AcCoA-
dependent N-acetylation of AGs. They modify the 1- 
and 3-amino groups of the central 2-deoxystreptamine 
(2-DOS) ring (Fig. 1.5) and the 2'- and 6'-amino groups 
of the 6-deoxy-6-aminoglucose ring (Fig. 1.5). Two 
AAC(1) enzymes have been found in E. coli and 
actinomycetes strains, but their clinical importance is 
minor due to the fact that their occurrence is extremely 
rare and neither has been reported in dangerous 
pathogenic bacterial strains.81,82 
 
The AACs that acetylate at the 2'-amino group are all 
chromosomally encoded and, interestingly, mutations in 
the aac(2')-Ia gene may cause increased levels of 
peptidoglycan O-acetylation, suggesting that peptidoglycan acetylation may be the 
original physiological function of the enzyme. The chromosomally encoded Mtb 
AAC(2')-Ic was shown, in contrast to some other AACs, to be active against AMK and 
KAN, both of which contain a 2'-hydroxyl group, suggesting that this enzyme may also 
catalyze O-acetylation.83  
 
The 6'-amino group plays an important role in rRNA binding as probed by the structural 
analysis of bound AGs to the 30S ribosomal subunit84,85 and, unsurprisingly, is the target 
of one of the major classes of AMEs, the AAC(6') sub-family, which consists of more 
 
Fig. 1.5. The positions of 
kanamycin B that are acetylated by 







































than 25 members. Interestingly, a recently discovered variant of AAC(6'), the AAC(6')-
Ib-cr, has been shown to be able to modify AGs as well as fluoroquinolones.86 It seems 
likely that the steady increase in the clinical use of ciprofloxacin (CIP) during the 1990s 
has generated selective pressure for this variant.87 
 
The AAC(3) sub-family is one of the largest AME families of enzymes and includes four 
major types, I-IV, based on the AG resistance profile. The AAC(3)-I from Serratia 
marcescens was the first AAC whose 3D structure was determined.88,89 The enzyme-CoA 
complex determined at 2.3 Å allowed for identification of the interactions between the 
enzyme and the product. Unfortunately, there is no structure of AAC(3) with bound AG 
substrate available at this time. 
 
1.1.4. Strategies for developing novel AGs 
1.1.4.1. Development of novel AGs via chemical synthesis 
Nature has evolved a number of very potent classes of antibacterials that effectively kill 
bacteria, and AGs are no exception. Owing to the difficulties associated with the 
synthesis of complex carbohydrates such as AGs, chemical synthesis remains a relatively 
ineffective tool in the total synthesis of large quantities of AG from basic chemical 
building blocks. This fact was evidenced in the early work on AGs reported by 
Hannesian and co-workers on a number of modified AGs, and it is still evident today.90-93 
The steps required to manipulate saccharide rings into the correct protection states is 
often staggering. Their synthesis, starting from grams or kilograms of starting materials, 
often provide only enough of the final product to test for minimum inhibitory 
concentration (MIC) and toxicity. In fact, the overall yields of syntheses of many types of 
complex molecules are often very low, and AGs are no exception.  
 
Many reported syntheses of AG derivatives begin with the protection and hydrolysis of 
neomycin B (NEO) to generate the neamine (NEA) core common to many many AGs, 
leaving the 5-hydroxyl group of the 2-DOS ring open for derivatization.94-96 This type of 
strategy often requires more than 20 steps,97 so, even when starting with a known AG 
scaffold, the chemical modification can be quite tedious. An example in which APR was 
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synthesized from NEA is illustrated, highlighting key steps, in Fig. 1.6.98 Some solutions 
to these problems have been found, such as syntheses that start from a known AG to 
produce novel compounds in few steps. Even though solutions like this are often specific 
to a particular problem or only lead to a small number of novel compounds, the progress 
made has been substantial.  
 
 
Fig. 1.6. Synthesis of APR starting from NEA. 
 
One alternative to multi-step protections and deprotections involves metal chelation 
directed reactions as used by Nudelman et al.17 In this example, zinc was used to 
preferentially protect the amino group at the 1-position. Afterwards they were able to 
preferentially react the N-1-position with γ-aminohydroxybutyric acid (AHB). After 
several more steps the novel PAR derivative, NB54, was generated. NB54 was found to 
suppress PTCs better than GEN, PAR, and its non-AHB containing counterpart NB30, 
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The appending of various chemical functionalities to known AGs is another popular 
strategy aimed at developing improved AG-based drugs. An increasing number of 
biochemical and structural studies have correlated the incorporation of the AHB at the N-
1-position of the 2-DOS ring, common in many AGs, with an improved antibacterial 
profile.27,99 Interestingly, the acyl moiety lowers the pKa of the N-1 nitrogen atom, and 
this alteration of the N-1 nitrogen of compounds such as AMK, butirosin B, and others, 
significantly enhances the binding of ring II to RNA. Additionally, the ammonium on the 
terminus of the AHB group provides another favorable interaction with a backbone 
phosphate.100 As a result of these observations, current strategies for increasing the 
antibacterial activity of AGs involve the incorporation of AHB or functionalized acyl 
groups to the scaffold of known AGs, a strategy that has produced results and shown 
enormous promise. A good example is the next-generation AG derived from sisomicin 
(SIS), ACHN-490 (Plazomicin, (PLZ)), which has shown very promising results against a 
number of bacterial strains that pose public health threats. PLZ incorporates an AHB at 
the N-1-position of SIS.101-103 
 
The incorporation of a number of other functionalized acyl groups to the amines of 
known AGs has proven a successful strategy for overcoming bacterial resistance and 
maintaining/or improving antibacterial activity. In contrast to other syntheses of AG 
derivatives, the incorporation of a 6'-N-glycinyl group to AGs has showed promise, and 
may be accomplished in only two steps (Fig. 1.7).104 MIC studies of 6'-N-glycinyl-TOB 
with bacterial strains harbouring AMEs showed that the compound could avoid the 
activity of AMEs while maintaining similar activity to the parent compound against the 
same strains that did not have the AMEs. 
 
 

























































The sensitivity to modification of natural AGs and the difficulty of enhancing compounds 
that Nature has spent thousands of generations optimizing has been well established. 
There is precedence in the literature that suggests potency, selectivity, and the ability to 
overcome resistance may be achieved by synthetically modifying known AGs, though it 
is rarely easy to control or predict. Nonetheless, many efforts have quite successfully 
yielded active compounds, and knowledge in the field continues to grow. 
 
1.1.4.2. Development of novel AGs via chemoenzymatic methods 
Recently it has been shown that chemoenzymatic methods hold great promise in 
generating large libraries of compounds. Generating large amounts of compound 
chemoenzymatically can be challenging. However, using these methods, enough 
compound can be produced for initial testing to help decide which compounds are worth 
pursuing synthetically, expediting the process of novel AG development significantly. 
There are also many other techniques currently being developed or already in practice 
that will allow for a simplified approach which is less time consuming and more efficient 
than the classical synthetic methods for developing novel AGs. 
 
 
Fig. 1.8. A chemoenzymatic approach to the generation of mono-N-acylated AGs as well 
as homo- and hetero-di-N-acylated AGs via two sequential acylations by AACs utilizing 
acyl-CoA as cosubstrates. R groups accepted include, but are not necessarily limited to 
acetyl-, n-propionyl-, 4-bromo-thiophene-2-carbonyl-, 6-fluoro-picolinyl-, glycinyl-, and 
malonyl-CoA. 
 












































































While it is clear that N-acetylation of AGs by AACs evolved as a mechanism of 
resistance in bacteria, there have been many reports of N-acylated AGs, both natural and 
semi-synthetic, that show a retention or even improvement in activity.105-107 N-acetylation 
by AACs is a common means of deactivation in bacteria that results in decreased efficacy 
of the AG. However, the semi-synthetic N-acylation with groups other than the normal 
acetyl has resulted in highly potent AGs, as mentioned in the preceding sub-section. 
Adopting this approach led to the development of AMK by N-1-acylation of KAN with 
AHB,105 and arbekacin, which was produced by a combination of 3',4'-dideoxygenation 
and N-1-acylation.106 While these advancements in AGs are exciting, the synthesis of the 
compounds is subject to the previously discussed pitfalls, making it difficult to generate a 
large number of novel compounds quickly and efficiently. Current strategies aimed at 
circumventing this particular problem include the application of enzymes to regio-
specifically acylate an amine on the AG scaffold. 
 
Our laboratory recently reported a methodology which utilizes AACs and unnatural acyl-
CoA analogs to chemoenzymatically generate N-acylated AGs (Fig. 1.8).107 Two AACs, 
(AAC(6')/APH(2'') and AAC(3)-IV) were utilized, and both enzymes showed diverse 
substrate promiscuity towards a number of AGs as well as acyl-CoA derivatives. The 
method allows for the generation of mono-N-acylated AGs as well as homo- and hetero-
di-N-acylated AGs in quantities sufficient to screen each analog’s antibacterial potential. 
Thus, it is possible to decide which of the novel compounds show promising activity that 
is worth investigating on a larger scale all the while avoiding an arduous chemical 
synthesis that leads to a dead end. 
 
Baasov and co-workers reported a similar, yet distinct chemoenzymatic approach to the 
development of novel acylated AG derivatives in 2008. They applied recombinant 
enzymes involved in butirosin biosynthesis to selectively acylate the N-1-position of a 
series of 2-DOS containing pseudo-di and trisaccharide AGs using a synthetic acyl 
donor.108 Similarly, Llewellyn and Spencer recently used the enzymes responsible for 
synthesizing butirosin B in Staphylococcus aureus to generate AMK and neokacin from 
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NEO.109 As is the case when applying AACs to chemoenzymatically alter AGs, this 
method greatly reduces the synthetic workload required to make such compounds via 
purely synthetic methods.  
 
1.2. Tuberculosis (TB) 
Causing 1.4 million deaths globally in 2010, TB is the second leading pathogen-related 
cause of death,110 and the most common cause of death among immuno-compromised 
people living with HIV/AIDS.111-115 Although as much as a third of the global population 
may be infected with TB,110 in most cases (~90%), the infection remains dormant and 
may never lead to a life-threatening infection.116 The global distribution of Mtb infection, 
latent or otherwise, is very skewed towards developing countries, especially those in 
which relatively large portions of the populations are immuno-compromised.117 TB 
primarily affects the lungs and pulmonary function, although it may spread to other 
organs- pulmonary TB is the infectious, lethal form of the disease. Massive efforts to 
combat this global pandemic have seen some success,110,118 though they have failed to 
bring the spread of the disease under full control. 
 
1.2.1. Anti-TB drugs 
A large number of anti-TB drugs, with varying mechanisms of action, have been 
discovered, and many are effective in curing infections caused by Mtb. The first drug that 
was successfully used to treat TB was a natural product from Streptomyces griseus, the 
AG antibiotic STR.119-121 While STR is still currently used in special cases, it is generally 
no longer used in the treatment of TB due to extremely high rates of resistance, likely the 
result of its long-term use as a mono-therapy.122,123 Currently, the use of mono-therapies 
has been abandoned because Mtb rapidly develops resistance when treated with only a 
single drug. Instead, current therapeutic strategies incorporate several drugs into a single 
regimen that generally lasts up to or in excess of 6 months.124,125 There are four first-line 
drugs for the treatment of TB, including isoniazid (INH), rifampicin (RMP), 
pyrazinamide (PZA), and ethambutol (EMB), all of which are applied in a typical anti-
TB regimen (Fig. 1.9). There are also a number of second-line therapies including the 
AGs KAN and AMK, the polypeptides capreomycin (CAP) and viomycin (VIO), the 
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fluoroquinolones such as CIP and moxifloxacin (MXF), as well as ethionimide. The 
second-line therapeutics are generally used against Mtb that is resistant to the first-line 
therapies. While these two lines of anti-TB drugs generally show efficacy against TB, 
there are many problems- cost, patient compliance, toxicity and the development of 




Fig. 1.9. Commonly used first-line (red) and second-line (blue) anti-TB drugs. 
 
1.2.2. TB resistance and enhanced intracellular survival (Eis) protein 
1.2.2.1. Resistance to anti-TB drugs 
Bacterial communities naturally evolve resistance to the drugs commonly used against 
them through natural selection. The development of resistance to first- and second-line 
drugs is outpacing the discovery and development of novel, effective treatments against 
resistant strains of many bacteria, a process that may be accelerated when patients fail to 
complete the full course of treatment. This occurs most frequently in areas with sub-
standard TB control programs, which often are also the places greatly affected by HIV, 
greatly complicating the issue. The development of resistance to anti-TB drugs by Mtb is 
especially problematic, considering that Mtb is naturally resistant to many common 
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Bacteria that display resistance to INH and RMP, the two most powerful first-line 
treatments for TB, are designated as multidrug-resistant (MDR). MDR-TB is fatal in 
more than one-third of the cases. It is likely that this type of resistance emerged due to 
therapy employing a single drug, allowing selective pressure to more rapidly cause the 
evolution of resistance.128,129 Although multiple drug therapy is now used more 
commonly, the development of resistance is still rapidly progressing, and has led to 
extensively drug-resistant TB (XDR-TB). XDR-TB, a more severe form of MDR-TB 
identified in 2006, is characterized by resistance to RMP and INH, in addition to a 
fluoroquinolone, such as CIP, and at least one of the second-line anti-TB drugs including 
KAN, AMK, or CAP.130-132 Recently, some of the most drug-resistant forms of TB ever 
encountered have been reported in India- extremely drug-resistant (XXDR-TB) and 
totally drug-resistant TB (TDR-TB)- though there is some controversy over the 
nomenclature, which has not yet been accepted by the World Health Organization 
(WHO).133,134,135 The difficulty in treating drug-resistant strains of Mtb is a limiting factor 
in our ability to maintain effective treatments for TB infections. Thus, there is a great 
demand for anti-TB drugs with efficacy against MDR- and XDR-TB.136-139 
 
1.2.2.2. Eis 
The structural and functional characterization of the enhanced intracellular survival (Eis) 
protein from Mtb has been the goal of many research efforts recently.75,140-148 The eis 
gene and its protein product, Eis, were discovered in Mtb H37Rv during an effort to 
identify Mtb genes necessary for survival within macrophages, leading it to be named as 
such.147 Bioinformatic analysis predicted that Eis belonged to the GCN5-related N-
acetyltransferase (GNAT) family of proteins,145 and that it is capable of conferring 
resistance to KAN in the AG-susceptible Mtb strain H37Rv.75 In one-third of cases, 
covering a large, diverse set of strains, clinical resistance of Mtb to KAN was shown to 
be the result of mutations in the promoter of the eis gene.147,149 These studies led to the 
idea that Eis may confer resistance by acting as an AAC. Subsequently, through 
biochemical and structural studies (Fig. 1.10), our laboratory demonstrated that Eis acts 




Fig. 1.10. Illustrations of the X-ray crystal structure of Eis from Mtb depicted in A. hexameric form and B. 
monomeric form with CoA bound in one monomer (PDB: 3R1K).140 
 
It was recently reported that Eis from Msm (Eis_Msm) and Eis from Mtb (Eis_Mtb) are 
also capable of acetylating dual-protein phosphatase 16 (DUSP16)/mitogen-activated 
protein kinase phosphatase-7 (MKP-7) (DUSP16/MPK-7).148 These modifications occur 
at Lys55, and this ability to modify primary amines on the amino acid residues of 
proteins suggests that Eis may have a much broader substrate profile than might be 
expected. Additionally, AACs are capable of acetylating classes of drugs other than AGs, 
including the second-line anti-TB drug CIP.151 The identification of novel substrates of 
Eis, including both protein and small molecules, as well as the development of 
inhibitors141,150 will likely continue to be the focus of many research efforts in the near 
future. 
 
1.3. Chloramphenicol (CAM) and CAM acetyltransferase (CAT) 
1.3.1. CAM as an antibacterial agent 
Chloramphenicol (CAM) (Fig. 1.11) is a potent broad-
spectrum antibacterial agent that was isolated from 
Streptomyces venezuelae in 1948.152 CAM was one of the 
most effective antibiotics in use for decades and was used to 
treat many different varieties of bacterial infections. 
Although toxicity issues are relatively rare, bone marrow toxicity may be a very serious 
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issue.153-156 Despite the toxicity issues, CAM was often applied to the treatment of brain 
infections, such as those caused by Neisseria meningitides, due to its ability to cross the 
blood-brain barrier. CAM use has been almost completely halted in the United States and 
Europe due to the aforementioned bone marrow toxicity. However, owing to the rapid 
emergence of resistance to many common antibiotics, many believe that CAM should be 
seriously reconsidered as a wider-spectrum therapeutic.157 
 
CAM antibacterial activity is achieved via inhibition of bacterial protein biosynthesis by 
binding to the 50S subunit of the bacterial ribosome. Crystal structures of the 50S subunit 
of the Escherichia coli and Thermus thermophilus ribosome in complex with CAM 
confirmed binding to A-site of the 50S subunit and showed that CAM occupies the 
binding site for the amino-acyl moiety of the A-site tRNA.158,159 The 3-hydroxyl of CAM 
(Fig. 1.11), which interacts with the ribosome through direct hydrogen bonding, 
potassium ion-mediated electrostatic interactions, and van der Waals interactions with the 
RNA phosphosugar backbone, is critical for antibacterial activity.158,159 Additionally, the  
1-hydroxyl of CAM forms hydrogen bonds with RNA bases. Thus, any modification of 
the 1-hydroxyl or the 3-hydroxyl of CAM is likely to disrupt CAM-ribosome binding.159 
  
1.3.2. Resistance to CAM 
Similarly to AGs, there are multiple mechanisms of resistance to CAM. The least 
common mechanism of resistance to CAM is mutation of the 50S ribosomal target, 
specifically at the 23S rRNA, which decreases the affinity of CAM for its target.160-162 A 
more common mechanism of resistance to CAM is the decreased permeability of the 
outer membrane of the bacteria.163-165 This type of resistance manifests in lower 
concentrations of CAM reaching the interior of the cell. Because CAM is not transported 
into the cell in an energy-dependent manner, in contrast to AGs, the decrease in 
permeability generally only leads to low levels of resistance.  
 
The covalent modification of CAM is catalyzed by a number of bacterial resistance 
enzymes, similar to the manner in which AGs are modified by AMEs (Fig. 1.12). In 
addition to the CAM acetyltransferases (CATs) discussed at length in the following 
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subsection, CAM O-phosphotransferases (CPTs) have been reported.166-168 CAM 
nitroreductases have also been confirmed to confer resistance to CAM.169 Additionally, in 
mammals, a number of modifications may take place that deactivate CAM, including 
dehalogenation, and glucuronidation, as well as reduction of the nitro group.170  
 
 
Fig. 1.12. Modifications causing resistance to CAM by A. CAT, B. a nitroreductase, and C. CPT. 
 
1.3.2.1. Resistance conferred by CATs 
The most common and most clinically relevant bacterial resistance to CAM is conferred 
by CAT enzymes, which catalyzes the transfer of an acetyl group from acetyl-coenzyme 
A (AcCoA) to the 3-hydroxyl group of CAM (Fig. 1.12).171 Although two acetylations 
may be catalyzed by CAT, the second occurring after a intramolecular transfer of the first 
acetyl group, a single acetylation of CAM is sufficient to abolish its affinity for the 
ribosome172 which is rationalized in the previously discussed structural 
observations.158,159 CAT proteins are divided into three types- CATI, CATII, and CATIII- 
but the differences between the three types are not particularly well-defined in terms of 
their amino acid sequences. Rather, certain functional properties of the proteins have 
been used to delineate the boundaries. For example, in addition to binding and acetylating 
CAM,171 CATI, unlike CATIII, binds a much bulkier antibiotic, fusidic acid (FA).173 FA is 
a steroidal antibacterial agent that is generally applied against infections caused by Gram-
positive pathogens. CATI does not covalently modify FA as with CAM, but instead it 








































































































recently, the physical properties of CATI that confer this ability have not been well 
characterized. 
 
This dissertation summarizes a significant amount of the research I performed under the 
supervision Professor Sylvie Garneau-Tsodikova. It is comprised of six chapters. Chapter 
one is the introduction providing relevant background on AG antibiotics, CAM, and 
acetyltransferases that confer resistance to antibiotics, as well as strategies used to 
overcome resistance. Chapter six suggests a number of future directions for these projects. 
Chapter two discusses the characterization of Eis from Mtb focusing on the development 
of NMR methodology to efficiently determine of the order and positions modified on 
various AGs. Chapter three reports the acetylation of CAP, a second-line drug for TB, by 
Eis and the activity of CAP against various mycobacteria. Chapter four focuses on the 
chemical synthesis of novel AGs aimed at overcoming antibacterial resistance. Chapter 
five describes the first crystal structure of CATI bound to CAM, focusing on the 
structural differences between CATI and CATIII that lead to the increased substrate 
binding profile of CATI. 
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The escalation of drug resistance, in many species of virulent bacteria, is a serious public 
health concern worldwide, and the emergence of drug-resistant tuberculosis (TB) is 
particularly troubling given the prevalence of the disease. One of the most recently 
characterized resistance mechanisms of TB is initiated by the expression of enhanced 
intracellular survival (Eis) protein. Eis has recently been shown to act as an unusually 
regio-versatile AAC, capable of multiply acetylating AGs, a characteristic unique among 
known AACs. It is known that Eis can sequentially modify the AG neamine (NEA) at 3 
positions, but the reaction of additional AGs with Eis has not been characterized to date. 
Herein, we determined the number, position, and order of the acetylation of five 
additional AGs using NMR spectroscopy. These studies further our understanding of the 
capabilities of Eis as an AAC, and will guide future studies aimed at overcoming the 
resistance conferred by Eis. 
 
2.2. Introduction 
Antibacterial resistance is a growing health concern worldwide, and the emergence of 
resistance to many frontline and even second-line drugs is outpacing the discovery and 
development of novel, effective treatments against resistant infections. Bacterial 
communities naturally evolve such that resistance to the drugs employed against them 
arises through natural selection, and this process is often accelerated by improper 
treatment or poor patient compliance. Multidrug-resistant (MDR) and extensively drug-
resistant (XDR) strains of the intracellular pathogen Mycobacterium tuberculosis (Mtb) 
are two prime examples of this paradigm that currently pose a serious, worldwide health 
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threat. It is estimated that there were 440,000 cases of MDR-TB that emerged in 2008 
and over 1.6 million deaths related to Mtb infections in 2009. Our understanding of the 
resistance mechanisms adopted by MDR- and XDR-Mtb against second-line antibacterial 
therapies, such as the (AG) kanamycin A (KAN) and amikacin (AMK), is limited. Up-
regulation of the enhanced intracellular survival (eis) gene bearing mutations in its 
promoter was the lone cause of KAN resistance in one-third of a large, diverse set Mtb 
clinical isolates,1,2 and efforts to characterize the Eis protein are progressing rapidly.1-11 
The menace presented by drug-resistant strains of Mtb combined with our limited 
knowledge regarding the resistance mechanisms involved highlights a glaring gap in 
knowledge and serves as a limiting factor in our ability to keep pace with an aggressively 
evolving adversary. 
 
The eis gene and its protein product, Eis, were discovered in Mtb H37Rv during an effort 
to identify Mtb genes necessary for survival within macrophages.1 Bioinformatic analysis 
predicted that Eis belongs to the GCN5-related N-acetyltransferase (GNAT) family of 
proteins,8 which was later supported by studies showing that overexpression of Eis leads 
to KAN resistance in Mtb.10 GNAT proteins generally catalyze the transfer of an acetyl 
group from acetyl coenzyme A (AcCoA) to the primary amine of a substrate, liberating 
free coenzyme A (CoA) in the process. We have recently reported biochemical, 
spectroscopic, and crystallographic data confirming that Eis is an AAC that displays 
unusual regio-versatility against NEA and is capable of acetylating many other AGs, 
including those used as second-line MDR- and XDR-TB treatments such as KAN and 
AMK.3  
 
To further understand the nature of Eis as an AAC, we characterized the reactions 
catalyzed by Eis with two sets of similar AG substrates. Tobramycin (TOB) (Fig. 2.5), 
KAN (Fig. 2.1), and AMK (Fig. 2.3) were chosen for their structural similarities, and the 
latter two compounds’ relevance in the treatment of MDR- and XDR-TB. We also chose 
to investigate netilmicin (NET) and sisomicin (SIS) because they are both structurally 
distinct from TOB, KAN, and AMK, but nearly identical to one another, the N-1-ethyl 
group of NET being the only difference between the two structures. Using thin layer 
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chromatography (TLC) and nuclear magnetic resonance spectroscopy (NMR), we sought 
to determine the number, order, and regio-specificity of the multiple acetylations by Eis. 
We found that not only does Eis show a novel ability to catalyze multiple acetylations to 
each of the AGs studied, but also that these modifications occur at positions never before 
shown to be modified by other AACs.  
 
2.3. Results: determination of positions of AGs modified by Eis via NMR and TLC 
Eis exhibits unusual regio-versatility as an acetyltransferase, modifying some AGs as 
many as four times, which makes it unique among known AACs.3 TLC may be used to 
qualitatively study the reaction progress of Eis with various AGs by following the 
appearance of compounds with increased retention factor (Rf) values, indicating 
acetylation has occurred. Side-by-side comparison of an Eis-modified AG to the 
analogous AG product formed by other AACs with known specificity allows for the 
prediction, and in some cases identification of the Eis-modified products (Table 2.1 and 
Figs. 2.1-2.5). AACs capable of acetylating the 6'-, 2'-, 3-, and 1-amines of various AGs 
have been reported, and examples of each, except AAC(1), were applied in this study. 
AAC(1) was reported in the past but is very rare and our significant efforts to obtain 
DNA or plasmids with the gene were not successful.  
 
Table 2.1. Rf valuesa of mono- and di-, acetylated AGs by the AAC(2')-Ic, AAC(3)-IV, AAC(6'), and Eis proteins. 
  Enzymes utilized 
  None (2')e (3)f (6')g (3)/(2') (6')/(2') (6')/(3) Eis 
AG         1 min 5 min 10 min 30 min 2 h O/N 
AMK Parentb 0.06       0.06 0.06 0.06 0.06   









 Did     ×h ×h ×i     0.46 0.46 
KAN Parent 0.28       0.28      







 Di     ×h ×h 0.49     0.56 0.56 
NET Parent 0.06       ×j ×j ×j  ×j  
 Mono  ×j ×j 0.26       0.26   
 Di     --k 0.37 0.41      0.37 
SIS Parent 0.05             
 Mono  0.08 0.16 0.24    0.24 0.24 0.24 0.24 0.24  
 Di     0.23 0.26 0.30      0.24 -
0.30 
TOB Parent 0.24       0.24 0.24     
 Mono  0.27 0.36 0.48    0.48 0.29l / 
0.48 
0.48 0.48   
 Di     --k --k 0.71   0.62 0.62 0.62 0.62 
aThe eluent systems used for TLCs were 5:2/MeOH:NH4OH, 5:2/MeOH:NH4OH, 25:1/MeOH:NH4OH, 12:1/MeOH:NH4OH, and 
5:2/MeOH:NH4OH for AMK, KAN, NET, SIS, and TOB, respectively. bParent indicates no acetylation. cMono indicates mono-acetylation. dDi 
indicates di-acetylation. e(2') indicates AAC(2')-Ic. f(3) indicates AAC(3)-IV. g(6') indicates AAC(6') of the AAC(6')/APH(2"). h× Because the 2'-
NH2 does not exist in AMK or KAN, these controls were not performed. i×AMK is not a substrate for AAC(3)-IV. j×These reactions were not 
performed. k-- Indicates that the di-acetylated product could not be visualized as it had an Rf value overlapping with that of the glycerol in the 




To determine the position and order of the multiple acetylation reactions carried out by 
Eis, we first compared the Rf of Eis-modified AMK, KAN, SIS, NET, and TOB to the 3-, 
2'-, and 6'-acetyl counterparts, and when applicable, to the 6',3-, 6',2'-, and 3,2'-N-di-
acetyl compounds formed by sequential acylation, as previously described (Table 2.1 and 
Figs. 2.1-2.5).3,12 No combination of AACs was found to be capable of generating tri-
acetylated AGs. 
 
Previous studies indicated that KAN and AMK were di-acetylated by Eis, and the N-1 
AHB-containing AMK could be tri-acetylated to some extent, as determined by liquid 
chromatography-mass spectrometry (LCMS), but the positions modified and the order in 
which those acetylations occurred was not established.3 The reaction progress followed 
by TLC indicated that KAN rapidly underwent two acetylations, but the modifications 
were not sequential in nature. The Rf value of the di-acylated KAN product of Eis did not 
match the product of any other AAC, or sequential combination thereof, capable of 
modifying KAN (Table 2.1 and Fig. 2.1). The Rf values of two of the intermediate mono-
acetylated products did closely correlate to the 6'- and 3-N-acetyl-KAN (Table 2.1 and 
Fig. 2.1). The reaction was scaled up and the di-acetylated product was purified by flash 
chromatography for NMR analysis. A comparison of the 1D- and 2D-NMR spectra of 
KAN (Figs. 2.14-2.18) to the di-acetylated KAN product (Figs. 2.19-2.23) clearly 
indicated that the reactions occurred at the 6'-amine and the 3"-amine (Fig. 2.1 and 
Tables 2.4 and 2.5), showing Eis to be the first AAC reported to acetylate an AG at the 
3"- position. TLC analysis of the Eis reaction with AMK suggested that as many as three 
total mono- or di-acetylated products may be formed over the course of the reaction, and 
that, similarly to KAN, their formation was not sequential in nature. AMK is only a good 
substrate for AAC(6') of all the enzymes used in this study, limiting the information that 





Fig. 2.1. The di-acetylation of KAN by Eis. 
Of the three products formed by Eis that are visible over the course of the reaction, that 
with the lowest Rf value closely matched that of 6'-N-acetyl AMK (Table 2.1 and Fig. 
2.2). The reaction was scaled up and purified by flash chromatography for NMR analysis. 
In order to reduce the amount of costly materials, namely AcCoA, and hasten the 
characterization process, our method was adapted to use solely 1H-detected NMR studies. 
In doing so, we eliminated superfluous data that was ultimately unnecessary for the 
analysis of the products while at the same time greatly reducing the cost and amount of 
instrument time required. The results indicated that the ultimate product of the Eis 
reaction with AMK was di-acetylated (Fig. 2.2), similarly to KAN. However, in this case 
comparison of the AMK standard (Figs. 2.7-2.9) to those of the product (Figs. 2.10-2.13) 
showed that the reactions had taken place at the 3"-position and the γ-amine of the AHB 
moiety as determined by NMR (Fig. 2.2 and Table 2.3), making Eis the first AAC 
reported to modify the AHB of an AG. 
 
1 2 3 4 5 6 7 8 9 10 
1.  KAN (Rf 0.28) 
2.  KAN + AcCoA + Eis_Mtb (1 min) (Rf 0.28, 0.33) 
3.  KAN + AcCoA + Eis_Mtb (5 min) (Rf 0.33, 0.43) 
4.  KAN + AcCoA + Eis_Mtb (10 min) (Rf 0.33, 0.43) 
5.  KAN + AcCoA + Eis_Mtb (30 min) (Rf 0.33, 0.43) 
6.  KAN + AcCoA + Eis_Mtb (2 h) (Rf 0.33, 0.56) 
7.  KAN + AcCoA + Eis_Mtb (O/N) (Rf 0.56) 
8.  6'-acetyl-KAN (Rf 0.43) 
9.  3-acetyl-KAN (Rf 0.33) 




Fig. 2.2. The di-acetylation of AMK by Eis. 
 
Time-course TLC analysis of the acetylation of SIS and NET by Eis showed that the 
reactions proceeded in a sequential manner and that the second sites of acetylation were 
converted significantly more slowly than with KAN, AMK, or TOB. For both SIS and 
NET, TLC indicated that Eis specifically and rapidly acetylated a single amine, and by 
comparing the Rf value of the Eis products to those of known AACs indicated the 6'-
amine was likely the acetylated position in both cases (Table 2.1 and Fig. 2.3). This was 
then followed by a single, much slower reaction in the case of NET. SIS underwent two 
such slower reactions, but it was unclear whether the products observed were di-
acetylated, tri-acetylated, or a mixture of both di- and tri-acetylated. In order to 
definitively determine the order of acetylation, we once again adapted our method. The 
experiments were designed so that the reaction progress was monitored in solution by 
NMR, negating the need for time-consuming purification of the products. The molar 
equivalents of AcCoA were regulated in order to control the reaction progress so that all 
NMR experiments on the mono-acetylated products could be performed before the 
subsequent acetylations had occurred. 
 
Monitoring the reaction progress of NET with Eis by TLC indicated that the 6'-position 
was likely the first to be modified, based on the similarity of the Rf of the first Eis product 
1 2 3 4 5 6 7 8 9 
1.  AMK (Rf 0.06) 
2.  AMK + AcCoA + Eis_Mtb (1 min) (Rf 0.06) 
3.  AMK + AcCoA + Eis_Mtb (5 min) (Rf 0.06, 0.10, 0.36) 
4.  AMK + AcCoA + Eis_Mtb (10 min) (Rf 0.06, 0.10, 0.36) 
5.  AMK + AcCoA + Eis_Mtb (30 min) (Rf 0.06, 0.10, 0.36) 
6.  AMK + AcCoA + Eis_Mtb (2 h) (Rf 0.10, 0.36, 0.46) 
7.  AMK (Rf 0.06) 
8.  AMK + AcCoA + Eis_Mtb (O/N) (Rf 0.46) 
9.  6'-acetyl-AMK (Rf 0.10) 
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with that known to be 6'-N-acetyl-NET (Table 2.1 and Fig. 2.3). NMR analysis of a 
reaction mixture containing a 1:1 ratio of AcCoA and NET with Eis showed rapid, 
complete conversion (>95%) of NET (Table 2.6 and Figs. 2.24-2.26) to 6'-N-acetyl-NET 
(Table 2.6 and Figs. 2.27-2.29), as was predicted by TLC. Addition of a second 
equivalent of AcCoA yielded a single di-acetylated product. This second sequential 
acetylation occurred at the 2'-amine to give the 6',2'-N-di-acetyl NET product (Table 2.7 
and Fig. 2.3), as determined by 1D- and 2D-NMR (Table 2.7 and Figs. 2.30-2.32). 
 
 
Fig. 2.3. The di-acetylation of NET by Eis. 
 
Similarly to NET, the conversion of SIS by Eis, as monitored by TLC, indicated that the 
6'-position was likely the first to be modified by Eis (Fig. 2.4 and Table 2.1). At first, the 
NMR analysis was carried out identically as with NET using a reaction mixture 
containing a 1:1 ratio of AcCoA and SIS. Complete conversion (>95%) of SIS (Figs. 
2.33-2.38 and Table 2.8) into 6'-N-acetyl-SIS (Figs. 2.39-2.41 and Table 2.8) was 
observed as indicated by 1D- and 2D-1H NMR. TLC experiments of the Eis reaction 
showed that like NET, SIS also underwent further reactions, but in this case two different 
products were formed. Comparison of the Rf values of the two additional SIS Eis 
products to those of known di-acetylated SIS products, indicated a close correlation to the 
6',2'- and 6',3-N-di-acetyl-SIS (Fig. 2.4 and Table 2.1). The secondary Eis products 
1.  NET (Rf 0.06) 
2.  6'-acetyl-NET (Rf 0.26) 
3.  NET + AcCoA + Eis_Mtb (30 min) (Rf 0.26) 
4.  NET + AcCoA + Eis_Mtb (O/N) (Rf 0.37) 
5.  6',3-di-acetyl-NET (Rf 0.41) 
6.  6',2'-di-acetyl-NET (Rf 0.37) 
7.  NET + AcCoA + Eis_Mtb (O/N) (Rf 0.37) 
1 2 3 4 5 6 7 
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formed much more slowly than in the previous cases, and due to the slow hydrolysis of 
AcCoA under the conditions, an additional 4 molar equivalents of AcCoA were required 
to drive the reaction to completion (>95% conversion from the 6'-product). The CoA, 
formed upon reaction with Eis in addition to that formed by hydrolysis of the thioether of 
AcCoA, significantly hindered our ability to fully characterize the peaks of interest and 
consequently, a mixture of the two products was purified by flash chromatography for 
further NMR experiments. The relatively small difference in Rf values made complete 
separation of the two desired products extremely difficult, and as such, a mixture of the 
two compounds was used for NMR studies.  
 
Analysis of the NMR data indicated that SIS was converted into two distinct di-
acetylated products by Eis (Figs. 2.42-2.47 and Table 2.9), and that a tri-acetylated 
product was not formed in significant enough quantity to be detected by NMR. One of 
the products was unambiguously determined to be 6',2'-N-di-acetyl-SIS (Figs. 2.42-2.47 
and Table 2.9). The second di-acetylated product was modified by Eis on the central 2-
deoxystreptamine (2-DOS) ring, at either the 1- or 3-position (Figs. 2.42-2.47 and Table 
2.9). The exact position could not be assigned with certainty, due to the symmetrical 
nature of the 2-DOS ring, but 1-N-acetylation is suspected because no 3-N-acetylation by 





Fig. 2.4. The multiple di-acetylations of SIS by Eis. 
 
Previous studies have shown qualitatively that TOB may be acetylated as many as four 
times by Eis, as determined by LCMS.3 Reactions monitored by TLC indicated that TOB 
was di-acetylated (Fig. 2.5 and Table 2.1), but the modifications were not sequential, 
similar to KAN and AMK. Comparison of the Rf values of the Eis product to those with 
AACs of known specificity indicated that one of the mono-acetylated compounds formed 
en route to the di-acetylated products was likely modified at the 6'-amine (Fig. 2.5 and 
Table 2.1). NMR analysis of the reaction with Eis using a 1:1 ratio of TOB and AcCoA 
indicated that two products formed in an approximately 3:2 ratio (data not shown). 
Addition of a second molar equivalent of AcCoA resulted in the complete conversion of 
TOB to a single, di-acetylated product. 1D- and 2D-NMR analysis indicated that TOB 
1.  SIS (Rf 0.05) 
2.  SIS + AcCoA + Eis_Mtb (1 min) (Rf 0.24) 
3.  SIS + AcCoA + Eis_Mtb (5 min) (Rf 0.24) 
4.  SIS + AcCoA + Eis_Mtb (10 min) (Rf 0.24) 
5.  SIS + AcCoA + Eis_Mtb (30 min) (Rf 0.24) 
6.  SIS (Rf 0.05) 
7.  SIS + AcCoA + Eis_Mtb (2 h) (Rf 0.24) 
8.  SIS + AcCoA + Eis_Mtb (O/N) (Rf 0.24-0.30) 
9.  6'-acetyl-SIS (Rf 0.24) 
10.  SIS (Rf 0.05) 
11.  2'-acetyl-SIS (Rf 0.08) 
12.  3-acetyl-SIS (Rf 0.16) 
13.  3,2'-di-acetyl-SIS (Rf 0.23) 
14.  6',2'-di-acetyl-SIS (Rf 0.26) 
15.  6',3-di-acetyl-SIS (Rf 0.30) 
16.  SIS + AcCoA + Eis_Mtb (72 h) (Rf 0.24-0.30) 
1 2 3 4 5 6 7 8 9 10 12 13 14 15 16 11 
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(Figs. 2.48-2.50 and Table 2.9) was converted to 6',3"-di-acetyl TOB (Figs. 2.51-2.53 and 
Table 2.9) similarly to KAN (Fig. 2.5).  
 
Fig. 2.5. The di-acetylation of TOB by Eis. 
 
2.4. Discussion  
Herein, we have reported that Eis is the first and only AAC reported that is capable of 
modifying either the 3"- or 1-N-AHB moiety of an AG in a manner dependent on the 
scaffold of the AG. Not only is it the first AAC that has shown regio-versatility as 
previously reported, but, since the acetylation pattern varies with the particular AG 
scaffold presented to Eis, it also the first and only AAC to demonstrate regio-promiscuity. 
Previous studies with Eis showed that it was capable of tri-acetylating NEA, a small AG 
that contains 4 primary amines (1, 3, 2', and 6') on two aminocyclitol rings, rather than 
the three or four ring system common to most AGs.3 The novel regio-versatility was a 
surprising result because no other AACs had been proven to perform multiple 
acetylations on the same AG. However, the 1-, 3-, 2'-, and 6'-amines are all known to be 
modified on AGs by AACs belonging to one or another of the four classes previously 
reported in the literature. Furthermore, the number of acetylations performed by Eis on a 
particular AG was always observed to be less than or equal to the total number of 1-, 3-, 
2', and 6'-amines present on the same AG. As such, the discovery that Eis not only shows 
unprecedented activity towards the amines at the 3"- and γ-amine of AHB, but also 
1.  TOB (Rf 0.24) 
2.  TOB + AcCoA + Eis_Mtb (1 min) (Rf 0.24, 0.48) 
3.  TOB + AcCoA + Eis_Mtb (5 min) (Rf 0.24, 0.29, 0.48) 
4.  TOB + AcCoA + Eis_Mtb (10 min) (Rf 0.48, 0.62) 
5.  TOB + AcCoA + Eis_Mtb (30 min) (Rf 0.48, 0.62) 
6.  TOB + AcCoA + Eis_Mtb (2 h) (Rf 0.62) 
7.  TOB + AcCoA + Eis_Mtb (O/N) (Rf 0.62) 
8.  TOB (Rf 0.24) + 3-acetyl-TOB (Rf 0.36) 
9.  TOB (Rf 0.24) + 6'-acetyl-TOB (Rf 0.48) 
10.  TOB (Rf 0.24) + 2'-acetyl-TOB (Rf 0.27) 
11.  TOB (Rf 0.24) + 6',3-di-acetyl-TOB (Rf 0.71) 
1 2 3 4 5 6 8 9 10 11 7 
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acetylates various amine positions based on the chemical structure of a given AG makes 
it unique among AG-modifying enzymes (AMEs). 
 
Three different patterns of acetylation were observed with the three distinct AG scaffolds 
investigated. The patterns of acetylation seen on the chemically distinct scaffold of NET 
and SIS are relatively unsurprising because, as seen with NEA, there were multiple 
acetylations but only in positions known to be modified by other AACs. The reasons for 
the sequential nature of the reactions of Eis with SIS and NET are unclear. A probable 
explanation for the trend seen with KAN, AMK, and TOB is that there exist (at least) two 
possible binding orientations in which the AGs may initially bind with similar affinities 
that will ultimately lead to acetylation. Since KAN, AMK, and TOB are di-acetylated by 
Eis in random order, it stands to reason that two of the possible binding orientations are 
in an equilibrium that does not significantly favor one over the other, allowing either of 
the respective positions to be acetylated. Conversely, NMR and TLC analysis suggests 
that there is one orientation that is initially preferred with SIS as well as one for NET that 
leads to complete conversion at the 6'-amine before a second acetylation may occur, 
suggesting the corresponding 6'-acetyl compound is the substrate for the second, slower 
reaction. 
 
TOB, which has distinct molecular scaffold compared to NET and SIS and a similar 
scaffold to KAN and AMK, behaved more similarly to KAN and AMK, showing a 
random order of acetylation and identical pattern of acetylation to that of KAN with Eis. 
It would be reasonable to expect that one of the AGs that undergo a sequential acetylation 
might be a better candidate for crystallization, and further attempts to obtain 




That fact that Eis modifies AGs in a way that varies from AG to AG is at the same time 
very interesting as well as very alarming in terms of the evolution of antibiotic resistance. 
The development of novel, synthetically modified AGs that avoid resistance enzymes, 
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reduce toxicity, and improve antimicrobial activity has been the goal of numerous 
research efforts. Together, the lack of effective treatments for TB and the increasing 
number and severity of outbreaks of MDR- and XDR-TB highlight a situation that 
requires prompt action within the scientific community. The combined versatility and 
promiscuity of Eis, particularly toward the AHB moiety which has been shown to 
improve many AGs when incorporated at the N-1 position, will make it particularly 
difficult to develop novel AGs as treatments, suggesting another course of action may be 
necessary. Developing inhibitors of bacterial resistance enzymes, such as the β-lactamase 
inhibitor clavulanic acid, has been a successful means of overcoming an analogous 
problem associated with β-lactam antibiotics such as ampicillin, and studies to this affect 
with Eis have been performed.4,13 
 
We have shown that Eis is the most regio-versatile and regio-promiscuous AAC 
characterized to date. Its role in conferring resistance to AGs used in the treatment of TB 
is a serious concern, as few drugs are efficient treatments. The overall lack of effective 
treatments is exacerbated by the development and rapid spread of MDR- and XDR-TB. 
We are left to ask whether the expanded AG modifying capabilities of Eis as an AAC is 
the next advancement in bacteria’s defensive arsenal or just an isolated evolutionary 
coincidence? If this type of capability starts expanding to other bacteria, it may mean that 
AGs begin to see an even smaller role as useful therapies against many types of bacteria. 
In any case, it highlights both the necessity to develop next generation antibacterial drugs, 
as well as the need to advance our understanding of these processes as thoroughly and 
rapidly as possible. 
 
2.6. Materials and instrumentations 
The Eis,3 AAC(2')-Ic,3 AAC(3)-IV,12 and AAC(6')/APH(2")12 enzymes were 
overexpressed and purified as previously described. For sake of simplicity, in the text that 
follows we will refer to the bifunctional AAC(6')/APH(2") enzyme as AAC(6') since 
none of the reactions performed in this study contain a nucleotide substrate for the 
APH(2") domain of this enzyme. Acetyl-CoA (AcCoA) and aminoglycosides (AGs) 
(AMK, KAN, and SIS) were bought from Sigma-Aldrich (Milwaukee, WI) (Fig. 2.1). 
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The AGs NET and TOB were purchased from AK Scientific (Mountain View, CA) (Fig. 
2.1.). TLCs (Merck, Silica gel 60 F254) were visualized using a cerium-molybdate stain 
((NH4)2Ce(NO3)6 (5 g), (NH4)6Mo7O24•4H4O (120 g), H2SO4 (80 mL), H2O (720 mL)). 
AMK, KAN, and SIS acetylated products were purified by SiO2 flash chromatography 
(Dynamic Absorbents 32-63 m). 1H, 13C, gCOSY, gHMBC, gHSQC, and zTOCSY NMR 
spectra were recorded either on a Bruker Avance IIITM 600 MHz spectrometer equipped 
with a 3 mm cryo-probe, a Varian 400 MHz equipped with a 5 mm OneProbe, or a 
Varian 500 MHz equipped with a 3 mm OneProbe, as indicated in the figure legends of 
the NMR spectra. All NMR spectra were recorded either in D2O or in 9:1/H2O:D2O at 
either pH 3.0 or 8.0, as indicated in the appropriate figure captions. LCMS was 
performed on a Shimadzu LCMS-2019EV equipped with a SPD-20AV UV-Vis detector 
and a LC-20AD liquid chromatograph. 
 
2.7. Methods 
2.7.1. Determination of amine positions acetylated by Eis on AMK, KAN, NET, SIS, 
and TOB 
2.7.1.1. TLC assays 
In order to establish the amine positions acetylated by Eis on AMK, KAN, NET, SIS, and 
TOB, we first performed TLC assays. Control experiments were done with three AG 
acetyltransferases of known specificity (AAC(2')-Ic, AAC(3)-IV, and AAC(6')) that were 
confirmed by us by UV-Vis assays and LCMS to acetylate only at the 2'-, 3-, and 6'-
positions, respectively (whenever available) of all AG substrates used in this study. The 
eluent system utilized for all TLCs of reactions performed with AMK, KAN, NET, SIS, 
and TOB were 5:2/MeOH:NH4OH, 5:2/MeOH:NH4OH, 25:1/MeOH:NH4OH, 
12:1/MeOH:NH4OH, and 5:2/MeOH:NH4OH, respectively. The Rf values observed are 
reported in Table S1. The exact reaction conditions are reported below. The Rf values of 







2.7.1.1.1. Control TLCs of AGs mono-acetylated at the 2'-, 3-, and 6'-position by 
AAC(2')-Ic, AAC(3)-IV, and AAC(6'), respectively 
Reactions (15 µL) were carried out at rt in MES buffer (50 mM, pH 6.6 adjusted at rt) for 
AAC(3)-IV and AAC(6') or in Na2HPO4 buffer (100 mM, pH 7.0 adjusted at rt) for 
AAC(2')-Ic in the presence of AcCoA (0.96 mM, 1.2 eq), AG (0.8 mM, 1 eq), and AAC 
enzyme (10 µM). After overnight incubation, aliquots (5 µL) of the reaction mixtures 
were loaded onto a TLC plate and eluted with the proper eluent system. 
 
2.7.1.1.2. Control TLCs of AGs di-acetylated sequentially by pairwise treatment 
with AAC(2')-Ic, AAC(3)-IV, and AAC(6') 
Di-acetylation reactions for use as reference standards were carried out by sequentially 
using the following pairs of enzymes: (i) AAC(6') followed by AAC(2')-Ic, (ii) AAC(3)-
IV followed by AAC(2')-Ic, or (iii) AAC(6') followed by AAC(3)-IV. Reactions (10 µL) 
were carried out at rt in MES buffer (50 mM, pH 6.6 adjusted at rt) in the presence of 
AcCoA (1.92 mM, 2.4 eq), AG (0.8 mM, 1 eq), and the first AAC enzyme (10 µM). 
After overnight incubation, the second AAC enzyme (10 µM) was added to the reaction 
mixture, which was incubated for at least an additional 16 h. Aliquots (5 µL) of each di-
acetylation reaction mixture were loaded onto a TLC plate and eluted with the proper 
eluent system. 
 
2.7.1.1.3. TLCs of the time course of multi-acetylation of KAN, AMK, NET, SIS, 
and TOB by Eis 
Reactions (30 µL) were carried out at rt in Tris-HCl buffer (50 mM, pH 8.0 adjusted at rt) 
in the presence of AcCoA (4 mM, 5 eq), AGs (0.8 mM, 1 eq), and Eis (5 µM). Aliquots 
(4 µL) were loaded onto a TLC plate after 0, 1, 5, 10, 30, and 120 min as well as after 
overnight incubation and eluted with the proper eluent system. Rf values are reported in 






2.7.1.2. Mass spectrometry analysis of the multi-acetylated AMK, KAN, NET, SIS, 
and TOB Eis products 
The masses of the AGs multi-acetylated by Eis were obtained by LCMS in positive ion 
mode using H2O (0.1% formic acid) after dilution of the NMR samples described below 
(1 µL of 15 mM stock) with H2O (1 mL) and injection of 20 µL (Table 2.2 and Fig. 2.6). 
 
 
Table 2.2. Mass analysis of aminoglycosides (AGs) acetylated by Eis. 
AG  Calculated [M]+ Observed [M+H]+ 
AMK Dia 669.31 670.35 
KAN Di 568.26 569.30 
NET Monob 517.31 518.35 
 Di 559.32 560.30 
SIS Di 531.29 532.35 (554.20 +Na) 
TOB Di	   551.28 552.25 (574.20 +Na) 




































































































































































































2.7.1.3. NMR analysis of the multi-acetylated AMK, KAN, NET, SIS, and TOB Eis 
products 
2.7.1.3.1. Di-acetylation of AMK by Eis and NMR analysis of the 3",AHB-di-acetyl-
AMK product 
To determine which two positions of AMK are acetylated by Eis, a reaction was 
performed to yield sufficient amount of product for NMR analysis. Briefly, a reaction 
mixture (4 mL) containing AMK (5 mM, 1 eq), AcCoA (20 mM, 4 eq), and Eis (0.5 
mg/mL) in Na2HPO4 buffer (50 mM, pH 8.0 adjusted at rt; Note: Na2HPO4 replaced Tris-
HCl to simplify purification) was incubated with gentle shaking at rt for 24 h prior to 
supplementing with additional portions of AcCoA (5 mM) and Eis (0.1 mg/mL) followed 
by further incubation for 48 h (Note: the reaction was pH adjusted using 1.0 M KOH 
solution prior to addition of enzyme as necessary to maintain pH 8.0). The progress of the 
Eis reaction was monitored by TLC. After >90% conversion of AMK into di-acetyl-
AMK, the Eis enzyme was removed by addition of an equal volume of MeOH, cooling to 
4 °C for 30 min, and centrifugation (15,000 rpm, 10 min, rt). The solution was separated 
from the precipitate and the solvents evaporated under reduced pressure. The residue was 
purified by flash chromatography (SiO2) using a gradient of 0.0-2.0% Et3N in MeOH. 
Fractions containing the product were pooled and the solvents removed under reduced 
pressure. The residue was dissolved in minimal volume of D2O, adjusted to pH 3 with 
dilute sulfuric acid (0.5%), and lyophilized to give 3",AHB-di-acetyl-AMK as a white 
powder. For NMR analyses, 3",AHB-di-acetyl-AMK was dissolved in D2O (400 mL), 
centrifuged (15,000 rpm, 10 min, rt) to remove any particulate, and the supernatant 
collected for analysis. The positions of acetylation, purity, and structure identification 
were confirmed by 1H, zTOCSY, and gCOSY NMR as well as LCMS. Proton 
connectivity was assigned using zTOCSY and gCOSY spectra. Representative spectra for 
3",AHB-di-acetyl-AMK are provided (Figs. 2.10-2.13). 
 
To unambiguously establish the two acetylated positions on the AMK scaffold, the NMR 
spectra of the di-acetylated-AMK were compared to those of a standard of pure non-
acetylated AMK (Tables 2.3). The sample of AMK for NMR was prepared as described 
for the 3",AHB-di-acetyl-AMK NMR sample. Additionally, the compound was prepared 
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in 9:1/H2O:D2O and both a 1H and a zTOCSY spectra of the compound were obtained at 
600 MHz resolution in order to resolve the amide bonds for further confirmation of the 
structure. Representative spectra for AMK are provided (Figs. 2.7-2.9) 
 
Table 2.3. Proton chemical shifts determined for AMK and 3",AHB-di-acetyl-AMK.a 
Ring H position AMK 3",AHB-di-acetyl-AMK Δppm 
II 1 4.10-3.95 (m)b [4.06]c 4.14-4.00 (m) [4.07] 0.01 
 2ax 1.80 (m) 1.87-1.70 (m) [1.80] 0.00 
 2eq 2.22-2.09 (m) [2.19]  2.23-2.17 (m) [2.20] 0.01 
 3 3.53 (m) 3.65-3.40 (m) [3.56] 0.03 
 4 3.90-3.80 (m) [3.85] 3.95-3.65 (m) [3.90] 0.05 
 5 3.90-3.80 (m) [3.88] 3.95-3.65 (m) [3.90] 0.02 
 6 3.90-3.80 (m) [3.83] 3.95-3.65 (m) [3.84] 0.01 
 C=OCH(OH)CH2CH2NH2 
(A1) 
4.24 (dd, JA1,A2a = 2.8 Hz, JA1,A2b = 9.4 Hz) [4.12] (dd, JA1,A2a = 2.8 Hz, JA1,A2b = 9.4 Hz) -0.12 
 C=OCH(OH)CH2CH2NH2 
(A2a) 
1.93 (m) 1.87-1.70 (m) [1.74] -0.19 
 C=OCH(OH)CH2CH2NH2 
(A2b)	  
2.13 (m) 2.03-1.92 (m) [1.98] -0.15 
 C=OCH(OH)CH2CH2NH2 
(A3)	  
3.18-3.10 (m) [3.15] 3.31-2.26 (m) [3.29] 0.14 
I 1' 5.54 (d, J1',2' = 3.6 Hz) 5.57 (d, J1',2' = 3.7 Hz) 0.03 
 2' 368-3.62 (m) [3.63] 3.95-3.65 (m) [3.66] 0.03 
 3' 3.80-3.70 (m) [3.74] 3.95-3.65 (m) [3.78] 0.04 
 4' 3.37-3.32 (m) [3.35] 3.35 (dd (app. t), J4',3' = J4',5' = 9.5 Hz) 0.00 
 5' 4.10-3.95 (m) [3.98] 4.14-4.00 (m) [4.02] 0.04 
 6'a 3.43-3.31 (m) [3.41] 3.65-3.40 (m) [3.45] 0.04 
 6'b 3.18-3.10 (m) [3.14] 3.14 (dd, J = 13.3 Hz, J = 8.7 Hz) 0.00 
III 1" 5.14 (d, J1",2" = 3.3 Hz) 5.13 (d, J1",2" = 3.7 Hz) -0.01 
 2" 3.80-3.70 (m) [3.75] 3.65-3.40 (m) [3.51] -0.24 
 3" 3.37-3.32 (m) [3.36] 4.14-4.00 (m) [4.05] 0.69 
 4" 368-3.62 (m) [3.66] 3.65-3.40 (m) [3.46] -0.20 
 5" 4.10-3.95 (m) [4.05] 4.14-4.00 (m) [4.08] 0.03 
 6"a 3.87-3.72 (m) [3.78] 3.95-3.65 (m) [3.78] 0.00 
 6"b 3.87-3.72 (m) [3.76] 3.95-3.65 (m) [3.72] -0.04 
Amide NH-1 7.62‡ 8.52 (d, J = 9.8 Hz)*  
 C=OCH(OH)(CH2)2NH-
C=OCH3 
× 8.00 (t, J = 6.2 Hz)*  
 NH-3" × 8.08 (d, J = 10.4 Hz)*  
Acetyl CH3C=O on AHB × 1.97 (s)  
 CH3C=O on 3" × 2.03 (s)  
aThe chemical shift were established based on 1H (400 MHz), zTOCSY, and gCOSY NMR. bMultiplicity and J are given in (). cThe numbers in [] were 
determined from gCOSY and zTOCSY. *Indicates that the values were determined from spectra taken in 9:1/H2O:D2O at 600 MHz. ×Indicates that the 






Fig. 2.7. 1H NMR of AMK in D2O at pH 3 (400 MHz). The full spectrum is 
shown in panel A and the expansions in panels B-E. 
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Fig. 2.10. 1H NMR of 3",AHB-di-acetyl-AMK in D2O at pH 3 (400 MHz). 
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Fig. 2.11. gCOSY of 3",AHB-di-acetyl-AMK in D2O at pH 3 (400 MHz). 












































































Fig. 2.12. 1H NMR of 3",AHB-di-acetyl-AMK in 9:1/H2O:D2O (600 MHz). 
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Fig. 2.13. zTOCSY of 3",AHB-di-acetyl-AMK in 9:1/H2O:D2O (600 MHz). 
The full spectrum is shown in panel A and the expansion showing the amide 
protons coupling to the protons at the 1-, 3"-, and AHB-positions in panel B. 
A red box in panel A indicates the portion of the spectrum expanded and 
shown in panel B. In panel B, the coupling of the amide protons at the 1-, 3"-, 










































































2.7.1.3.2. Di-acetylation of KAN by Eis and NMR analysis of the 3",6'-di-acetyl-
KAN product 
To determine which two positions of KAN are acetylated by Eis, a reaction was 
performed to yield sufficient amount of product for NMR analysis. Briefly, a reaction 
mixture (4 mL) containing KAN (5 mM, 1 eq), AcCoA (20 mM, 4 eq), and Eis (0.5 
mg/mL) in Na2HPO4 buffer (50 mM, pH 8.0 adjusted at rt; Note: Na2HPO4 replaced Tris-
HCl to simplify purification) was incubated with gentle shaking at rt for 24 h prior to 
addition of supplementing with additional portions of AcCoA (5 mM) and Eis (0.1 
mg/mL) followed by further incubation for 48 h (Note: the reaction was pH adjusted prior 
to addition of enzyme as necessary to maintain pH 8.0). The progress of the Eis reaction 
was monitored by TLC. After >90% conversion of KAN into di-acetyl-KAN, the Eis 
enzyme was removed by addition of an equal volume of MeOH, cooling to 4 °C for 30 
min, and centrifugation (15,000 rpm, 10 min, rt). The solution was separated from the 
precipitate and the solvents evaporated under reduced pressure. The residue was purified 
by flash chromatography (SiO2) using a gradient of 0.0-2.0% Et3N in MeOH. Fractions 
containing the product were pooled and the solvents removed under reduced pressure. 
The residue was dissolved in minimal volume of D2O, adjusted to pH 3 with dilute 
sulfuric acid (0.5%), and lyophilized to give 3",6'-di-acetyl-KAN as a white powder. For 
NMR analyses, 3",6'-di-acetyl-KAN was dissolved in D2O (400 µL), centrifuged (15,000 
rpm, 10 min, rt) to remove any particulate, and the supernatant collected for analysis. The 
positions of acetylation, purity, and structure identification were confirmed by 1H, 13C, 
gCOSY, gHMBC, and gHSQC NMR as well as LCMS. Proton connectivities were 
assigned using 1H, zTOCSY, and gCOSY spectra. Signals of all carbons were assigned 
using the 13C, gHSQC, and gHMBC spectra. Representative spectra for 3",6'-di-acetyl-
KAN are provided (Figs. 2.19-2.23). 
 
To unambiguously establish the two acetylated positions on the KAN scaffold, the 1H and 
13C NMR spectra of the di-acetylated-KAN were compared to those of a standard of pure 
non-acetylated KAN (Tables 2.4-2.5). The sample of KAN for NMR was prepared as 
described for the 3",6'-di-acetyl-KAN NMR sample. Representative spectra for KAN are 
provided (Figs. 2.14-2.18). 
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Table 2.4. Proton chemical shifts determined for KAN and 3",6'-di-acetyl-KAN.a 
Ring H position KAN 3",6'-di-acetyl-KAN Δppm 
II 1 3.61-3.54b (m)c [3.59]d 3.63-3.45 (m) [3.53] -0.06 
 2ax 2.02 (ddd (app. q), J2ax,2eq = J2ax,1 = J2ax,3 = 12.5 Hz) 1.93 (ddd (app. q), J2ax,2eq = J2ax,1 = J2ax,3 = 12.8 Hz) -0.09 
 2eq 2.54 (ddd (app. dt), J2eq,2ax = 12.5 Hz, J2eq,1 = J2eq,3 = 
4.0 Hz) 
2.54 (ddd (app. dt), J2eq,2ax = 12.8 Hz, J2eq,1 = J2eq,3 = 
4.2 Hz) 
0.00 
 3 3.61-3.54b (m) [3.57] 3.63-3.45 (m) [3.59] 0.02 
 4 4.01-3.89e (m) [3.90] 3.94-3.66 (m) [3.85] -0.05 
 5 3.84-3.74 (m) [3.81] 3.94-3.66 (m) [3.73] -0.08 
 6 4.01-3.89e (m) [3.95] 3.94-3.66 (m) [3.90] -0.05 
I 1' 5.62 (d, J1',2' = 3.9 Hz) 5.45 (d, J1',2' = 3.9 Hz) -0.17 
 2' 3.64 (dd, J1',2' = 3.9 Hz, J2',3' = 10.1 Hz) 3.60 (dd, J2',1' = 3.9 Hz, J2',3' = 9.8 Hz) -0.04 
 3' 3.84-3.74 (m) [3.78] 3.94-3.66 (m) [3.72] -0.06 
 4' 3.35 (dd (app. t), J4',3' = J4',5' = 9.5 Hz) 3.51-3.43 (m) [3.31] -0.04 
 5' 4.01-3.89 (m) [3.96] 3.94-3.66 (m) [3.81] -0.15 
 6'a 3.45 (dd, J6'a,6'b = 13.3 Hz, J6'a,5' = 2.9 Hz) 3.65-3.45 (m) [3.60] 0.15 
 6'b 3.14 (dd, J6'b,6'a = 13.3 Hz, J6'b,5' = 8.7 Hz) 3.65-3.45 (m) [3.52] 0.38 
III 1" 5.14 (d, J1",2" = 3.9 Hz) 5.07 (d, J1",2" = 3.5 Hz) -0.07 
 2" 4.01-3.89 (m) [3.93] 3.69 (dd, J1",2" = 3.5 Hz)† -0.24 
 3" 3.50 (dd (app. t), J3",2" = J3",4" = 10.5 Hz) 4.11 (dd (app. t), J3",2" = J3",4" = 10.3 Hz) 0.61 
 4" 3.69 (dd (app. t), J4",3" = J4",5" = 10.5 Hz) 3.49 (dd (app. t), J4",3" = J4",5" = 10.3 Hz) % -0.20 
 5" 4.01-3.89 (m) [3.93] 3.94-3.66 (m) [3.93] -0.00 
 6"a 3.84-3.74 (m) [3.81] 3.94-3.66 (m) [3.80] -0.01 
 6"b 3.84-3.74 (m) [3.78] 3.94-3.66 (m) [3.76] -0.02 
Acetyl NH-3" × 8.14 (d, JNH,3" = 9.7 Hz)  
 NH-6' × 8.06 (t, JNH,6' = 6.0 Hz)  
 CH3C=O on 
3" 
× 2.04 (s)  
 CH3C=O on 
6' 
× 2.00 (s)  
aThe chemical shift were established based on 1H (400 MHz), zTOCSY, and gCOSY NMR. bCould be analogous position of the 2-deoxystreptamine 
(DOS) ring. cMultiplicity and J are given in (). dThe numbers in [] were determined from gCOSY and/or zTOCSY. eCould be analogous position of the 




Table 2.5. Carbon chemical shifts determined for KAN and 3",6'-di-acetyl-KAN.a 
Ring C position KANb 3",6'-di-acetyl-KAN Δppm 
II 1 47.69 48.15 0.46 
 2 27.36 27.50 0.14 
 3 49.67 49.63 -0.04 
 4 77.33 79.06 1.73 
 5 83.70 83.45 -0.25 
 6 72.72 72.95 0.23 
I 1' 95.82 97.70 1.88 
 2' 70.64 70.95 0.31 
 3' 71.83 72.01 0.18 
 4' 70.94 70.14 -0.95 
 5' 68.56 71.08 2.52 
 6' 40.34 39.44 -0.90 
III 1" 100.40 100.84 0.44 
 2" 68.06 69.99 1.93 
 3" 54.77 53.85 -0.92 
 4" 65.30 66.92 1.62 
 5" 72.56 72.80 0.24 
 6" 59.73 60.09 0.36 
Acetyl CH3C=O on 3" × 175.20  
 CH3C=O on 6'	   × 174.57  
 CH3C=O	   × 22.0  
 CH3C=O	   × 21.7  
aThe chemical shift were established based on 13C, gHSQC, and gHMBC NMR. ×Indicates 









Fig. 2.14. 1H NMR of KAN in D2O at pH 3 (400 MHz). The full spectrum is 
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Fig. 2.15. gCOSY of KAN in D2O at pH 3 (400 MHz). The insert shows a 





Fig. 2.16. 13C NMR of KAN in D2O at pH 3 (100 MHz). The full spectrum is 
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Fig. 2.17. gHSQC of KAN in D2O at pH 3 (400 MHz). The insert shows a 
portion of the spectrum more clearly (Note: CH2 shown in blue, CH and CH3 





























































































Fig. 2.19. 1H NMR of 3",6'-di-acetyl-KAN in D2O at pH 3 (400 MHz). The 
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Fig. 2.20. gCOSY of 3",6'-di-acetyl-KAN in D2O at pH 3 (400 MHz). The 






Fig. 2.21. 13C NMR of 3",6'-di-acetyl-KAN in D2O at pH 3 (100 MHz). The 
full spectrum is shown in panel A and the expansions in panels B-D. 
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Fig. 2.23. gHMBC of 3",6'-di-acetyl-KAN in D2O at pH 3 (100 MHz). The 





























































































2.7.1.3.3. Di-acetylation of NET by Eis and NMR analysis of the 2',6'-di-acetyl-NET 
product 
To determine which two positions of NET are acetylated by Eis, the reaction was 
designed such that it could be monitored in solution by NMR without the need for 
purification. To determine which modification occurred first, a solution (400 mL) 
containing NET (15 mM, 1 eq), AcCoA (15 mM, 1 eq), and Eis (0.5 mg/mL) in Na2HPO4 
buffer (25 mM, pH 8.0 adjusted at rt) containing 10% D2O was prepared and allowed to 
proceed to >90% completion by TLC. 1H, gCOSY, and zTOCSY NMR experiments were 
performed on the reaction solution, applying PURGE solvent suppression.14 After the 
first acetylation was complete and all spectra obtained, an additional aliquot of AcCoA 
and Eis in 10% D2O were added to yield a solution (600 mL) containing NET (10 mM, 1 
eq), AcCoA (20 mM, 2 eq), and Eis (0.1 mg/mL) in Na2HPO4 buffer (25 mM, pH 8.0 
adjusted at rt) containing 10% D2O. Additional spectra were obtained after 48 h to 
determine the second site of acetylation. The positions of acetylation, purity, and 
structure identification were confirmed by 1H, zTOCSY, and gCOSY NMR as well as 
LCMS. Proton connectivity was assigned using zTOCSY and gCOSY spectra. 
Representative spectra for 6'-acetyl-NET are provided (Figs. 2.27-2.29). Representative 
spectra for 2',6'-di-acetyl-NET are provided (Figs. 2.30-2.32). 
 
To unambiguously establish the two acetylated positions on the NET scaffold, the NMR 
spectra were compared to those of a standard of pure NET [15 mM in Na2HPO4 buffer 
(25 mM, pH 8.0 adjusted at rt) containing 10% D2O], which was prepared identically to 
the reaction mixture but omitted AcCoA and Eis (Tables 2.6-2.7). Representative spectra 










Table 2.6. Proton chemical shifts determined for NET and 6'-acetyl-NET.a 
Ring H position NET 6'-acetyl-NET Δppm 
II 1 3.26-3.17 (m)b [3.22]c 3.60-3.35 (m) [3.38] 0.16 
 2ax 1.75 (ddd (app. q), J2ax,2eq = J2ax,1 = J2ax,3 = 12.4 Hz) 1.87 (ddd (app. q), J2ax,2eq = J2ax,1 = J2ax,3 = 12.0 Hz) 0.12 
 2eq 2.47 (ddd (app. dt), J2eq,2ax = 12.4, J2eq,1 = J2eq,3 = 4.1 
Hz) 
2.64-2.55 (m) [2.60] 0.13 
 3 3.40-3.31 (m) [3.34] 3.60-3.35 (m) [3.42] 0.08 
 4 3.80-3.70 (m) [3.75] 3.92-3.70 (m) [3.89] 0.14 
 5 3.80-3.70 (m) [3.75] 3.92-3.70 (m) [3.75] = 
 6 3.86 (dd (app. t), J6,1 = J6,5 = 9.4 Hz) 3.92-3.70 (m) [3.89] 0.03 
 7 (NHCH2CH3) 3.10 (dq, J7,7  = 12.1 Hz, J78 = 7.0 Hz) / 
3.26-3.17 (m) [3.21] 
3.05 (dq, J7,7  = 12.3 Hz, J7,8 = 7.0 Hz) / 
3.28 (dq, J7,7  = 12.3 Hz, J7,8 = 7.0 Hz) 
-0.05 
0.07 
 8 (NHCH2CH3) 1.29 (t, J = 7.0 Hz)  1.30 (t, J = 7.0 Hz) 0.01 
I 1' 5.61 (bs) 5.50 (s) -0.11 
 2' 3.80-3.70 (m) [3.75] 3.86-3.78 (m) [3.83] 0.08 
 3'ax 2.60 (ddd (app. dt), J 3'ax,3'eq= 18.0 Hz) 2.64-2.55 (m) [2.57] -0.03 
 3'eq 2.32 (ddd (app. dt), J3'eq,3'ax = 18.0 Hz) 2.30 (ddd (app. bd), J3'eq,3'ax = 18.4 Hz) -0.02 
 4' 5.18 (m (app. bdd))^ [4.87]£ -0.31 
 6'a 3.66 (s) 3.92-3.70 (m) [3.76] 0.10 
 6'b 3.66 (s) 3.92-3.70 (m) [3.76] 0.10 
III 1" 5.12 (d, J1",2" = 3.7 Hz)  5.14 (d, J1",2" = 3.5 Hz) 0.02 
 2" 4.23 (dd, J2",1" = 3.7 Hz, J2",3" = 10.8 Hz ) 4.29-4.23 (m) [4.26] 0.03 
 3" 3.38 (d, J3",2" = 10.8 Hz) 3.60-3.35 (m) [3.42] 0.04 
 5"ax 3.49 (d, J5"a,5"b = 12.8 Hz) 3.60-3.35 (m) [3.50] 0.01 
 5"eq 4.02 (d, J5"b,5"a = 12.8 Hz) [3.99] -0.03 
 CH3-4" 1.35 (s) 1.34 (s) -0.01 
 NHCH3 2.92 (s) 2.93 (s) 0.01 
Acetyl NH-6' × 8.32 (t, JNH,6' = 6.0 Hz)  
 CH3C=O on 6' × 2.02 (s)  
aThe chemical shift were established based on 1H (400 MHz), zTOCSY, and gCOSY NMR. bMultiplicity and J are given in (). cThe numbers in [] were 




Table 2.7. Proton chemical shifts determined for NET and 2',6'-di-acetyl-NET.a 
Ring H position NET 2',6'-di-acetyl-NET Δppm 
II 1 3.26-3.17 (m)b [3.22]c [3.13] -0.09 
 2ax 1.75 (ddd (app. q), J2ax,2eq = J2ax,1 = J2ax,3 = 12.4 Hz) [1.72] -0.03 
 2eq 2.47 (ddd (app. dt), J2eq,2ax = 12.4, J2eq,1 = J2eq,3 = 4.1 
Hz) 
[2.49] 0.02 
 3 3.40-3.31 (m) [3.34] [3.34] = 
 4 3.80-3.70 (m) [3.75] [3.80-3.60]§ X 
 5 3.80-3.70 (m) [3.75] [3.80-3.60]§ X 
 6 3.86 (dd (app. t), J6,1 = J6,5 = 9.4 Hz) [3.80-3.60]§ X 
 7 
(NHCH2CH3) 
3.10  (dq, J7,7  = 12.1 Hz, J7,8 = 7.0 Hz) / 







1.29 (t, J = 7.0 Hz)  1.28 (t, J = 6.8 Hz) -0.01 
I 1' 5.61 (bs) [5.32] -0.29 
 2' 3.80-3.70 (m) [3.75] [4.20] 0.45 
 3'ax 2.60 (ddd (app. dt), J 3'ax,3'eq= 18.0 Hz) [2.29] -0.31 
 3'eq 2.32 (ddd (app. dt), J3'eq,3'ax = 18.0 Hz) [2.11] -0.21 
 4' 5.18 (m (app. bdd))^ [4.87] -0.31 
 6'a 3.66 (s) [3.73] 0.07 
 6'b 3.66 (s) [3.73] 0.07 
III 1" 5.12 (d, J1",2" = 3.7 Hz)  5.14 (d, J1",2" = 3.5 Hz) 0.02 
 2" 4.23 (dd, J2",1" = 3.7 Hz, J2",3" = 10.8 Hz ) [4.25] 0.02 
 3" 3.38 (d, J3",2" = 10.8 Hz) [3.37] -0.01 
 5"ax 3.49 (d, J5"a,5"b = 12.8 Hz) [3.48] -0.01 
 5"eq 4.02 (d, J5"b,5"a = 12.8 Hz) [4.00] -0.02 
 CH3-4" 1.35 (s) 1.33 (s) -0.02 
 NHCH3 2.92 (s) 2.92 (s) = 
Acetyl NH-2' × [8.06]  
 NH-6' × [8.30]  
 CH3C=O on 2' × 2.01 (s)  
 CH3C=O on 6' × 2.01 (s)  
aThe chemical shift were established based on 1H (400 MHz), zTOCSY, and gCOSY NMR. bMultiplicity and J are given in (). cThe numbers in [] were 
determined from gCOSY and zTOCSY. ×Indicates that the acetyl moiety is not present in the molecule. §Indicates that the peaks were not resolved due to 






Fig. 2.24. 1H NMR of NET (9:1/H2O:D2O, pH 8, 25 mM KH2PO4) (400 
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Fig. 2.27. 1H NMR of 6'-acetyl-NET Eis reaction mixture (9:1/H2O:D2O, pH 
8, 25 mM KH2PO4) (400 MHz). The full spectrum is shown in panel A and 
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Fig. 2.28. gCOSY of 6'-acetyl-NET Eis reaction mixture (9:1/H2O:D2O, pH 
8, 25 mM KH2PO4) (400 MHz). The insert shows the amide protons 






Fig. 2.29. zTOCSY of 6'-acetyl-NET Eis reaction mixture (9:1/H2O:D2O, 





























































































Fig. 2.30. 1H NMR of 2',6'-di-acetyl-NET Eis reaction mixture 
(9:1/H2O:D2O, pH 8, 25 mM KH2PO4) (400 MHz). The full spectrum is 
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Fig. 2.31. gCOSY of 2',6'-di-acetyl-NET Eis reaction mixture (9:1/H2O:D2O, 
pH 8, 20 mM KH2PO4) (400 MHz). The insert shows the amide protons 






Fig. 2.32. zTOCSY of 2',6'-di-acetyl-NET Eis reaction mixture 































































































2.7.1.3.4. Dual di-acetylation of SIS by Eis and NMR analysis of the 2',6'- and 1/3,6'-
di-acetyl-SIS products 
To determine which positions of SIS are acetylated by Eis, the reaction was scaled-up 
and designed such that the initial acetylation reaction could be monitored in solution by 
NMR without the need for purification. To determine which modification occurred first, a 
solution (400 µL) containing SIS (15 mM, 1 eq), AcCoA (15 mM, 1 eq), and Eis (~0.05 
mg/mL) in Na2HPO4 buffer (25 mM, pH 8.0 adjusted at rt) containing 10% D2O was 
prepared and allowed to proceed to >90% completion by TLC. 1H, gCOSY, and 
zTOCSY experiments were performed on the reaction solution, applying PURGE solvent 
suppression 14 and compared to a standard that was prepared identically without Eis and 
AcCoA. After the first acetylation was complete and all spectra obtained, additional 
aliquots of AcCoA (total of 4 eq) were added and additional spectra were obtained after 
incubating for 48 h to determine the subsequent sites of acetylation. Due to the 
complexity of the resulting spectra, the final mixture of di-acetlyated products was 
purified for further analysis. After >90% conversion of SIS into two distinct di-acetyl-SIS 
products, the Eis enzyme was removed by the addition of an equal volume of MeOH, 
cooling to 4 °C for 30 min, and centrifugation (15,000 rpm, 10 min, rt). The solution was 
separated from the precipitate and the solvents evaporated under reduced pressure. The 
residue was purified by flash chromatography (SiO2) using a gradient of 0.0-2.0% Et3N in 
MeOH. Fractions containing the product were pooled and the solvents removed under 
reduced pressure. The residue was dissolved in a minimal volume of D2O and lyophilized 
to give a mixture of the two di-acetyl-SIS products as a white powder. For NMR analyses, 
the mixture of products was dissolved in 9:1/H2O:D2O (400 µL), yielding a solution of 
pH 8 which was centrifuged (15,000 rpm, 10 min, rt) to remove any particulate, and the 
supernatant collected. However, the spectra obtained under these conditions were 
insufficient to fully characterize the compounds. As such, the solution was adjusted to pH 
3 with diluted sulfuric acid (0.5%) for further unambiguous analysis of the two di-
acetylated products (Note: The values in Tables 2.8 and 2.9 are of the product at pH 3). 
The positions of acetylation, purity, and structure identifications were confirmed by 1H, 
zTOCSY, and gCOSY NMR as well as LCMS. Proton connectivity was assigned using 
zTOCSY and gCOSY spectra. Representative spectra for 6'-acetyl-SIS are provided (Figs. 
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2.39-2.41). Representative spectra for the mixture of 2',6'-di-acetyl-SIS and 1/3,6'-di-
acetyl-SIS are provided (Figs. 2.42-2.47). 
To unambiguously establish the first position acetylated on the SIS scaffold, the NMR 
spectra were compared to those of a standard prepared identically to the reaction mixture 
from which Eis and AcCoA were omitted (Tables 2.8). The SIS standard and the solution 
containing the two di-acetyl-SIS products to which it was compared were prepared in an 
identical fashion. Representative spectra of these standards are provided (Figs. 2.36-2.38). 
Spectra of the standard at pH 8 in 9:1/H2O:D2O are provided (Figs. 2.33-2.35), but no 
values are reported in the tables. Note: The chemical shifts of the protons of Ring III of 
the di-acetylated-SIS compounds were omitted because they could not be distinguished 
from one another and, also, there are no possible sites of modification.	  
Table 2.8. Proton chemical shifts determined for SIS and 6'-acetyl-SIS.a 
Ring H position SIS 6'-acetyl-SIS Δppm 
II 1 3.41-3.27b (m)c [3.31]d 3.50-3.30 (m) [3.36] 0.05 
 2ax 1.82 (ddd (app. q), J2ax,2eq = J2ax,1 = J2ax,3 = 12.4 Hz) 1.84 (ddd (app. q), J2ax,2eq = J2ax,1 = J2ax,3 = 12.5 
Hz) 
0.02 
 2eq 2.40-2.30 (m) [2.38] 2.64-2.44 (m) [2.49] 0.11 
 3 3.41-3.27b (m) [3.36] 3.50-3.30 (m) [3.45] 0.09 
 4 3.75-3.65e (m) [3.68] 3.89-3.64 (m) [3.72] 0.04 
 5 3.75-3.65 (m) [3.70] 3.89-3.64 (m) [3.76] 0.06 
 6 3.91e (dd (app. t), J6,1 = J6,5 = 9.4 Hz) 3.89-3.64 (m) [3.85] -0.06 
I 1' 5.60 (s) 5.51£ -0.09 
 2' 3.79 (bs) 3.89-3.64 (m) [3.81] 0.02 
 3'ax 2.40-2.30 (m) [2.34]  2.30 (dd (app. bd), J3'ax,3'eq = 17.8 Hz) -0.04 
 3'eq 2.63 (dd (app. bd), J3'eq,3'ax = 18.2 Hz) 2.64-2.44 (m) [2.58] -0.05 
 4' 5.18 (bs) 4.89 -0.29 
 6'a 3.75-3.65 (m) [3.67] 3.89-3.64 (m) [3.81] 0.14 
 6'b 3.75-3.65 (m) [3.67] 3.89-3.64 (m) [3.81] 0.14 
III 1" 5.15 (d, J1'',2'' = 3.6 Hz) 5.15 = 
 2" 4.20 (dd, J2'',1'' = 3.6 Hz, dd, J2'',3'' = 10.8 Hz) 4.26-4.19 (m) [4.22] 0.02 
 3" 3.40 (d, J3'',2'' = 10.8 Hz)  3.50-3.30 (m) [3.43] 0.03 
 5"ax 4.05 (dd, J5"a,5"b = 12.7 Hz) 4.02 (dd, J5"a,5"b = 12.9 Hz) -0.03 
 5"eq 3.47 (dd, J5"b,5"a = 12.7 Hz) 3.50-3.30 (m) [3.48] 0.01 
 CH3-4" 1.35 (s) 1.35 (s) = 
 NHCH3 2.92 (s) 2.92 (s) = 
Acetyl NH-6' × 8.20 (t)  
 CH3C=O on 6' × 2.03 (s)  
aThe chemical shift were established based on 1H (400 MHz), zTOCSY, and gCOSY NMR. bCould be analogous position of the DOS ring. cMultiplicity 
and J are given in (). dThe numbers in [] were determined from gCOSY. eCould be analogous position of the DOS ring. ×Indicates that the acetyl moiety 










Table 2.9. Proton chemical shifts determined for SIS and 6',2'-di-acetyl-SIS as well as 6',3 or 1-di-acetyl-SIS.a 
Ring H position SIS 6',3 or 1- 
(Δppm) 
6',2'- (Δppm) 
II 1 3.62-3.54b (m)c  [3.57]d [3.53b] (-0.04) [3.45] (-0.12)  
 2ax 2.12 (ddd (app. q), J2ax,2eq = J2ax,1 = J2ax,3 = 12.6 Hz) [1.78] (-0.34) [1.99] (-0.13) 
 2eq 2.58 (ddd (app. dt), J2eq,2ax = 12.6 Hz, J2eq,1 = J2eq,3 = 
4.3 Hz) 
[2.25] (-0.33) [2.59] (-0.01) 
 3 3.62-3.54b (m)  [3.57] [3.99b] (0.42) [3.58] (0.01) 
 4 3.87e (dd (app. t), J4,3 = J4,5 = 9.6 Hz) [3.83e] (-0.03) [3.79] (-0.08) 
 5 4.15 (dd (app. t), J5,4 = J5,6 = 9.6 Hz) [4.12] (-0.03) [4.04] (-0.11) 
 6 3.80e (dd (app. t), J6,1 = J6,5 = 9.6 Hz) [3.76e] (-0.04) [3.80] (0.00) 
I 1' 5.64  (s) [5.54] (-0.10) [5.39] (-0.25) 
 2' 3.96 (d (app. bd), J2',3' = 4.3 Hz) [3.88] (-0.08) [4.26] (0.20) 
 3'ax 2.75 (ddd (app. dt), J 3'ax,3'eq= 18.9 Hz) [2.63] (-0.12) [2.35] (-0.40) 
 3'eq 2.40 (ddd (app. bd), J3'eq,3'ax = 18.9 Hz) [2.33] (-0.07) [2.15] (-0.25) 
 4' 5.21 (t, J4',3' = 3.7 Hz) [4.90] (-0.31) [4.92] (-0.29) 
 6'a 3.70 (d, J6'a,6'b = 14.0 Hz) [3.83] (0.13) [3.81] (0.11) 
 6'b 3.75 (d, J6'b,6'a = 14.0 Hz) [3.83] (0.08) [3.81] (0.06) 
III 1" 5.16 (d, J1",2" = 3.7 Hz)  
 2" 4.24 (dd, J2",1" = 3.7 Hz, J2’',3’' = 10.8 Hz)  
 3" 3.62-3.48 (m) [3.51]  
 5"a 4.03 (d, J5"a,5"b = 12.6 Hz)  
 5"b 3.51 (d, J5"b,5"a = 12.6 Hz)  
 CH3-4" 1.37 (s)  
 NHCH3 2.95 (s)  
Acetyl NH-6' × 8.35 8.27 
 NH-3/1 or NH-2' × 8.21 (NH-3/1) 8.12 (NH-2') 
 CH3C=O on X ×   
 CH3C=O on 6' ×   
aThe chemical shift were established based on 1H (400 MHz), 2D-TOCSY and 2D-COSY NMR. bCould be analogous position of 
the 2-deoxystreptamine (DOS) ring. cMultiplicity and J are given in (). dThe numbers in [] were determined from gCOSY. eCould 








Fig. 2.33. 1H NMR of SIS (9:1/H2O:D2O, pH 8, 25 mM KH2PO4) (400 
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Fig. 2.36. 1H NMR of SIS (9:1/H2O:D2O, pH 3) (400 MHz). The full 
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Fig. 2.39. 1H NMR of 6'-acetyl-SIS Eis reaction mixture (9:1/H2O:D2O, pH 
8, 25 mM KH2PO4) (400 MHz). The full spectrum is shown in panel A and 
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Fig. 2.40. gCOSY of 6'-acetyl-SIS Eis reaction mixture (9:1/H2O:D2O, pH 8, 
25 mM KH2PO4) (400 MHz). The inserts show part of the spectra that is 
obscured in the 1H (top left) and the amide protons coupling to the proton at 





Fig. 2.41. zTOCSY of 6'-acetyl-SIS Eis reaction mixture (9:1/H2O:D2O, pH 
8, 25 mM KH2PO4) (400 MHz). The inserts show part of the spectra that is 
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Fig. 2.42. 1H NMR of a mixture of two di-acetylated SIS products 
(9:1/H2O:D2O, pH 3) (400 MHz). The full spectrum is shown in panel A 
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Fig. 2.43. gCOSY of a mixture of two di-acetylated SIS products 
(9:1/H2O:D2O, pH 3) (400 MHz). The inserts show part of the spectra that 
is obscured in the 1H (top left) and the amide protons coupling to the 







Fig. 2.44. zTOCSY of a mixture of two di-acetylated SIS products 
(9:1/H2O:D2O, pH 3) (400 MHz). 
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Fig. 2.45. 1H NMR of a mixture of two di-acetylated SIS products 
(9:1/H2O:D2O, pH 8) (400 MHz). The full spectrum is shown in panel A 
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Fig. 2.46. gCOSY of a mixture of two di-acetylated SIS products 
(9:1/H2O:D2O, pH 8) (400 MHz). The insert shows part of the spectra that 





Fig. 2.47. zTOCSY of a mixture of two di-acetylated SIS products 
(9:1/H2O:D2O, pH 8) (400 MHz). The insert shows part of the spectra that 
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2.7.1.3.5. Di-acetylation of TOB by Eis and NMR analysis of the 3",6'-di-acetyl-TOB 
product 
To determine which two positions of TOB are acetylated by Eis, the reaction was scaled-
up and designed such that it could be monitored in real time by NMR. To determine 
which modification occurred first, a solution (150 µL) containing TOB (15 mM, 1 eq), 
AcCoA (15 mM, 1 eq), and Eis (~0.02 mg) in Na2HPO4 buffer (25 mM, pH 8.0 adjusted 
at rt) containing 10% D2O was prepared and allowed to proceed until the AcCoA was 
completely consumed as indicated by TLC. 1H, gCOSY, and zTOCSY experiments were 
performed on the reaction solution, applying PURGE solvent suppression 14. This 
reaction was not sequential in nature, yielding a mixture of mono-acetylated products: 3"- 
and 6'-acetyl-TOB (data not shown). After the first equivalent of AcCoA was consumed 
to give a mixture of products and all spectra obtained (not reported), an additional aliquot 
containing AcCoA (1 eq) was added and additional spectra were obtained after 
incubating for 12 h in order confirm that a single di-acetylated product, the 3",6'-di-
acetyl-TOB, had been formed. 
 
To unambiguously establish the two acetylated positions on the TOB scaffold, the NMR 
spectra were compared to those of a standard of pure TOB [15 mM in Na2HPO4 buffer 
(25 mM, pH 8.0 adjusted at rt) containing 10% D2O], which was prepared identically to 
the reaction mixture but omitted AcCoA and Eis (Table 2.10). Proton connectivity of the 
final product was assigned using zTOCSY and gCOSY spectra. Representative spectra 
for 3",6'-di-acetyl-TOB are provided (Figs. 2.51-2.53).Representative spectra of the TOB 











Table 2.10. Proton chemical shifts determined for TOB and 3",6'-di-acetyl-TOB.a 
Ring H position TOB 3",6'-di-acetyl-TOB Δppm 
II 1 3.21-3.11b (m)c [3.18]d [3.38] 0.20 
 2ax 1.68 (ddd (app. q), J2ax,2eq = J2ax,1 = J2ax,3 = 12.7 Hz) [1.85] 0.17 
 2eq 2.29-2.21 (m) [2.27] [2.49] 0.22 
 3 3.43-3.31c (m) [3.34] [3.52] 0.18 
 4 3.72-3.58e (m) [3.63] [3.73] 0.10 
 5 3.80-3.75 (m) [3.77] [3.79] 0.02 
 6 3.72-3.58e (m) [3.70] [3.79] 0.19 
I 1' 5.68 (bs) 5.47 (bs) -0.21 
 2' 3.51-3.46 (m) [3.48] [3.59] 0.11 
 3'a 1.68 (ddd (app. q), J3'a, 3'b = J3'a, 2' = J3'a, 4' = 11.8 Hz) [1.95] 0.27 
 3'b 2.29-2.21 (m) [2.23] [2.26] 0.03 
 4' 3.66-3.58 (m) [3.63] [3.46] -0.17 
 5' 3.96-3.88 (m) [3.90] [3.78] -0.12 
 6'a 3.43-3.31 (m) [3.41] [3.60] 0.19 
 6'b 3.43-3.31 (m) [3.41] [3.60] 0.19 
III 1" 5.11 (bs) 5.06 (bs) -0.05 
 2" 3.86-3.75 (m) [3.83] (m) [3.69] -0.14 
 3" 3.43-3.31 (m) [3.36] (m) [4.09]  0.73 
 4" 3.66-3.58 (m) [3.60] (m) [3.45] -0.15 
 5" 3.96-3.88 (m) [3.93] (m) [3.91] -0.02 
 6"a (m) [3.79] (m) [3.70] -0.09 
 6"b (m) [3.79] (m) [3.70] -0.09 
Acetyl NH-3" × (m) [8.14]   
 NH-6' × (m) [8.11]  
 CH3C=O on 3" × 2.03 (s)  
 CH3C=O on 6' × 1.98 (s)  
aThe chemical shift were established based on 1H (400 MHz), zTOCSY, and gCOSY NMR bCould be analogous position of the DOS ring. cMultiplicity 
and J are given in (). dThe numbers in [] were determined from gCOSY and/or zTOCSY. eCould be analogous position of the DOS ring. ×Indicates that 









Fig. 2.48. 1H NMR of TOB (9:1/H2O:D2O, pH 8, 25 mM KH2PO4) (500 
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Fig. 2.51. 1H NMR of 3'',6'-di-acetyl-TOB Eis reaction mixture 
(9:1/H2O:D2O, pH 8, 25 mM KH2PO4) (500 MHz). The full spectrum is 
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Fig. 2.52. gCOSY of 3'',6'-di-acetyl-TOB Eis reaction mixture 





Fig. 2.53. zTOCSY of 3'',6'-di-acetyl-TOB Eis reaction mixture 
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Unexpected modification of capreomycin by the mycobacterial enzyme Eis 
 
3.1. Abstract 
The enhanced intracellular survival (Eis) protein from Mycobacterium tuberculosis 
(Eis_Mtb), a regio-versatile N-acetyltransferase active towards many aminoglycosides 
(AGs), confers resistance to KAN in some cases of multidrug-resistant-tuberculosis 
(MDR-TB). We assessed the activity of Eis_Mtb, and the homologous Eis from 
Mycobacterium smegmatis (Eis_Msm), against a panel of anti-TB drugs. In addition to 
the AGs previously reported to be acetylated by Eis, both enzymes were capable of 
acetylating capreomycin (CAP) but not the other drugs tested. Modeling studies predicted 
the site of modification to be one of two primary amines located on the β-lysine side-
chain. It was confirmed, with Eis_Mtb, that acetylation occurs on the terminal amine of 
the β-lysine side-chain via NMR spectroscopy. Additionally, MIC studies with CAP 
against several strains of mycobacteria were performed for comparison to reported values 
against susceptible and resistant strains of Mtb, indicating that CAP may be a useful anti-
mycobacterial drug against strains other than Mtb.  
 
3.2. Introduction 
Causing 1.4 million deaths globally in 2010, TB is the second leading pathogen-related 
cause of death, surpassed only by HIV/AIDS. Although worldwide incidences of TB are 
beginning to modestly decline, occurrences of multidrug-resistant TB (MDR-TB) and 
extensively drug-resistant TB (XDR-TB) are increasing rapidly- the former proving fatal 
in more than one-third of the cases. Drug resistance to TB occurs when infected patients 
are treated with the wrong regimen of antibiotics or when the patients fail to complete the 
full course of treatment, which occurs most frequently in areas with sub-standard TB 
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control programs. Bacteria that are resistant to at least isoniazid (INH) and rifampicin, the 
two most powerful first-line treatments for TB, are designated as MDR-TB. Strains of 
Mtb are classified as XDR if they are shown to be resistant to rifampicin and INH, in 
addition to a fluoroquinolone, and at least one of the second-line anti-TB drugs such as 
kanamycin A (KAN), amikacin (AMK), or CAP.  
 
Clinical resistance of Mtb to KAN was shown, in one-third of cases covering a large and 
diverse set of strains, to be the result of mutations in the promoter of the enhanced 
intracellular survival (eis) gene, named for its ability to enhance survival of mycobacteria 
in macrophages.1,2 The mutation causes up-regulation of eis, a gene that encodes for the 
Eis protein. The structural and functional characterization of Eis from Mtb has been the 
goal of many research efforts recently.2-10 Our laboratory has shown that Eis acts as an 
unusually regio-versatile AG acetyltransferase (AAC) in Mtb3 and Msm,11 and it has also 
been shown that Eis is capable of conferring resistance to KAN in the AG-susceptible 
Mtb strain H37Rv.9 Additionally, it was recently reported that Eis from Msm (Eis_Msm) 
and Eis from Mtb (Eis_Mtb) are also capable of acetylating lysine residues of dual-
protein phosphatase 16/mitogen-activated protein kinase phosphatase-7 (DUSP16/MPK-
7).10  
 
Due to the promiscuity of Eis towards a large number of AGs and precedents showing 
that some AACs are capable of acetylating classes of drugs other than AGs, including the 
second-line anti-TB drug ciprofloxacin (CIP) (Fig. 3.1),12 it is plausible that Eis is 
capable of conferring resistance to other anti-TB drugs. CAP (Fig. 3.1), a cyclic peptide 
antibiotic with a β-lysine side-chain, is particularly effective against Mtb. Correlation 
between mutations in the eis promoter and resistance to CAP have been suggested,13 
though similar correlations are lacking with other non-AG anti-TB drugs. 
 
In this study we sought to gain a greater understanding of the potential of Eis to acetylate 
other non-AG anti-TB drugs, with a focus on the second-line drug, CAP. We 
demonstrated that the Eis_Mtb and/or the Eis_Msm are both capable of acetylating CAP 
IA and CAP IB, but neither shows activity against other anti-TB drugs that were 
87 
	  
investigated. The position of acetylation on CAP was confirmed as the terminal amine of 
the β-lysine using Eis_Mtb. 
 
3.3. Results and discussion 
3.3.1. Exploration of anti-TB drugs as potential substrates of Eis 
It has been shown previously that Eis_Mtb and Eis_Msm are both capable of multi-
acetylating AGs, and that a wide range of AGs are substrates for both enzymes, including 
KAN and AMK, two important second-line anti-TB drugs.3,10,11 In addition to acting as 
an AAC against wide panels of AG antibiotics, Eis proteins from Mtb and Msm have 
demonstrated acetylation activity against lysine residues of DUSP16/MPK-7.10 Given the 
substrate promiscuity of Eis, investigation of further possible acetylation targets was 
explored, focusing on anti-TB drugs. CAP was chosen for these experiments because 
aside from its use as a popular second-line anti-TB drug, its structure includes a β-lysine 
side-chain, which could potentially be acetylated. Previous studies have shown that INH 
(Fig. 3.1) becomes acetylated by arylamine N-acetyltransferase 2 on the hydrazide 
functional group, demonstrating its potential for deactivation via acetylation.14,15 
Pyrazinamide (PZA) (Fig. 3.1) was chosen for its structural similarity to INH, allowing 
for the comparison of INH to a similar drug that is not likely to be acetylated. CIP was 
selected since previous studies have identified AACs capable of conferring resistance to 
fluoroquinolones via acetylation.12 Owing to the vast number of AG substrates previously 
identified as substrates for Eis enzymes, streptomycin (STR) (Fig. 3.1), the first AG used 
in anti-TB treatment, was chosen. 
 
 
Fig. 3.1. Structures of anti-TB drugs tested against Eis proteins in this study. CAP = 






















































CAP IA: R = CH2OH








In order to determine whether Eis proteins from Mtb or Msm were capable of deactivating 
any of these anti-TB drugs, CAP, CIP, INH, PZA, and STR were screened using a UV-
Vis spectrophotometric assay. We found that Eis proteins from Mtb and Msm, in the 
cases of CIP, INH, PZA, and STR, did not show any acetylation activity. In the cases of 
STR and PZA, these results are not particularly surprising, given the lack of nucleophilic 
primary amines likely to undergo acetylation.  
 
 
Fig. 3.2. Confirmation of mono-acetylation of CAP by Eis from Mtb and Msm. A. Scheme showing the 
acetylation of CAP by Eis from Mtb, B. TLC showing the mono-acetylation of CAP. C. UV-Vis assay 
confirming the mono-acetylation of CAP by Eis from Mtb and Msm. D. Confirmation of mono-
acetylation by LCMS. E. Michaelis-Menten kinetics of the acetylation of CAP by Eis from Mtb. 
 
We demonstrated using a UV-Vis spectrophotometric assay that Eis_Mtb and Eis_Msm 
are both capable of efficiently acetylating CAP (Figs. 3.2A and 3.2C). In contrast to the 
multiple acetylations carried out by both Eis enzymes on AGs, we confirmed, by TLC 
(Fig. 3.2B) and LCMS (Fig. 3.2D), that both CAP IA and CAP IB were converted to the 
respective mono-acetylated products. Given the ability of Eis to accommodate proteins in 
its substrate-binding site, it is not surprising that a relatively large biomolecule such as 
CAP is a substrate for Eis. CAP is a peptidic molecule, so given the ability of Eis to 
acetylate proteins, it is not surprising it is modified, despite its structure being very 
different from that of AGs. In fact, determination of the kinetic parameters for CAP with 
Eis_Mtb (Fig. 3.2E) indicated that the Km and kcat values were 654 ± 45 µM and 1.25 ± 
















































CAP IA: R = CH2OH
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the AGs studied to date with both Eis_Mtb and Eis_Msm, the kcat and Km were both 
slightly higher than with most AGs.3,10,11 As a result, the catalytic efficiency (kcat/ Km) of 
1911 ± 139 s-1M-1 is equivalent to or greater than many of the AGs previously tested.3,11 
This suggests that while CAP does not have as strong an affinity to the substrate binding 
pocket of Eis, it is still capable of undergoing a particularly facile and efficient 
acetylation, possibly due to Eis’ affinity for the lysine moiety. 
 
3.3.2. Regio-specificity of CAP acetylation by Eis_Mtb 
In order to predict which amine of CAP Eis_Mtb acetylates, molecular modeling studies 
were performed. These studies were performed using Sybyl-X for energy minimization of 
the CAP IB structure and GOLD for docking the energy-minimized molecule into the 
structure of Eis_Mtb (PDB code: 3R1K).3 The resultant binding prediction was used to 
identify the most likely site(s) of modification of CAP IB by Eis_Mtb. The energy-
minimized complex of CAP IB with Eis_Mtb indicated that the large binding pocket of 
Eis_Mtb could accommodate the scaffold of CAP (Fig. 3.3A). CAP is predicted to bind 
in a manner that places both amines of the β-lysine side-chain in proximity of the acetyl 
thioester of AcCoA (Fig. 3.3B). This suggests the potential for multiple acetylations, yet, 
in contrast to the activity of Eis towards most AGs, CAP is only mono-acetylated. (Figs. 
3.2A and 3.2B). The acetylation of the lysine 55 residue in DUSP16/MPK-7 occurs at the 
α-amine or the terminal/ε-amine, with Eis_Msm and Eis_Mtb, respectively.10 Given these 
observations, it was predicted that the terminal amine is favored for acetylation. This 
probability was further enhanced by the supposition that the terminal amine position 
would have increased flexibility and superior nucleophilic behavior, due to lower steric 
hindrance and increased electron density, respectively. 
 
In order to unambiguously establish the specificity of Eis_Mtb towards CAP, 1D- and 
2D-NMR experiments were performed on the Eis_Mtb reaction product for comparison 
to a CAP standard. Tables were constructed to allow for simple side-by-side analysis of 
the chemical shifts of the protons of interest (Table 3.2). Analysis of the Eis_Mtb reaction 
with CAP indicated that the terminal primary amine of the β-lysine side-chain was 
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acetylated, as indicated by a change in the chemical shift of the protons directly adjacent 
to the terminal amine of the β-lysine side-chain. 
 
 
Fig. 3.3. Docking of CAP in the binding pocket of Eis from Mtb showing A. CAP and AcCoA bound to Eis 
from Mtb and B. the potential for acetylation at either amine of the β-lysine side-chain. 
 
A recent systematic review of Mtb mutations that are associated with resistance to CAP, 
as well as KAN and AMK, found that Eis promoter mutations have been reported in as 
many as 9% of CAP-resistant strains.13 The same study suggested that CAP-resistance of 
Mtb may be predicted by concurrent mutations in the rrs gene and eis promoter region, 
suggesting that Eis may have some role in inactivating CAP, although evidence suggests 
that mutations in the eis promoter region alone are insufficient to cause significant levels 
of resistance to CAP in Mtb. Additionally, X-ray crystal structures of CAP with the 70S 
ribosome have indicated that the β-lysine side-chain of CAP does not appear to be crucial 
to its ability to bind to the ribosome,16 implying that acetylation of the β-lysine side-chain 
may not be sufficient to rescue bacteria harboring Eis from the effects of CAP.  
 
3.3.3. MIC values for CAP against various mycobacteria 
To assess the relative susceptibility of mycobacteria to CAP, MIC values were 
determined against Msm str. MC2155 and four additional strains of mycobacteria, 
including M. avium subsp. avium ATCC 25291, M. abscessus ATCC 19977, M. 




general, CAP showed anti-mycobacterial activity in the strains tested, though the MIC for 
M. abscessus was notably higher. This is not surprising based on recent reports of the 
difficulties in treatment of infections caused by M. abscessus.17 MIC values for the other 
four strains, compared to previously reported MIC values18 against wtMtb strains as well 
as those with a combination of 
mutations in rrs or tlyA and the eis 
promoter region or only the eis 
promoter region, suggest that CAP 
could be an equally viable anti-
mycobacterial treatment for those 




We have assessed the potential of Eis proteins from Mtb and Msm to acetylate various 
first- and second-line anti-TB drugs, finding that CAP is the only non-AG drug tested to 
date that is modified by either protein. This finding expands upon our understanding of 
Eis proteins as acetyltransferases, specifically in terms of their ability to modify a broad 
range of small molecules as well as proteins- to date, all known acetylations occur at a 
primary amine. We conclusively confirmed via NMR spectroscopy that CAP is modified 
at the terminal amine of the β-lysine residue, which studies have suggested, may not be 
crucial for binding to the ribosome. In silico assessment of the binding mode of a novel 
peptide scaffold such as CAP with Eis will aid the discovery of novel inhibitors of Eis, an 
emerging strategy for overcoming the resistance conferred by Eis.4,11 Additionally, we 
assessed the MIC values for CAP against several strains of mycobacteria, our results 
suggest that CAP could be used in the treatment of mycobacteria other than Mtb. MIC 
studies of Mtb that have shown A1401G rrs mutations combined with mutations in the 
eis promoter may confer some low level resistance to CAP. These previous studies 
coupled with our current studies suggest the possibility that CAP resistance may in fact 
be mediated or enhanced via acetylation.  
 
Table 3.1. MIC (µg/mL) values for CAP against 
mycobacteria. 
Species MIC  
M. abscessus ATCC 19977 75 
M. avium subsp. avium ATCC 25291 18.8 
M. intracellulare ATCC 13950 9.4 
M. parascrofulaceum ATCC BAA-614 18.8 
M. smegmatis str. MC2155 4.7 
M. tuberculosis (wt) < 4.018 
M. tuberculosis + eis mutation 1-418 
M. tuberculosis + rrs mutation 0.5-3218 
M. tuberculosis + eis + rrs mutations 1-1618 
M. tuberculosis + tylA mutation 0.5-16.018 
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3.5. Materials and methods 
3.5.1. Materials and instrumentation 
The Eis enzymes from Mycobacterium tuberculosis (Eis_Mtb)19 and Mycobacterium 
smegmatis (Eis_Msm)11 were overexpressed and purified as previously described. Acetyl-
CoA (AcCoA), capreomycin (CAP; as a mixture of CAP IA and IB) (Note: If IA or IB 
are not indicated, CAP represents the mixture of both CAP IA and IB), isoniazid (INH), 
pyrazinamide (PZA), streptomycin (STR), ciprofloxacin (CIP), and DTNB were bought 
from Sigma-Aldrich (Milwaukee, WI) (Fig. 3.1). TLCs (Merck, Silica gel 60 F254) were 
visualized using iodine. 1H, gCOSY, gHSQC, and zTOCSY NMR spectra were recorded 
on a Varian 500 MHz equipped with a 3 mm OneProbe. All NMR spectra were recorded 
either in D2O or 9:1/H2O:D2O at pH 8.0. Liquid chromatography-mass spectrometry 
(LCMS) was performed on a Shimadzu LCMS-2019EV equipped with a SPD-20AV UV-
Vis detector and a LC-20AD liquid chromatograph. UV-Vis assays were performed using 
a multimode SpectraMax M5 plate reader and 96-well plates (Fisher Scientific). M. 
avium subsp. avium ATCC 25291, M. abscessus ATCC 19977, M. intracellulare ATCC 
13950, and M. parascrofulaceum ATCC BAA-614 were purchased from the American 
Type Culture Collection (ATCC; Manassas, VA). M. smegmatis str. MC2 155 was a 
generous gift from Dr. Sabine Ehrt (Weill Cornell Medical College). 
 
3.5.2. Determination of Eis_Mtb and Eis_Msm acetylation activity with anti-TB 
drugs by UV-Vis assays 
The acetylation of the anti-TB drugs INH, PZA, STR, CIP, and CAP was explored using 
the previously described Ellman method4,11 monitoring the reaction of CoASH released 
by the Eis enzymes with the Ellman’s reagent (DTNB). Briefly, Eis (from Mtb or Msm, 
0.5 mM) was added to a mixture containing Tris (50 mM, pH 8.0, adjusted at rt), AcCoA 
(500 µM), anti-TB drug (100 µM), and DTNB (2 mM) to initiate reactions (200 µL total 
volume). The reaction progress at 25 °C was monitored at 412 nm (ε412 = 14,150 M-1cm-1) 
by taking measurements every 30 s for 1 h (Fig. 3.2C). 
 
The kinetic parameters (Km and kcat) for CAP were determined as above using varying 
concentrations of CAP (0, 20, 50, 100, 250, 500, 1000, 2000 µM) and AcCoA (500 µM). 
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The first 2-5 min of reactions were used to calculate the initial rates and the data were fit 
to a Michaelis-Menten curve using SigmaPlot 11.0 to determine the Km and kcat values 
(Fig. 3.2E). 
 
3.5.3. TLC and LCMS assays showing the conversion of CAP into mono-acetyl-CAP 
(Ac-CAP) products 
An aliquot (5 µL) of the CAP acetylation reaction used for NMR analysis (10 mM in 
Na2HPO4 buffer (25 mM, pH 8.0 adjusted at rt)) and an aliquot of the CAP standard used 
for NMR analysis (10 mM in D2O) were loaded onto a silica gel TLC plate and eluted in 
a mixture of phenol:H2O:NH4OH/30:10:1. After drying for 2 h, the TLC plate was 
stained for visualization in a sealed chamber containing I2/SiO2 for 8 h (Fig. 3.2B). 
 
To confirm the single N-acetylation of both CAP IA and IB, the masses of the novel 
acetylated CAP were determined using the NMR sample (20 µL) by LCMS in positive 
mode using H2O (0.1% formic acid). The mass spectrum obtained is provided in Fig. 
3.2D. 
 
3.5.4. Molecular modeling of CAP IB with Eis_Mtb 
The CAP IB structure was built with Sybyl-X software and minimized to 0.01 kcal/mol 
by the Powell method, using Gasteiger-Hückel charges and the Tripos force field. The 
protein coordinates (PDB code: 3R1K)19 were downloaded from the Protein Data Bank 
website. With the exception of CoA, the H2O molecules, acetamide, and all other 
substructures were removed from the structure. An acetyl group was added to CoA by 
modifying the natural ligand using Sybyl-X. The surrounding protein residues were then 
kept frozen while the AcCoA was subjected to energy minimization using the Steepest 
Descent method to get rid of steric clashes. Hydrogen atoms were added to the Eis_Mtb-
AcCoA complex and its energy was minimized using the Amber force field with Amber 
charges. The energy-optimized CAP IB was docked into the AG binding site in the 
Eis_Mtb protein using GOLD.20 The parameters were set as the default values for GOLD. 
The maximum distance between hydrogen bond donors and acceptors for hydrogen 
bonding was set to 3.5 Å. After docking, the top three CAP IB conformations were 
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individually merged into the minimized Eis_Mtb-AcCoA complex. To relax the protein 
side chains, the three new Eis_Mtb-AcCoA-CAP IB complexes were subsequently 
subjected to energy minimization using the Amber force field with Amber charges. 
During the energy minimization, the structure of CAP IB and residues within an 8-Å 
radius were allowed to move. The remaining residues were kept frozen in order to reduce 
calculation time. The energy minimization, in all three cases, was performed using the 
Powell method with a 0.05 kcal/mol energy gradient convergence criterion and a distance 
dependent dielectric function. The model of the Eis_Mtb-AcCoA CAP IB complex is 
depicted in Figs. 3.3A and 3.3B. 
 
3.5.5. Acetylation of CAP by Eis_Mtb analyzed by NMR: analysis of the 6'-N-acetyl-
CAP (Ac-CAP) products and comparison to the parent compounds 
To determine which position of CAP becomes acetylated by Eis_Mtb, the reaction was 
performed by monitoring the solution via NMR in a manner that did not require the need 
for purification of the acetylated products. A solution (200 µL) containing CAP (10 mM, 
1 eq), AcCoA (25 mM, 2.5 eq), and Eis_Mtb (5 µM) in Na2HPO4 buffer (25 mM, pH 8.0 
adjusted at rt) containing 10% D2O was prepared and allowed to proceed to completion 
(O/N) at rt. 1H, gCOSY, zTOCSY, and gHSQC NMR experiments were performed on 
the reaction solution, applying PURGE solvent suppression.21 Proton connectivity was 
assigned using zTOCSY and gCOSY spectra. Representative spectra for 6'-N-acetyl-CAP 
products are provided in Figs. 3.8-3.11. (Note: According to standard nomenclature, the 
terminal amine of the β-lysine is notated as the 6'-position, which is indicated on the 
spectra of the appropriate figures.) 
 
To unambiguously establish the position acetylated on CAP, the NMR spectra of the 
product were compared to those of a standard of pure CAP (as a mixture of CAP IA and 
IB) [10 mM in 10% D2O] (Tables 3.2 and 3.3). Representative spectra for the CAP 








Fig. 3.4. 1H of CAP (9:1/H2O:D2O, 25 mM Na2HPO4, pH 8.0) (500 MHz). The full 























































CAP IA: R = CH2OH






































































CAP IA: R = CH2OH



























































CAP IA: R = CH2OH


































































CAP IA: R = CH2OH









Fig. 3.8. 1H of 6'-N-acetyl CAP in 9:1/H2O:D2O (500 MHz). The full spectrum is 










































Ac-CAP IA: R = CH2OH



















































































Ac-CAP IA: R = CH2OH




























































Ac-CAP IA: R = CH2OH














Table 3.2. Proton chemical shifts determined for CAP IA and 6'-N-acetyl-CAP IA (Ac-CAP IA).a 
H position CAP IA 6'-N-acetyl-CAP IA Δppm 
1 4.48-4.41 (m)b [4.44]c 4.41-4.33 (m) [4.38] -0.06 
2a/b 3.75 (m) 3.77-3.70 (m) [3.72] -0.03 
5 5.00 (d, J5,22 = 2.2 Hz) 5.06-4.93 (m) [5.02] 0.02 
11 4.29 (dd, J11,20a = 5.0 Hz, J11,20b = 10.0 Hz) 4.20-4.12 (m) [4.16] -0.13 
14 [4.81]£ [4.83]£ 0.02 
17 8.02 (s) 8.05-7.99 (m)† † 
20a 4.03 (dd, J20a,11 = 5.0 Hz, J20a,20b = 13.7 Hz) 4.03-3.95 (m) [3.97] -0.06 
20b 3.17 (dd, J20b,11 = 10.0 Hz, J20b,20a = 13.7 Hz) 3.22-3.09 (m) [3.13] -0.04 
21 3.86-3.81 (m) [3.85] 3.85-3.81 (m) [3.84] -0.01 
22 4.48-4.41 (m) [4.46] 4.42-4.33 (m) [4.38] -0.08 
23a 2.07 (ddd (app. dq), J23a,22 = 5.3 Hz, J22,23b = J22,24 = 13.7 Hz) 2.07-1.98 (m) [2.06] -0.01 
23b 1.75-1.65 (m) [1.69] 1.73-1.54 (m) [1.69] = 
24 3.34-3.28 (m) [3.31] 3.36-3.22 (m) [3.31] = 
2'a 2.78 (dd (app. t), J2'a,2'b = 16.2 Hz, J2'a,3' = 15.0 Hz) 2.79-2.60 (m) [2.73] -0.05 
2'b 2.68 (dd, J2'b,2'a = 16.2 Hz, J2'b,3' = 8.2 Hz) 2.79-2.60 (m) [2.65] -0.03 
3' 3.70-3.63 (m) [3.66]  3.68-3.60 (m) [3.64] -0.02 
4' 1.84-1.75 (m) [1.80] 1.73-1.55 (m) [1.70] -0.10 
5' 1.84-1.75 (m) [1.80] 1.73-1.55 (m) [1.60] -0.20 
6' 3.07-3.02 (m) [3.05] 3.36-3.10 (m) [3.19] 0.14 
NH-6' × 8.06-7.99 (m) [8.03]  
CH3C=O on 6' × 1.97 (s)  
aThe chemical shift values were established based on 1H (500 MHz), zTOCSY, and gCOSY NMR. bMultiplicity and J are 
given in (). cThe numbers in [] were determined from gCOSY and zTOCSY. ×Indicates that acetyl moiety is not present in 































































Ac-CAP IA: R = CH2OH








Table 3.3. Proton chemical shifts determined for CAP IB and 6'-N-acetyl-CAP IB (Ac-CAP IB).a 
H position CAP IA 6'-N-acetyl-CAP IA Δppm 
1 4.48-4.41 (m)b [4.42]c 4.41-4.33 (m) [4.36] -0.06 
2a 3.86-3.81 (m) [3.83] 3.88-3.79 (m) [3.84] 0.01 
2b 3.70-3.63 (m) [3.68] 3.68-3.60 (m) [3.61] -0.07 
5 4.97 (d, J5,22 = 2.5 Hz) 5.06-4.93 (m) [4.94] -0.03 
11 4.24 (dd, J11,20a = 8.1 Hz, J11,20b = 5.0 Hz) 4.20-4.12 (m) [4.14] -0.10 
14 4.64 (q, J14,21 = 7.3 Hz) 4.67-4.62 (m) [4.64] = 
17 8.01 (s) 8.05-7.99 (m)† † 
20a 4.06 (dd, J20a,11 = 5.0 Hz, J20a,20b = 13.7 Hz) 4.03-3.95 (m) [3.97] -0.09 
20b 3.24 (dd, J20b,11 = 8.1 Hz, J20b,20a = 13.7 Hz) 3.22-3.09 (m) [3.17] -0.07 
21 1.40 (d, J21,14 = 7.3 Hz)  1.39 (d, J21,14 = 7.2 Hz) -0.01 
22 4.39 (dd, J22,5 = 2.5 Hz, J22,23a = 5.3 Hz, J22,23b = 8.1 Hz) 4.42-4.33 (m) [4.34] -0.05 
23a 2.07 (ddd (app. dq), J23a,22 = 5.3 Hz, J22,23b = J22,24 = 13.7 Hz) 2.07-1.98 (m) [2.06] -0.01 
23b 1.75-1.65 (m) [1.69] 1.73-1.54 (m) [1.69] = 
24 3.34-3.28 (m) [3.31] 3.36-3.22 (m) [3.31] = 
2'a 2.77 (dd (app. t), J2'a,2'b = 16.2 Hz, J2'a,3' = 15.0 Hz) 2.79-2.60 (m) [2.73] -0.04 
2'b 2.68 (dd, J2'b,2'a = 16.2 Hz, J2'b,3' = 8.2 Hz) 2.79-2.60 (m) [2.65] -0.03 
3' 3.70-3.63 (m) [3.66] 3.68-3.60 (m) [3.64] -0.02 
4' 1.84-1.75 (m) [1.80] 1.73-1.55 (m) [1.70] -0.10 
5' 1.84-1.75 (m) [1.80] 1.73-1.55 (m) [1.60] -0.20 
6' 3.07-3.02 (m) [3.05] 3.36-3.10 (m) [3.19] 0.14 
NH-6' × 8.06-7.99 (m) [8.03]  
CH3C=O on 6' × 1.97 (s)  
aThe chemical shift values were established based on 1H (500 MHz), zTOCSY, and gCOSY NMR. bMultiplicity and J are 
given in (). cThe numbers in [] were determined from gCOSY and zTOCSY. ×Indicates that acetyl moiety is not present in 
the molecule. †No correlation in spectra so specific chemical shift undetermined. 
 
3.5.6. Determination of the MIC values for CAP against various mycobacteria 
MIC experiments were performed against a variety of mycobacteria, using the double 
dilution method. Compounds were added to 7H9 media containing ADC supplement. M. 
avium subsp. avium ATCC 25291, M. abscessus ATCC 19977, M. intracellulare ATCC 
13950, and M. parascrofulaceum ATCC BAA-614 were grown for 6 days before MIC 
readings were taken, while M. smegmatis readings were taken 1-3 days after dilution. 
Concentrations of CAP tested ranged from 150 mg/mL to 0.3 mg/mL. All experiments 
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Towards the development of novel aminoglycosides via chemical modification of 
known aminoglycosides 
 
4.1. Abstract  
Despite issues with toxicity and resistance, aminoglycosides (AGs) have remained an 
effective and widely used class of antibacterials since their discovery. Efforts to 
synthesize novel AGs that overcome some of the problems with this class of compounds, 
including their toxicity and bacterial resistance, have been a major focus research efforts 
for decades. 1-N-acylation has proved to be one of the most successful strategies for 
improving the overall properties of AGs, including their ability to avoid certain resistance 
mechanisms. More recently, 6'-N-acylation arose as another possible strategy, leading us 
to question what other positions could be modified and what types of acyl groups will 
lead to increased activity of AGs. In this study we report on the progress of strategies to 
generate novel AGs with improved activity and the ability to avoid resistance. Also we 
report progress towards the synthesis of AGs with the most reactive amines protected, for 
future use in the synthesis of AGs acylated at positions previously difficult to selective 
access in a short number of steps. 
 
4.2. Introduction  
AGs are a potent class of natural product antibacterial agents that are effective in the 
treatment of many Gram-positive and Gram-negative antibacterial infections, including 
those that accompany other diseases such as cancer and HIV.1,2 The synthesis of complex 
carbohydrates like AGs, which are comprised of as few as two or as many as five 
aminosugars, and in some cases, ribose, is often a daunting task, and their total synthesis 
from basic chemical building blocks is rarely an efficient means of developing novel, 
effective compounds. Additionally, the numerous protecting group manipulations 
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required to selectively modify known AGs in a predictable manner is also quite difficult 
owing to the large number of amine and hydroxyl groups with similar reactivity.3-10	  In 
most cases, the overall yields of syntheses are rather low, requiring large quantities of 
starting material and many steps to achieve a single product. 
 
The manifestation of a number of resistance mechanisms that reduce the efficacy of AGs 
is another obstacle in the development of novel AGs. Some mechanisms, such as the 
increased efflux or decreased uptake of AGs by bacterial cells1,11-19 and modifications of 
the ribosome,20-23 are generally effective against most AGs, because they reduce the 
intracellular concentration of AGs or modify the binding site common to most AGs, 
respectively. In these cases, modifying the AG scaffold may not provide any benefit. 
However, AG-modifying enzymes (AMEs), which covalently modify AGs leading to 
decreased affinity for the ribosome, are the most common mechanism of resistance and 
tend to be more specific towards particular AGs.24-29	  The activity of AMEs may, in fact, 
be circumvented by small manipulations of the scaffolds of known AGs to yield products 
that retain their activity against bacteria but are no longer modified by AMEs. The 
development of semi-synthetic AGs has proven a successful strategy in overcoming, to 
some extent, the AG resistance problem.30-37	  In particular, the incorporation of a γ-amino-
β-hydroxybutyric acid (AHB), exemplified by plazomicin (PZN),36,37 or glycinyl group to 
the scaffold of known AGs has been one successful strategy used to circumvent AMEs 
while retaining or improving upon their antibacterial properties.30 Herein, we report 
progress towards the development of strategies to further expand our ability to access 
novel AGs through facile synthetic methods.3-5,10,38 
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4.3. Results and discussion  
A series of 6'-N-glycinyl compounds (9-13) (Fig. 4.3) were prepared using an activated 
ester in the form of O-azidoacetyl-N-hydroxysuccinimide (1) to selectively append an 
α-zidoacetyl group. Compound 1 was prepared via the DCC mediated coupling of α-
azidoacetic acid and N-hydroxysuccinimide in THF (Fig. 4.2).  
 
 
Fig. 4.2. Synthesis of coupling reagents (1-3) used in this study. 
 
The reaction of tobramycin (TOB), kanamycin A (KAN), amikacin (AMK), sisomicin 
(SIS), or netilmicin (NET) with 1 using potassium carbonate as base in a 1:1 mixture of 
H2O and MeOH afforded the 6'-N-azidoacetyl compounds (4-8) in yields ranging from 
26-60% after purification by SiO2 flash chromatography. The 6'-N-azidoacetyl compound 
was the primary product in each of the reactions (Fig. 4.3A) and was in each case isolable 
as pure compound for use in the following steps. Some side-products were present, such 
as di-N-azidoacetyl as well as a mixture of other mono-N-azidoacetyl (i.e. 6'-, 3-, or 1-N-
azidoacetyl), but isolation of these compounds revealed that the other compounds were 
purified as mixtures of various side products. The 6'-N-azidoacetyl compounds were all 
isolated as single spots on TLC and used directly in the following step. In the case of 
AMK, the acylation reaction occurred at a relatively equal rate at the 6'-amine and 
terminal amine of the AHB. For this reason, 6 was prepared in the same fashion as all 
other 6'-N-azidoacetyl compounds but with an additional molar equivalent of the 



























































Fig. 4.3. A. Representative synthetic scheme illustrating the preparation of the 6'-N-
azidoacetyl compounds (4-8). B. Representative synthetic scheme illustrating the 
conversion of 6'-N-azidoacetyl compounds 4-6 to the respective 6'-N-glycinyl compounds 
9-11 by catalytic hydrogenation. C. Representative synthetic scheme illustrating the 
conversion of 6'-N-azidoacetyl compounds 7 and 8 to the respective 6'-N-glycinyl 
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For compounds 4-6, the azide functionalities were then converted to the free amines to 
yield afford compounds 9-11 via catalytic hydrogenation (Fig. 4.3B), and, after removal 
of the catalyst by filtration through Celite, no further purification was necessary. The 
synthetic strategy and purification were adapted from a previously reported method that 
takes advantage of the increased nucleophilicity of the 6'-amine to selectively acylate that 
position, without additional acylation at the other primary amines.30 
 
6'-N-azidoacetyl compounds 7 and 8 both contain an alkene that is not compatible with 
catalytic hydrogenation, and for that reason they were converted to the repective 6'-N-
glycinyl compounds using a Staudinger reaction. Treatment of compound 7 and 8 with 
trimethyl phospine in a 1:1 mixture of aqueous NaOH (1 mM) and THF yielded 
compounds 12 and 13, respectively (Fig. 4.3C).  
 
The synthesis and antibacterial testing of 6'-N-glycinyl-TOB (9) was previously 
reported,30 but we report a slightly modified method that improved yield, achieved by 
slower addition of the acylating reagent and use of an adjusted solvent gradient during the 
purification process. Previous reports have indicated that 9 demonstrates potent 
antibacterial activity against a number of bacterial strains,30 including those that express 
AMEs that are capable of conferring resistance to the parent compound. It was shown 
that the ability of AAC(3) and AAC(6') to modify and deactivate TOB was reduced 
significantly by the incorporation of a 6'-N-glycinyl moiety. Interestingly, this same trend 
was not observed with the compound in this study- TOB was more effective or equally as 
ineffective against all strains tested compared to 9 (Tables 4.1-4.3). One possible 
explanation for this is the formulation of the compound used in MIC testing- previous 
studies used a sulfate salt generated at pH 3, whereas the compound was used in MIC 
testing in its free-base form (~pH 8). Contamination of the sample was unlikely to be a 
factor as they were otherwise prepared in an identical fashion. In this study, compound 9 
did show some antibacterial activity, but in each case, the parent compound, TOB, was 




MIC values for 10 against all strains were all poor and no improvement compared to 
KAN was observed (Tables 4.1-4.3). The same was true of compound 11, which showed 
poor activity against all strains (Tables 4.1-4.3). These results suggest that in the case of 
KAN, the 6'-amine is likely crucial to antibacterial activity, and therefore, its affinity for 
the ribosome target. The same is true of the combination of the 6'-amine and terminal 
amine of AHB from AMK. The syntheses of mono-glycinyl-AMK derivatives were 
attempted using chelation control with zinc acetate and by selectively protecting the AHB 
amine with a Cbz group followed by selective acylation of the 6'-amine. These strategies 
did not lead to the desired products, possibly because protection of the 6'-amine interferes 
with the chelation. Further efforts to identify other possible methods of chelation and or 
variations on the protecting groups will be pursued.  
 
The best compounds, in terms of MIC values, were compounds 12 and 13, 6'-N-glycinyl-
SIS and -NET derivatives, respectively (Tables 4.1-4.3). SIS and NET both showed the 
overall best antibacterial activity in these studies, so it is not necessarily surprising that 
this was the case. However, compounds 12 and 13 were, in all cases, inferior to the parent 




Table 4.1. Antibacterial activity of AGs against Gram-negative bacteria: MIC values (µg/mL) determined by double dilution. 
CPD A B C D E F G H I J K 
KAN >150 >150 9.4 4.7 4.7 150 >150 2.3 >150 >150 >150 
10 >150 >150 150 75 150 >150 >150 150 >150 >150 >150 
AMK 37.5 75 9.4 4.7 9.4 >150 75 2.3 150 75 75 
11 >150 >150 >150 >150 >150 >150 >150 >150 >150 >150 >150 
17 >150 >150 >150 >150 >150 >150 >150 >150 >150 >150 >150 
18 >150 >150 >150 37.5 >150 >150 >150 75 >150 >150 >150 
TOB 9.4 9.4 9.4 4.7 2.3 75 >150 1.2 >150 >150 >150 
9 75 150 18.8 18.8 18.8 >150 >150 37.5 >150 >150 >150 
19 >150 >150 150 37.5 150 >150 >150 75 >150 >150 >150 
NET 4.7 9.5 4.7 1.2 2.3 37.5 >150 0.6 4.7 >150 >150 
13 37.5 159 75 9.4 18.8 >150 >150 4.7 37.5 >150 >150 
SIS 4.7 9.4 9.4 2.3 2.3 37.5 >150 0.6 4.7 >150 >150 
12 37.5 150 75 9.4 18.8 >150 >150 9.4 37.5 >150 >150 
A. B. subtilis 168, B. B. subtilis 168 with pBF16 harboring AAC(6')/APH(2''), C. B. cereus ATCC 17788, D. B. anthtacis str. Sterne, 
E. L. monocytogenes ATCC 19115, F. E. faecalis ATCC 29212, G. E. faecium BM4105-RF, H. S. aureus ATCC 29213, I. MRSA, J. 









Table 4.2. Antibacterial activity of AGs against Gram-positive bacteria: MIC values (µg/mL) determined by double dilution. 
CPD L M N O P Q R S T U V W 
KAN >150 >150 >150 >150 37.5 9.4 37.5 150 >150 37.5 >150 >150 
10 >150 >150 >150 >150 >150 150 >150 >150 >150 150 >150 >150 
AMK 150 75 75 75 37.5 37.5 2.3 4.7 37.5 9.4 18.8 4.7 
11 >150 >150 >150 >150 >150 >150 >150 150 >150 >150 >150 >150 
17 >150 >150 >150 >150 >150 >150 >150 >150 >150 >150 >150 >150 
18 >150 >150 >150 >150 >150 >150 150 150 >150 >150 >150 >150 
TOB 150 150 9.4 9.4 9.4 4.7 0.6 X 4.7 4.7 9.4 4.7 
9 >150 >150 150 150 75 75 18.8 X >150 75 150 37.5 
19 >150 >150 >150 >150 >150 >150 75 X >150 >150 >150 >150 
NET 37.5 150 9.4 4.7 9.4 2.3 2.3 2.3 9.4 4.7 2.3 2.3 
13 150 >150 150 75 75 37.5 37.5 75 150 75 >150 37.5 
SIS 75 75 9.4 9.4 9.4 4.7 1.2 2.3 9.4 4.7 9.4 4.7 
12 >150 >150 150 75 75 37.5 18.8 37.5 150 75 >150 37.5 
L. E. coli BL21 (DE3) with pET22b harboring AAC(6')/APH(2''), M. E. coli BL21 (DE3) with pET19b-pps harboring AAC(3)-IV, N. 
E. coli BL21 (DE3) with pET28a harboring Eis, O. E. coli BL21 (DE3) with pET22b, P. E. coli MC1061, Q. H. influenzae ATCC 
51907, R. P. aeruginosa PA01, S. P. aeruginosa PA14, T. S. enterica ATCC 14028, U. K. pneumoniae ATCC 27736, V. A. 





Table 4.3. Antibacterial activity of AGs against various 
mycobacteria: MIC values (µg/mL) determined by double 
dilution. 
CPD X Y Z AA AB 
KAN 0.3 >150 >150 >150 9.4 
10 4.7 >150 >150 >150 >150 
AMK <0.3 150 9.4 2.3 4.7 
11 37.5 >150 >150 >150 >150 
17 18.8 >150 >150 >150 >150 
18 4.7 >150 >150 75 >150 
TOB 0.3 >150 150 2.3 9.4 
9 2.3 >150 >150 9.4 >150 
19 9.4 >150 >150 >150 >150 
NET 0.3 37.5 2.3 >150 18.8 
13 2.3 >150 18.8 >150 >150 
SIS 2.3 18.8 4.7 >150 9.4 
12 4.7 >150 18.8 >150 >150 
X. M. smegmatis str. MC2 155, Y. M. abscessus ATCC 19977, Z. 
M. parascrofulaceum ATCC BAA-614, AA. M. intracellulare 





Fig. 4.4. A. Representative synthetic scheme illustrating the preparation of the 6'- 
and di-N-(CbzAHB) compounds (14-16) from TOB or KAN. B. Representative 
synthetic scheme illustrating the conversion of 6'- and di-N-(CbzAHB) 
compounds 14-16 to the respective 6'- and di-N-(CbzAHB) compounds 17-19 by 
catalytic hydrogenation. 
 
Since the incorporation of an AHB group has proven a successful strategy in the 
development of novel AGs, attempts to expand the current methodology to selectively 
incorporate the AHB group at the N-1 position of TOB were attempted. Similar reaction 
conditions, in which 1 was replaced by O-γ-benzyloxycarbonylamino-α-
hydroxybutyrate-N-hydroxysuccinimide (2), were used in our attempts to prepare 
compounds with an AHB group at the N-1 position. The use of chelation with zinc di-
acetate has been shown to work well to incorporate protecting groups with KAN. 
However, attempts to use the same strategy starting from TOB under several conditions 
proved unsuccessful, as our attempts led only to a mixture of products. However, the 
reaction of TOB with 2, using potassium carbonate as base in a 1:1 mixture of H2O and 
MeOH, afforded compound 14 (Fig. 4.4A). Two additional N-(CbzAHB) derivatives, 
compounds 15 and 16 (Fig. 4.4A), were synthesized. Catalytic hydrogenation of 
compounds 14-16 (Fig. 4.4B) provided the respective N-AHB products, 17-19, which 
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moiety showed improved activity against any of the bacterial strains tested compared to 
their respective parent compounds.  
 
 
Fig. 4.5. Representative synthetic scheme illustrating the preparation of the N-
Cbz compounds (20-22). 
 
We have shown that it is possible to acylate, for example, the 3-N and retain activity 
against some bacteria39 while in other cases it deleterious to antibacterial activity.40 
Therefore, the selective protection of the most nucleophilic groups (i.e. 6'- and AHB-
amine) of AGs to generate compounds for use in the synthesis of novel AGs that are 
modified at positions that are typically more difficult to selectively modify is a strategy 
that could potentially yield compounds with antibacterial activity. Towards this end, a 
method for the selective Cbz-protection of AGs at the 6'- and AHB-amine was developed 
(Fig 4.5). O-Cbz-N-hydroxyphthalimide (3) was synthesized from N-hydroxyphthalimide 
and benzylchloroformate using Et3N as a base in dichloromethane for use as the acylating 
reagent (Fig. 4.2). Compounds 20-22 were prepared from the reaction of the respective 
parent AG and 3, using potassium carbonate as base in a 1:1 mixture of H2O and MeOH 
(Fig. 4.5). These compounds were synthesized in order to provide a starting material for 
reactions that had the most reactive amine protected. We attempted syntheses using 
chelation control and without chelation, in an attempt to eventually generate compounds 
with mono- and di-acylations (glycinyl or AHB) at positions not generally accessible 
through concise synthetic routes. Unfortunately, the use of these compounds as starting 
materials did not yield novel AGs with the desired selectivity, giving, in all cases after 
purification, complex mixtures of compounds. Further experiments are necessary to 
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4.4. Conclusions  
Two series of novel N-acylated AGs were synthesized and tested against a large panel of 
Gram-positive and Gram-negative bacterial strains as well as several strains of 
mycobacteria. The determination of the MIC values of the compounds indicated that 
most of the synthetically modified AGs were inferior to their parent AG compounds. 
Interestingly, these results were not in agreement with previous reports of the activity of 
9. One possible reason for this is the formulation of the compounds for testing, which 
varied between studies. The compounds tested in this studied were utilized in their free 
base form, whereas previous studies employed compounds as sulfate salts that had been 
adjusted to pH 3 or lower prior to determination of the MIC values. The compounds 
reported herein will be reformulated for further investigation of this possibility. 
Additionally, a series of AGs that were Cbz-protected at the most reactive amine of each 
respective compound were synthesized, for use in the generation of further series of 
compounds modified at positions other than the 6'- or AHB-amines. However, results 
with this strategy were poor and further work will be necessary to accomplish a short, 
efficient method for generation of further N-glycinyl and N-AHB AGs. 
 
4.5. Materials and instrumentation 
The AGs AMK, KAN, and SIS were purchased from Sigma-Aldrich (Milwaukee, WI) 
(Fig. 4.1). The AGs NET and TOB were purchased from AK Scientific (Mountain View, 
CA) (Fig. 4.1). TLCs (Merck, Silica gel 60 F254) were visualized using a cerium-
molybdate stain ((NH4)2Ce(NO3)6 (5 g), (NH4)6Mo7O24•4H4O (120 g), H2SO4 (80 mL), 
H2O (720 mL)). Synthetic products were purified by SiO2 flash chromatography 
(Dynamic Absorbents 32-63 m). 1H, 13C, gCOSY, gHMBC, gHSQC, and zTOCSY NMR 
spectra were recorded either on a Varian 400 MHz equipped with a 5 mm OneProbe or a 
Varian 500 MHz equipped with a 3 mm OneProbe. Liquid chromatography-mass 
spectrometry (LCMS) was performed on a Shimadzu LCMS-2019EV equipped with a 
SPD-20AV UV-Vis detector and a LC-20AD liquid chromatograph. O-azidoacetyl-N-
hydroxysuccinimide (1)37 and N-hydroxysuccinimide ester of γ-
benzyloxycarbonylamino-α-hydroxybutyric acid (2) were prepared in the manner 





4.6.1.1. Preparation of coupling reagents 
O-azidoacetyl-N-hydroxysuccinimide (1). Azidoacetic acid (2.53 g, 25 
mmol) was dissolved in THF (20 mL) and cooled to 0 °C. N-
hydroxysuccinimide (2.88 g, 25 mmol) was added to the solution and stirred 
for 10 min.  DCC (5.16 g, 25 mmol) was dissolved in THF (15 mL) and added dropwise 
over 10 min, and the reaction was allowed to stir at 0 °C for 4 h. The mixture was 
vacuum filtered and the filtrate was added Et2O and stored at 4 °C overnight to form 
white crystals, which were then filtered, rinsed with Et2O (30 mL), and dried under 
vacuum to yield 1 as a white crystalline solid (4.08 g, 82%). Characterization of the 




hydroxybutyric acid (2.53 g, 10 mmol, 1 eq) was dissolved in 
EtOAc (80 mL) and cooled to 0 °C. N-hydroxysuccinimide (1.15 g, 10 mmol, 1 eq) was 
added to the solution and stirred for 10 min. DCC (2.07 g, 10 mmol, 1 eq) was dissolved 
in EtOAc (20 mL) and added dropwise over 10 min, and the reaction was allowed to 
warm to rt while stirring for 8 h. The mixture was vacuum filtered to remove the urea and 
the solvent removed under reduced pressure to give 2 (3.33 g, 95%). The resulting white 
solid was used without further purification. 1H NMR (400 MHz, CDCl3) δ 7.40-7.30 (m, 
5H), 5.15 (d, J = 12.1 Hz, 1H), 5.06 (d, J = 12.1 Hz, 1H), 3.65-3.53 (m, 1H), 3.44 (ddd 
(app. dq), J = 14.6, 5.7 Hz, 1H), 2.89-2.60 (m, 4H), 2.33-2.10 (m, 2H). 
 
O-Cbz-N-hydroxyphthalimide (3). N-hydroxyphthalimide (4.90 
g, 30 mmol, 1eq) was dissolved in CH2Cl2 (45 mL) and Et3N (4.18 
mL, 30 mmol, 1 eq) was added at rt before cooling the solution to 0 
ºC. Benzylchloroformate (4.45 mL, 30 mmol, 1 eq) was added dropwise to the stirring 
solution over 5 min. The reaction was allowed to warm to rt while stirring O/N (16 h). 
























chromatography (CH2Cl2:MeOH/98:2, Rf = 0.29) to yield the product as a white solid 
(8.2 g, 92%). 1H NMR (400 MHz, CDCl3) δ 7.82 (dd, J1 = 5.4, J2 = 3.1 Hz, 2H), 7.74 
(dd, J1 = 5.5, J2 = 3.1 Hz, 2H), 7.57-7.53 (m, 2H), 7.41-7.37 (m, 3H), 5.23 (s, 2H). 
 
4.6.1.2. General procedure for preparation of N-azidoacetyl compounds 
6'-N-azidoacetyl-TOB (4). TOB (468 mg, 1.0 mmol, 1 eq) 
and K2CO3 (276 mg, 2.0 mmol, 2 eq) were dissolved in 
MeOH:H2O/1:1 (5 mL) and O-azidoacetyl-N-
hydroxysuccinimide (1) (297 mg, 1.5 mmol, 1.5 eq) was 
added in three equal portions at least 2 h apart. The progress 
of the reaction was monitored by TLC (MeOH:NH4OH/4:1), while stirring at rt. After 20 
h, the reaction was complete. The mixture was concentrated under reduced pressure and 
purified by SiO2 flash chromatography, eluting with MeOH and a gradient of Et3N (0-2%) 
(Rf = 0.78 in MeOH:NH4OH/3:2). TLC was used to determine the fractions containing 
the product, which were then concentrated under reduced pressure. The residue was 
dissolved in a minimal volume of H2O and lyophilized to provide the pure product, 4, as 
white powder (348 mg, 63%). The product was a single spot by TLC and was used as 
directly in the following step without further characterization. NMR of the corresponding 
final product (9) is reported in Section 4.6.1.4. 
 
6'-N-azidoacetyl-KAN (5). 5 was prepared as described for 4. 
The reaction of KAN (1.75 g, 3.0 mmol, 1 eq), K2CO3 (830 
mg, 6.0 mmol, 2 eq), and O-azidoacetyl-N-
hydroxysuccinimide (1) (890 mg, 4.5 mmol, 1.5 eq) in 
MeOH:H2O/1:1 (16 mL) yielded, after SiO2 flash 
chromatography eluting with MeOH and a gradient of Et3N (0-2%), 5 (937 mg, 55%), as 
a white powder (Rf = 0.67 in MeOH:NH4OH/3:2). The product was a single spot by TLC 
and was used as directly in the following step without further characterization. NMR of 




































6',AHB-di-N-azidoacetyl-AMK (6). 6 was prepared 
as described for 4. The reaction of AMK (469 mg, 
0.6 mmol, 1 eq), K2CO3 (166 mg, 1.2 mmol, 2 eq), 
and O-azidoacetyl-N-hydroxysuccinimide (1) (297 
mg, 1.5 mmol, 2.5 eq) in MeOH:H2O/1:1 (8 mL) 
yielded the product 6 (110 mg, 26%) as a white powder (Rf = 0.53 in MeOH:NH4OH/3:2), 
after SiO2 flash chromatography eluting with MeOH and a gradient of Et3N (0-2%). The 
product was a single spot by TLC and was used as directly in the following step without 
further characterization. NMR of the corresponding final product (11) is reported in 
Section 4.6.1.4. 
 
6'-N-azidoacetyl-SIS (7). 7 was prepared as described for 4. The 
reaction of SIS (140 mg, 0.20 mmol, 1 eq), K2CO3 (55 mg, 0.4 mmol, 
2 eq), and O-azidoacetyl-N-hydroxysuccinimide (1) (59 mg, 0.3 mmol, 
1.5 eq) in MeOH:H2O/1:1 (2 mL) yielded, after SiO2 flash 
chromatography eluting with MeOH and a gradient of Et3N (0-2%), 7 
(42 mg, 40%) as a white powder (Rf = 0.42 in MeOH:NH4OH/4:1). 
The product was a single spot by TLC and was used as directly in the following step 
without further characterization. NMR of the corresponding final product (12) is reported 
in Section 4.6.1.4. 
 
6'-N-azidoacetyl-NET (8). 8 was prepared as described for 4. The 
reaction of NET (100 mg, 0.14 mmol, 1 eq), K2CO3 (39 mg, 0.28 
mmol, 2 eq), and O-azidoacetyl-N-hydroxysuccinimide (1) (42 mg, 
0.21 mmol, 1.5 eq) in MeOH:H2O/1:1 (2 mL) yielded, after SiO2 
flash chromatography eluting with MeOH and a gradient of Et3N 
(0-2%), 8 (45 mg, 57%) as a white powder (Rf = 0.50 in 
MeOH:NH4OH/4:1). The product was a single spot by TLC and was used as directly in 
the following step without further characterization. NMR of the corresponding final 



















































4.6.1.3. General procedure for preparation of N-γ-benzyloxycarbonylamino-α-
hydroxybutyric acid (N-(CbzAHB)) compounds 
6'-N-(CbzAHB)-TOB (14). TOB (234 mg, 0.5 mmol, 1 eq) 
and Zn(OAc)2 (110 mg, 0.6 mmol, 1.2 eq) were dissolved in 
DMF:H2O/5:1 (3 mL) and the mixture was stirred at rt for 16 
h. 3 (175 mg, 0.5 mmol, 1 eq) was added to the reaction 
mixture which was stirred for an additional 24 h. The reaction 
mixture was concentrated under reduced pressure and the residue was purified by SiO2 
flash chromatography, eluting with MeOH and a gradient of Et3N (0-2%). Fractions with 
the product were pooled and concentrated under reduced pressure. The residue was 
dissolved in minimal volume of H2O, flash frozen, and lyophilized to give the product 
(108 mg, 31%, Rf = 0.61 in MeOH:NH4OH/3:2) as a white powder. The product was a 
single spot by TLC and was used as directly in the following step without further 
characterization. NMR of the corresponding final product (17) is reported in Section 
4.6.1.4. 
 
6'-N-(CbzAHB)-KAN (15) and 
6',1-N-di-(AHB)-KAN (16). 
Both compounds were prepared 
in the same manner as 14. The 
reaction of KAN (291 mg, 0.5 
mmol, 1 eq), Zn(OAc)2 (110 mg, 0.6 mmol, 1.2 eq) and 3 (350 mg, 1.0 mmol, 2 eq) in 
DMF:H2O/5:1 (4 mL). (Note: The equivalents of acylating reagent were increased to 
generate both the mono- and di-N-(CbzAHB) KAN products.) Purification by SiO2 flash 
chromatography, eluting with MeOH and a gradient of Et3N (0-2%), yielded 15 (42 mg, 
12%, Rf = 0.32 in MeOH:NH4OH/3:2) and 16 (75 mg, 16%, Rf = 0.55 in 
MeOH:NH4OH/3:2). The product was a single spot by TLC and was used as directly in 
the following step without further characterization. NMR of the corresponding final 



























































4.6.1.4. General procedure for hydrogenation reactions 
6'-N-glycinyl-TOB (9). 4 (730 mg, 1.33 mmol) was 
thoroughly dissolved in MeOH:H2O/1:1 (4 mL) and 
hydrogenated using H2 and 10% Pd/C (100 mg) at rt for 4 h. 
The resulting mixture was monitored for completion by TLC 
and upon completion was filtered through Celite and 
concentrated under reduced pressure with gentle heating. The residue was dissolved in 
minimal volume of H2O and lyophilized to generate the pure product 9 (665 mg, 96%, Rf 
= 0.62 in MeOH:NH4OH/3:2) as a white powder. (Note: This procedure described above 
was used in each case to convert the N3 and/or the NHCbz into NH2.) 1H NMR 
(H2O:D2O/9:1, 400 MHz) δ 3.90-3.74 (m, 2H, CH2 of Gly), Ring I: 5.58 (d, J = 3.2 Hz, 
1H, H1), 4.05-3.90 (m, 1H, H5), 3.73-3.47 (m, 4H, H6a, H6a, H2, and H4), 2.57 (ddd 
(app. dt), J1 = 12.2, J2 = 4.1 Hz, 1H, H3a), 2.03 (m, 1H, H3b), Ring II: 3.73-3.47 (m, 1H, 
H5), 3.73-3.47 (m, 4H, H1, H3, H4 and H6), 2.34-2.20 (m, 1H. H2a), 2.03 (m, 1H, H2b), 
Ring III: 5.15 (d, J = 3.6 Hz, 1H, H1), 4.05-3.90 (m, 1H, H5), 3.90-3.74 (m, 3H, H6a, 
H6b, and H2), 3.73-3.47 (m, 1H, H4), 3.73-3.47 (m, 1H, H3). m/z calcd for C20H40N6O10: 
524.28; found 525.35 [M+H]+ and 547.25 [M+Na]+. 
 
6'-N-glycinyl-KAN (10). Compound 10 was prepared and 
purified as described for compound 9. The reaction of 5 (114 
mg, 0.2 mmol) with 10% Pd/C (114 mg) in MeOH:H2O/1:1 
(4 mL) under H2 atmosphere yielded 10 (104 mg, 96%, Rf = 
0.54 in MeOH:NH4OH/3:2). 1H NMR (H2O:D2O/9:1, 500 
MHz) δ 3.43-3.24 (m, 2H, CH2 of Gly), Ring I: 5.27 (d, J = 4.0 Hz, 1H, H1), 3.90-3.85 
(m, 1H, H3), 3.76-3.58 (m, 3H, H2, H5, and H6a), 3.50 (dd, J1 = 14.4, J2 = 6.9 Hz, 1H, 
H6b), 3.43-3.24 (m, 1H, H4), Ring II: 3.76-3.58 (m, 1H, H5), 3.43-3.24 (m, 2H, H4 and 
H6), 2.96 (ddd, J = 12.5, 9.6, 4.2 Hz, 1H, H3), 2.88 (ddd, J1 = 12.5, J2 = 9.6, J3 = 4.2 Hz, 
1H, H1), 2.01 (ddd (app. dt), J1 = 12.5, J2 = 4.2 Hz, 1H, H2a), 1.26 (ddd (app. q), J = 12.9 
Hz, 1H, H2b), Ring III: 5.07 (d, J = 3.8 Hz, 1H, H1), 3.94 (ddd (app. dt), J1 = 10.1, J2 = 



































H2), 3.43-3.24 (m, 1H, H4), 3.05 (dd (app. t), J = 10.2 Hz, 1H, H3). m/z calcd for 
C20H39N5O12: 541.26; found 542.45 [M+H]+ and 564.35 [M+Na]+. 
 
6',AHB-di-N-glycinyl-AMK (11). Compound 11 
was prepared and purified as described for 
compound 9. The reaction of 6 (75 mg, 0.1 mmol) 
with 10% Pd/C (75 mg) in MeOH:H2O/1:1 (3 mL) 
under H2 atmosphere yielded 11 (65 mg, 93%, Rf = 
0.44 in MeOH:NH4OH/3:2). 1H NMR (H2O:D2O/9:1, 500 MHz) δ 4.16 (dd, J1 = 9.5, J2 = 
3.5 Hz, 1H), 4.07-3.96 (m, 4H, CH2 of Gly), 3.47-3.29 (m, 1H, AHB), 2.08-1.95 (m, 1H, 
AHB), 1.85-1.77 (m, 1H, AHB), Ring I: 5.26 (d, J = 3.9 Hz, 1H, H1), 3.89 (ddd, J1 = 
10.0, J2 = 7.3, J3 = 2.8 Hz, 1H, H5), 3.82-3.65 (m, 2H, H3 and H6a), 3.63 (dd, J1 = 9.9, J2 
= 3.9 Hz, 1H, H2), 3.50 (dd, J1 = 14.4, J2 = 7.4 Hz, 1H, H6b), 3.47-3.29 (m, 1H, H4), 
Ring II: 4.07-3.96 (m, 1H, H1), 3.82-3.65 (m, 2H, H5 and H6), 3.47-3.29 (m, 1H, H4), 
2.93 (m, 1H, H3), 2.08-1.95 (m, 1H, H2a), 1.44 (ddd, (app. q), J = 12.6 Hz, 1H, H2b), 
Ring III: 5.09 (d, J = 3.8 Hz, 1H, H1), 4.07-3.96 (m, 1H, H5), 3.82-3.65 (m, 2H, H6a and 
H6b), 3.47-3.29 (m, 2H, H2 and H4), 3.07 (dd (app.t), J = 10.0 Hz, 1H, H3). m/z calcd for 
C26H29N7O15: 699.33; found 722.60 [M+Na]+. 
 
6'-N-AHB-TOB (17). Compound 17 was prepared and 
purified as described for compound 9. The reaction of 14 (50 
mg, 0.071 mml) with 10% Pd/C (50 mg) in MeOH:H2O/1:1 
(2 mL) under H2 atmosphere yielded 17 (37 mg, 92%, Rf = 
0.38 in MeOH:NH4OH/3:2). 1H NMR (H2O:D2O/9:1, 500 
MHz) δ 4.31 (dd, J1 = 8.6, J2 = 3.8 Hz, 1H, AHB), 3.22-2.99 (m, 2H, AHB), 2.19-1.89 
(m, 2H, AHB), Ring I: 5.19 (d, J = 3.8 Hz, 1H, H1), 3.84-3.73 (m, 1H, H5), 3.70-3.46 
(m, 3H, H4, H6a, and H6b), 3.22-2.99 (m, 1H, H2), 2.19-1.89 (m, 1H, H2a), 1.72 (ddd 
(app. q), J = 11.9 Hz, 1H, H2b), Ring II: 5.06 (d, J = 3.8 Hz, 1H, H1), 3.70-3.46 (m, 1H, 
H5), 3.44-3.32 (m, 2H, H4 and H6), 3.22-2.99 (m, 1H, H3), 2.96-2.89 (m, 1H, H1), 2.19-
1.89 (m, 1H, H2a), 1.33 (ddd (app. q), J = 12.4 Hz, 1H, H2b), Ring III: 3.95-3.90 (m, 1H, 








































3.22-2.99 (m, 1H, H3). m/z calcd for C22H44N6O11: 568.31; found 569.25 [M+H]+ and 
591.40 [M+Na]+. 
 
6'-N-AHB-KAN (18). Compound 18 was prepared and 
purified as described for compound 9. The reaction of 15 (40 
mg, 0.56 mmol) with 10% Pd/C (50 mg) in MeOH:H2O/1:1 
(2 mL) under H2 atmosphere yielded 18 (29 mg, 89%, Rf = 
0.12 in MeOH:NH4OH/3:2). 1H NMR (H2O:D2O/9:1, 500 
MHz) δ 4.30 (dd, J1 = 8.2, J2 = 3.7 Hz, 1H, AHB), 3.09-2.99 (m, 2H, AHB), 2.09 (dtd, J1 
= 14.6, J2 = 8.2, J3 = 3.7 Hz, 1H), 1.96-1.82 (m, 1H, AHB), Ring I: 5.28 (d, J = 3.9 Hz, 
1H, H1), 3.96-3.85 (m, 1H, H3), 3.83-3.50 (m, 4H, H2, H5, H6a, and H6b), 3.39-3.26 (m, 
1H, H4), Ring II: 3.83-3.50 (m, 1H, H5), 3.39-3.26 (m, 2H, H4 and H6), 2.98-2.91 (m, 
1H, H1), 2.90-2.84 (m, 1H, H3), 2.04-1.96 (m, 1H, H2a), 1.25 (ddd (app. q), J = 12.4 Hz, 
1H, H2b), Ring III: 5.07 (d, J = 3.8 Hz, 1H, H1), 3.96-3.85 (m, 1H, H5), 3.83-3.50 (m, 
3H, H2, H6a, and H6b), 3.39-3.26 (m, 1H, H4), 3.09-2.99 (m, 1H, H3). m/z calcd for 
C22H43N5O13: 585.29; found 586.30 [M+H]+ and 608.40 [M+Na]+. 
 
6',1-di-N-AHB-KAN (19). Compound 19 was prepared and 
purified as described for compound 9. The reaction of 16 (60 
mg, 0.063 mmol) with 10% Pd/C (60 mg) in MeOH:H2O/1:1 
(2 mL) under H2 atmosphere yielded 19 (38 mg, 88%, Rf = 
0.28 in MeOH:NH4OH/3:2). 1H NMR (H2O:D2O/9:1, 500 
MHz) δ 4.38-4.12 (m, 2H, AHB), 3.21-2.95 (m, 4H, AHB), 
2.14-2.03 (m, 2H, AHB), 2.02-1.84 (m, 2H, AHB), Ring I: 5.27 (d, J = 4.2 Hz, 1H, H1), 
4.06-3.86 (m, 1H, H3), 3.83-3.46 (m, 4H, H2, H5, H6a and H6b), 3.43-3.24 (m, 1H, H4), 
Ring II: 3.83-3.46 (m, 2H, H1 and H5), 3.43-3.24 (m, 2H, H4, and H6), 2.94-2.84 (m, 
1H, H3), 2.02-1.84 (m, 1H, H2a), 1.54-1.38 (m, 1H, H2b), Ring III: 5.08 (d, J = 3.7 Hz, 
1H, H1), 4.06-3.86 (m, 1H, H5), 3.83-3.46 (m, 3H, H2, H6a, and H6b), 3.43-3.24 (m, 1H, 
H4), 3.21-2.95 (m, 1H, H3). m/z calcd for C26H50N6O15: 686.33; found 687.75 [M+H]+ 










































4.6.1.5. General procedure for Staudinger reactions 
6'-N-glycinyl-SIS (12). Compound 12 was prepared from 7 using a 
Staudinger reaction. 7 (18 mg, 0.034 mmol) was dissolved in a 
mixture of aqueous NaOH (1 mM, 1.0 mL) and THF (1.0 mL) and 
stirred at rt for 15 min. PMe3 (1 M solution in THF, 0.51 mL, 0.51 
mmol, 15 eq) was added to the stirring solution, which was monitored 
for completion via TLC (MeOH:NH4OH/4:1). After 1 h, the solution 
was concentrated under reduced pressure and loaded onto a short SiO2 column. The 
column was washed thoroughly (THF (50 mL), EtOH (50 mL), and MeOH (50 mL)) and 
then eluted with 1% Et3N in MeOH. Fractions containing the product were pooled and 
concentrated under reduced pressure. The residue was then dissolved in minimal H2O, 
flash frozen, and lyophilized to give the pure product, 12, as a white powder (12 mg, 
67%, Rf = 0.76 in MeOH:NH4OH/3:2). 1H NMR (H2O:D2O/9:1, 400 MHz) δ 3.78-3.15 
(m, 2H, CH2 of Gly), Ring I: 5.41 (d, J = 3.6 Hz, 1H, H1), 4.83* (m, 1H, H5), 3.88-3.77 
(m, 2H, H6a, and H6b), 3.78-3.15 (m, 2H, H2 and H4), 2.38-2.26 (m, 1H, H3a), 2.18-2.06 
(m, 1H, H3b), Ring II: 3.78-3.15 (m, 3H, H4, H5, and H6), 3.13-2.85 (m, 2H, H1 and 
H3), 2.18-2.06 (m, 1H, H2a), 1.45-1.09 (m, 1H, H2b), Ring III: 5.04 (d, J = 3.4 Hz, 1H, 
H1), 4.18-3.98 (m, 1H, H2 and and H5a), 3.78-3.15 (m, 1H, H5b), 3.13-2.85 (m, 1H, H3), 
2.77 (s, 3H, NHCH3), 1.45-1.09 (m, 3H, CH3). m/z calcd for C21H40N6O8: 504.29; found 
527.35 [M+Na]+. 
 
6'-N-glycinyl-NET (13). Compound 13 was prepared and purified 
as described for compound 12. The reaction of 8 (15 mg, 0.027 
mmol, 1 eq) and PMe3 (1 M solution in THF, 0.345 mL, 0.405 
mmol, 15 eq) in a mixture of aqueous NaOH (1 mM, 1.0 mL) and 
THF (1.0 mL) yielded 13 as a white powder (9 mg, 60% Rf = 0.82 
in MeOH:NH4OH/3:2). 1H NMR (H2O:D2O/9:1, 400 MHz) δ 3.59-
3.16 (m, 2H, CH2 of Gly), Ring I: 5.42 (d, J = 2.1 Hz, 1H), 4.91* (m, 1H, H5), 3.89-3.78 
(m, 3H, H4, H6a, and H6b), 3.59-3.16 (m, 1H, H2), 2.42-2.27 (m, 1H, H3a), 2.17-2.06 (m, 
1H, H3b), Ring II: 3.68-3.60 (m, 1H, H5), 3.59-3.16 (m, 2H, H4 and H6), 3.09-2.85 (m, 





























1.09 (m, 4H, H2a and CH2CH3), Ring III: 5.04 (d, J = 3.8 Hz, 1H), 4.04 (m, 2H, H2 and 
H5a), 3.59-3.16 (m, 1H, 5b), 3.09-2.85 (m, 1H, H3), 2.80-2.67 (m, 3H, CH3 of NHCH3), 
1.44-1.09 (m, H, CH3). m/z calcd for C23H44N6O8: 532.32; found 533.45 [M+H]+ and 
555.35 [M+Na]+. Note: An asterix denotes peak obscured by solvent suppression that is 
detected in 2D spectra. 
 
4.6.1.6. General procedure for Cbz coupling reactions 
6'-N-Cbz-TOB (20). TOB (234 mg, 0.5 mmol, 1 eq) and 
K2CO3 (138 mg, 1.0 mmol, 2 eq) were dissolved in 
MeOH:H2O/1:1 (5 mL) and Cbz-N-hydroxyphthalimide (2) 
(223 mg, 0.75 mmol, 1.5 eq) was added. The progress of the 
reaction was monitored by TLC (MeOH:NH4OH/4:1), while 
stirring at rt. After 18 h, the reaction was complete. The mixture was concentrated under 
reduced pressure and purified by SiO2 flash chromatography, eluting with MeOH and a 
gradient of Et3N (0-2%). TLC was used to determine the fractions containing the product, 
which were then concentrated under reduced pressure. The residue was dissolved in a 
minimal volume of H2O and lyophilized to provide the pure product, 20, as white powder 
(195 mg, 64%, Rf = 0.82 in MeOH:NH4OH/3:2). 1H NMR (H2O:D2O/9:1, 400 MHz) δ 
7.65 (d, J = 7.5 Hz, 1H aromatic), 7.59-7.46 (m, 4H, aromatic), 4.83* (m, 2H, CH2 of 
Cbz), Ring I: 5.51 (d, J = 3.3 Hz, 1H, H1), 3.97-3.90 (m, 1H, H5), 3.86-3.64 (m, 3H, H6a, 
H6b, and H4), 3.61-3.48 (m, 1H, H2), 2.30-2.21 (m, 1H, H3a), 1.97 (ddd (app. q), J = 11.2 
Hz, 1H, H3b), Ring II: 3.86-3.64 (m, 1H, H5), 3.61-3.48 (m, 2H, H4 and H6), 3.27-3.19 
(m, 2H, H1 and H3), 2.30-2.21 (m, 1H, H2a), 1.66 (ddd (app. q), J = 12.6 Hz, 1H, H2b), 
Ring III: 5.09 (d, J = 3.7 Hz, 1H, H1), 3.97-3.90 (m, 1H, H5), 3.86-3.64 (m, 3H, H6a, 
H6b, and H2), 3.61-3.48 (m, 1H, H4), 3.31 (dd (app. t), J = 10.4 Hz, 1H, H3). Note: An 
asterix denotes peak obscured by solvent suppression that is detected in 2D spectra. 
 
6'-N-Cbz-KAN (21). Compound 21 was prepared as 
described for compound 20. The reaction of KAN (291 mg, 
0.5 mmol, 1 eq), K2CO3 (138 mg, 1.0 mmol, 2 eq), and 2 































chromatography (MeOH and a gradient of Et3N (0-2%)), compound 21 (124 mg, 40%, Rf 
= 0.73 in MeOH:NH4OH/3:2). 1H NMR (H2O:D2O/9:1, 400 MHz) δ 7.64 (dd, J = 7.4, 
1.6 Hz, 1H aromatic), 7.59-7.46 (m, 4H, aromatic), 4.80* (m, 2H, CH2 of Cbz), Ring I: 
5.49 (d, J = 3.9 Hz, 1H, H1), 3.96-3.90 (m, 1H, H5), 3.88-3.71 (m, 2H, H6a and H3), 
3.71-3.54 (m, 2H, H6b and H2), 3.53-3.39 (m, 1H, H4), Ring II: 3.88-3.71 (m, 1H, H5), 
3.71-3.54 (m, 1H, H6), 3.53-3.39 (m, 1H, H4), 3.36-3.08 (m, H, H1 and H3), 2.22 (ddd 
(app. dt), J1 = 12.7, J2 = 4.2 Hz, 1H, H2a), 1.61 (ddd (app. q), J = 12.7 Hz, 1H, H2b), 
Ring III: 5.08 (d, J = 3.6 Hz, 1H, H1), 3.96-3.90 (m, 1H, H5), 3.88-3.71 (m, 3H, H6a, 
H6b, and H2), 3.71-3.54 (m, 1H, H4), 3.36-3.08 (m, 1H, H3). Note: An asterix denotes 
peak obscured by solvent suppression that is detected in 2D spectra. 
 
AHB-N-Cbz-AMK (22). Compound 22 was prepared 
as described for compound 20. The reaction of AMK 
(291 mg, 0.5 mmol, 1 eq), K2CO3 (138 mg, 1.0 mmol, 
2 eq), and 2 (223 mg, 1.5 mmol, 1.5 eq) yielded, after 
SiO2 flash chromatography (MeOH and a gradient of Et3N (0-2%)), compound 22 (29 mg, 
8% Rf = 0.56 in MeOH:NH4OH/3:2). (Note: Di-N-Cbz-AMK was the major product, 
46%) 1H NMR (H2O:D2O/9:1, 400 MHz) δ 7.63 (d, J = 7.3 Hz, 1H, aromatic), 7.59-7.46 
(m, 4H, aromatic), 4.29 (dd, J1 = 3.9, J2 = 9.1 Hz, 1H, AHB), 3.68-3.47 (m, 2H, AHB), 
2.15-2.03 (m, 1H, AHB), 1.96-1.85 (m, 1H, AHB), Ring I: 5.54 (d, J = 3.8 Hz, 1H, H1), 
4.09-4.00 (m, 1H, H5), 3.85-3.70 (m, 1H, H3), 3.68-3.47 (m, 1H, H2), 3.45-3.34 (m, 2H, 
H4 and H6a), 3.22-3.12 (m, H, H6b), Ring II: 4.09-4.00 (m, 1H, H1), 3.85-3.70 (m, 2H, 
H5 and H6), 3.68-3.47 (m, 1H, H4), 2.15-2.03 (m, 1H, H2b), 1.57 (ddd (app. q), J = 12.5 
Hz, 1H, H2b), 3.22-3.12 (m, 1H, H3), Ring III: 5.20 (d, J = 3.8 Hz, 1H, H1), 4.09-4.00 
(m, 1H, H5), 3.85-3.70 (m, 3H, H2, H6a, and H6b), 3.68-3.47 (m, 1H, H4), 3.28 (dd (app. 

























4.6.2. Mass spectrometry analysis of the acylated AMK, KAN, NET, SIS, and TOB 
synthetic products 
The masses of the synthetic AGs were obtained by LCMS in positive ion mode using 
H2O (0.1% formic acid). 20 µL of a 1 µg/mL solution of the compound dissolved in H2O 
was injected for analysis. 
 
4.6.3. Determination of the MIC values against various bacteria 
MIC experiments were performed using the double dilution method against a variety of 
bacteria- values are reported in Tables 4.1-4.3 in the main text. A) B. subtilis 168, B) B. 
subtilis 168 with pBF16 harboring AAC(6')/APH(2''), C) B. cereus ATCC 17788, D) B. 
anthtacis str. Sterne, E) L. monocytogenes ATCC 19115, F) E. faecalis ATCC 29212, G) 
E. faecium BM4105-RF, H) S. aureus ATCC 29213, I) MRSA, J) VRE, K) S. aureus Nor 
A, L) E. coli BL21 (DE3) with pET22b harboring AAC(6')/APH(2''), M) E. coli BL21 
(DE3) with pET19b-pps harboring AAC(3)-IV, N) E. coli BL21 (DE3) with pET28a 
harboring Eis, O) E. coli BL21 (DE3) with pET22b, P) E. coli MC1061, Q) H. influenzae 
ATCC 51907, R) P. aeruginosa PA01, S) P. aeruginosa PA14, T) S. enterica ATCC 
14028, U) K. pneumoniae ATCC 27736, V) A. baumannii ATCC 19606, W) E. coli Tol 
C, X) M. smegmatis str. MC2 155, Y) M. abscessus ATCC 19977, Z) M. 
parascrofulaceum ATCC BAA-614, AA) M. intracellulare ATCC 13950, AB) M. avium 
subsp. avium ATCC 25291. 
 
M. avium subsp. avium ATCC 25291, M. abscessus ATCC 19977, M. intracellulare 
ATCC 13950, and M. parascrofulaceum ATCC BAA-614 were grown for 6 days before 
determining the MIC values, while the values for M. smegmatis str. MC2 155 were 
determined after 1-3 days. The rest of the MIC values were determined after 16 h. The 
concentrations of the compounds evaluated were in the range of 150 µg/mL to 0.3 µg/mL. 
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4.8. Appendix  
 
 
Fig. 4.6. 1H of Ο-(CbzAHB)-N-hydroxysuccinimide (2) in CDCl3 (400 MHz). 
 
 














































































































































Fig. 4.13. 1H of 6'-N-AHB-TOB (17) in 9:1/H2O:D2O (500 MHz). 
 
 









































































































Fig. 4.17. 1H of 6'-N-Cbz-KAN (21) in 9:1/H2O:D2O (500 MHz). 
 
 







































Fig. 4.18. 1H of 6'-N-Cbz-AMK (22) in 9:1/H2O:D2O (500 MHz). 
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Novel antibiotics are needed to overcome the challenge of continually evolving bacterial 
resistance. This has led to a renewed interest in mechanistic studies of once popular 
antibiotics like chloramphenicol (CAM). Chloramphenicol acetyltransferases (CATs) are 
enzymes that covalently modify CAM, rendering it inactive against its target, the 
ribosome, and thereby causing resistance to CAM. Out of the three major types of CAT 
(CATI-III), the CAM-specific CATIII has been studied extensively. Much less is known 
about another clinically important type, CATI. In addition to inactivating CAM and 
unlike CATIII, CATI confers resistance to a structurally distinct antibiotic, fusidic acid 
(FA). The origin of the broader substrate specificity of CATI has not been fully 
elucidated. To understand the substrate binding features of CATI, its crystal structures in 
the unbound (apo) and CAM-bound forms were determined. The analysis of these and 
previously determined CATI-FA and CATIII-CAM structures revealed interactions 
responsible for CATI binding to its substrates and clarified the broader substrate 
preference of CATI compared to that of CATIII. 
 
5.2. Introduction 
Chloramphenicol (CAM) (Fig. 5.1A) is a potent broad-spectrum antibacterial agent. 
Since its isolation from Streptomyces venezuelae in 1948,1 CAM was one of the primary 
agents used to treat many infections in the decades that followed. To date, despite its 
relatively high toxicity,2 CAM is used in many countries due to its affordability and its 
broad spectrum of activity. In the Western world, CAM is used in treatment of 
ophthalmic infections and as a last resort in cases of life-threatening brain infections, 
134 
	  
such as those caused by Neisseria meningitides, which do not respond to other agents. 
CAM’s ability to cross the blood-brain barrier makes it a potent therapeutic against brain 
infections. Due to the emergence of pathogens resistant to multiple drugs, CAM is now 
being reconsidered as a wider-spectrum therapeutic.3 
 
 
Fig. 5.1. A. Chemical structures of CAM and FA. B. Acetylation of CAM by CATs.  
 
CAM inhibits protein biosynthesis by binding to the 50S subunit of the bacterial 
ribosome. Recent crystal structures of the 50S subunit of the Escherichia coli and 
Thermus thermophilus ribosome in complex with CAM revealed that CAM binds to the 
A-site of the 50S subunit and occupies the binding site for the amino-acyl moiety of the 
A-site tRNA.4,5 The 3-hydroxyl of CAM is buried in the interface with the ribosome 
through direct hydrogen bonding, potassium ion-mediated electrostatic interactions, as 
well as through van der Waals interactions with the RNA phosphosugar backbone.4,5 The 
1-hydroxyl of CAM forms hydrogen bonds with RNA bases. Therefore, any modification 
of the 1-hydroxyl or the 3-hydroxyl of CAM is predicted to be disruptive of CAM-
ribosome binding.5 Bacterial resistance to CAM is caused by the chromosomally or 








































































transfer of an acetyl group from acetyl-coenzyme A (AcCoA) to the 3-hydroxyl group of 
CAM (Fig. 5.1B).6 A subsequent slow, non-enzymatic transfer of this acetyl group to the 
neighboring 1-hydroxyl group allows for a second CAT-catalyzed acetyl transfer from 
AcCoA onto the 3-hydroxyl group of the same CAM molecule, resulting in a di-
acetylated CAM.7,8 However, a single acetylation of CAM is sufficient to abolish its 
affinity for the ribosome9 as explained by the above structural observations.4,5 
 
CAT proteins are historically divided into three types: CATI, CATII, and CATIII, with all 
three types capable of catalyzing the acetyl transfer to CAM to generate 3-O-acetyl-CAM. 
Genomic analysis of different CAT sequences indicates that the boundaries between 
these CAT types are not sharp. Members of the CATI family are present in many 
important pathogens such as E. coli, Shigella flexneri, Serratia marcescens, and 
Salmonella enterica. CATI family enzymes display high sequence conservation among 
themselves (e.g. S. flexneri and S. marcescens CATI proteins are 98% and 99% identical 
to E. coli CATI, respectively); however, they display only a modest sequence identity to 
CATII (~46%) and CATIII (32% to 47%) (Fig. 5.2). The CATII family is not easily 
distinguishable from CATIII and has been defined historically only through its extreme 
susceptibility to thiol-modifying agents compared with that of CATI and CATIII.10 There 
are no obvious additional Cys residues or other sequence features in CATII distinguishing 
it from the type-III variants. A slight variation in the pKa of the Cys31 (in CATIII 
nomenclature), the only Cys in vicinity of the substrate or the cosubstrate binding sites, 
was suggested to be responsible for the difference in reactivity with thiol-modifying 
agents,11 although there is no evidence confirming this idea. 
 
The sequence differences between CATI and CATIII include several substitutions in the 
binding site (Fig. 5.2), potentially resulting in positional differences of CAM bound to 
these two proteins. A major consequence of this divergence is reflected in different 
substrate selectivities of CATI and CATIII. In addition to binding and modifying CAM,6 
CATI, unlike CATIII, binds a much bulkier antibiotic, fusidic acid (FA).12 FA (Fig. 5.1A) 
is a steroidal antibacterial agent that is used topically or systemically, usually against 





Fig. 5.2. Sequence alignment13 of CATI, CATII, and CATIII enzymes from various bacteria 
(EC = Escherichia coli, YP = Yersinia pestis, KP = Klebsiella pneumoniae, SM = Serratia 
marcescens, SF = Shigella flexneri, PM = Proteus mirabilis, HI = Haemophilus influenzae, 
SE = Salmonella enterica, VS = Vibrio sp., BC = Bacillus cereus, BA = Bacillus anthracis, 
SP = Streptococcus pneumoniae, EF = Enterococcus faecium, LM = Listeria monocytogenes, 
SA = Staphylococcus aureus, CD = Clostridium difficile, CB = Clostridium botulinum, and 
CT = Clostridium tetani). Important residues in the active site that are either conserved or 
non-conserved (vary) between CATI and CATIII are indicated by red and blue circles, 
respectively. Residues involved in CAM and FA binding are marked by orange and yellow 
circles, respectively. 
 
                                                                           EC_CATI  
1       10        20        30        40        50        60        70     
EC_CATI                 W R   F                  I              Y           N     R YT VD Q  KEH E F QCTY T QLD T LK VK KF P FI R  H EF MMEKKITG T IS H A QSVA NQ V AF T KNKH A HILA LM A P
YP_CATI                 W R   F                  I              Y           N     R YT VD Q  KEH E F QCTY T QLD T LK VK KF P FI R  H EF MMEKKITG T IS H A QSVA NQ V AF T KNKH A HILA LM A P
KP_CATI                 W R   F                  I              Y           N     R YT VD Q  KEH E F QCTY T QLD T LK VK KF P FI R  H EF MMEKKITG T IS H A QSVA NQ V AF T KNKH A HILA LM A P
SM_CATI                 W R   F                  I              Y           N     R YT VD Q  KEH E F QCTY T QLD T LK VK KF P FI R  H EF MMEKKITG T IS H A QSVA NQ V AF T KNKH A HILA LM A P
SF_CATI                 W R   F                  I              Y           N     R YT VD Q  KEH E F QCTY T QLD T LK VK KF P FI R  H EF MMEKKITG T IS H A QSVA NQ V AF T KNKH A HILA LM A P
PM_CATI                 W R   F                  I              Y           N     R YT VD Q  KEH E F QCTFS T QLD T LLK VKQ G KF P FIY I V H EF MMDTKRVG V LS G A QSFA Q V S T N Y T I SLL K A
EC_CATII                W R   F                  I              Y           N     R M FT ID N  N EH Y C FSLT LD T L E G KF P MIY I R V EF M..... N R L T R AL RQQIK G TK A RTALA T Y L L S A QFP
SE_CATII                W R   F                  I              Y           N     R M FT ID N  N EH Y C FSLT LD T L G KF P MIY I R V EF M..... N R L T R AL RQQIK G TK A RTALAKT Y L L S A QFP
HI_CATII                W R   F                  I              Y           N     R M FT ID N  N EH Y C FSLT LD T L E KF P MIY I RVV EF M..... N R L T R AL RQQIK G TK A RTALA TDY V L S QFP
VS_CATII                W R   F                  I              Y           N     R M FT ID N  N EH Y C FSLT LD T L E KF P MIY I RVV EF M..... N R L T R AL RQQIK G TK A RTALA TDY V L S QFP
EC_CATIII                W R   F                  I              Y           N     R M YT D N  EH E Y C FSLT D T L K D KF P MIY I V E  M..... N KF VK V R F RHRLP G SKI T K SLD SAY V L AQA QFD L
BC_CATIII                W R   F                  I              Y           N     R M F ID EN N Q  E Y CTFSMT N D T LLK Q G KF P FIY I RVV H EF ..... K HI R E Y H LK.LK V V R ELH K I V L S N K T
BA_CATIII                W R   F                  I              Y           N     R M F ID EN N Q  E Y CTFSMT N D T L K V Q G KF P FIY I RII H EF ..... K HV R E Y H LE.LK V V L I K H K I T I S K K T
SP_CATIII                W R   F                  I              Y           N     R M F ID ED N K  E Y CTYSMT NLE T LL IK G K  P LIY I VV H EF ..... K NL I PY H LNAVR A S RE LK L L T I TT R K T
CB_CATIII                W R   F                  I              Y           N     R M F ID E  N K  E Y CTYSMT N E T LL IK K  P LIY I VV H EF ..... K NL I H PY Y LHSVR A I N HE LKKL L T I AT N K T
EF_CATIII                W R   F                  I              Y           N     R M F ID DN  KE  N Y Q TFS T E D L IKQ G KF P FIF V RVI F ..... N NK L K I H LN.Q T I T I SV YRN E Y A L T SNTA T
SA_CATIII                W R   F                  I              Y           N     R M F ID DN  KE  N Y Q TFS T E D L IKQ G KF P FIF V RVI F ..... N NK L K I H LN.Q T I T I SV YRN E Y A L T SNTA T
LM_CATIII                W R   F                  I              Y           N     R M F IN E  D KE  N Y Q TYS T E D T L IKN G  P LIY I II F ..... T NI L T Y H FN.Q T V K F L KSM K YEL A T VN QNKV T
CD_CATIII                W R   F                  I              Y           N     R M F ID N  N KE  D Y CTYSMT D T IKE G K  P M Y I IV H EF ..... V EK K S Y H FASVP VKV ....Q K M L A L Y AM R S T
CT_CATIII                W R   F                  I              Y           N     R ID NN  KEH E F N F NLD T LK VKD F MVY V  DF .......MEY F A F KGAN PQ NICM HF F NDLS FS ASTY M EME Y
                                                                           EC_CATI  
    80        90       100       110       120       130        140        
EC_CATI                 P  T                      F                               S AM KDGELV WD  Y VFH QTETFSSLW EY DDF Q L Y DVA Y EN FPK I EN F V . I SVH C E S H R HI SQ C G LAY GF . .M F A
YP_CATI                 P  T                      F                               S AM KDGELV WD  Y VFH QTETFSSLW EY DDF Q L Y DIA Y EN FPK I EN F V . I SVH C E S H R HI SQ C G LAY GF . .M F A
KP_CATI                 P  T                      F                               S AM KDGELV WD  Y VFH QTETFSSLW EY DDF Q L Y DVA Y EN FPK I EN F V . I SIH C E S H R HI SQ C G LAY GF . .M F A
SM_CATI                 P  T                      F                               S AM KDGELV WD  Y VFH QTETFSSLW EY DDF Q L Y DVA Y EN FPK I EN F V . I SIH C E S H R HI SQ C G LAY GF . .M F A
SF_CATI                 P  T                      F                               S AM KDGELV WD  Y VFH QTETFSSLW EY DDF Q L Y DVA Y EN FPK EN V . I SVH C E S H R HI SX C G LAY XFX. .MXF A
PM_CATI                 P  T                      F                               S AM KDGELV WD N Y IFH QTETFSSLW Y D  L Y DIA Y DD FPK I EN F V . I SV G E SY HK INH KT SE Q G LAY EF . .M F A
EC_CATII                P  T                      F                               S AL KD ELIYWD D F VFH ETETFS L Y D E M Y A Y D LFP PEN I . N QS V K A SCR FP LS AG NAVT E QH TR QGNL .HLN S
SE_CATII                P  T                      F                               S AM KD ELIYWE D F VFH ETETFS L Y D E M Y A Y D LFP PEN I . N QS V K A SCR FP LS AG NAVT E QH TR QGNL .HLN S
HI_CATII                P  T                      F                               S AM KD LIYWD D F VFH ETETFS L Y D E M Y A Y N LFP PEN I . NA QT V K A FCR CP IS AG NAVM E QH TA QGAL .HLN S
VS_CATII                P  T                      F                               S AM KD LIYWD D F VFH ETETFS L Y D E M Y A Y N LFP PEN I . NA QT V K A FCR CP IS AG NAVM E QH TA QGAL .HLN S
EC_CATIII                P  T                      F                               S A KD ELI WD D F VFH ETETFS L Y D Q M Y Y D LFP PEN I I. D V SV Q Q A SCP SS ID VN LSVMER KS TK QGVT .HLN A
BC_CATIII                P  T                      F                               S EG L YWE  Y IFH D FSS W DY NDF  Y D Y N LF K VP N F I CFND V G EMI S K DKS I T S HI YKN EE MRC A VHG T EN P .V P S
BA_CATIII                P  T                      F                               S EG L YWE  Y IFH D FSS W DY DF  Y D Y L K IP N F I CFND V G EMI S K DKS I T SS RI YKN EE MRC ASVHG LT EN P .I P G
SP_CATIII                P  T                      F                               S NG L YWD N Y IFH D ETFSS W EY ENF  Y DI Y D PK P N V SFDQ K G SM S K N I T D PR YYN LE RN S VMNFM AGQ A .TIN S
CB_CATIII                P  T                      F                               S NGNL YWD  Y IFH D ETFSS W DY E F  Y DI Y PK P N F V CFDE G SMS S K N I T D S SC YND LD KN GAIMKFT LNE A .T P S
EF_CATIII                P  T                      F                               S DGEL YWD E Y IF TFS W NDF E Y DV Y LFPK IPEN F  GYNS G KL L DGVSK GI TPVK K YDL LS EK NGSGK TP .A SL I
SA_CATIII                P  T                      F                               S DGEL YWD E Y IF TFS W NDF E Y DV Y LFPK IPEN F  GYNS G KL L DGVSK GI TPVK K YDL LS EK NGSGK TP .A SL I
LM_CATIII                P  T                      F                               S EGNL YWD N Y VF ETE FS W E F  Y D Y D MFPK IPEN I GINS G KL L NK K NI T SNVS NS YNS KS LLE K KNE KP .TVP M
CD_CATIII                P  T                      F                               S A DGEL D  Y IFH DTETFSSLW E DF  L Y D Y NN M K PEN F V INQ GIY EMI S N T CKS KS AD ES TQR G HR EG PNA .I N M
CT_CATIII                P  T                      F                               S KDG V D  F N Y DD  Q FPK QD  KIR .I LH YLI S DMSNRD L KIITLPLS IKS STIAKKTSK...S QKF IDFD KLIYF C
 TT             TT              TT                                         EC_CATI  
150       160       170       180       190       200       210            
EC_CATI   PW  F               P     K          P   QV H   DG H        Q               VS T FDLNV N DNFFA VFTMG YY QGDKVLM L I  H AVC  F V R NEL Q CDE QN S A M T A G ML Y W GGA...
YP_CATI   PW  F               P     K          P   QV H   DG H        Q               VS T FDLNV N DNFFA VFTMG YY QGDKVLM L I  H AVC  F V R NEL Q CDE QN S A M T A G ML Y W GGA...
KP_CATI   PW  F               P     K          P   QV H   DG H        Q               VS T FDLNV N DNFFA VFTMG YY QGDKVLM L I  H AVC  F V R NEL Q CNE QN S A M T A G ML Y W GGA...
SM_CATI   PW  F               P     K          P   QV H   DG H        Q               VS T FDLNV N DNFFA VFTMG YY QGDKVLM L I  H AVC  F V R NEL Q CNE QN S A M T A G ML Y W GGA...
SF_CATI   PW  F               P     K          P   QV H   DG H        Q               VS T FDLNV N DNFFA VFTMG YY QGDKVLM L I  H AVC  F V R NEL Q CDE QN S A M T A G ML Y W GGA...
PM_CATI   PW  F               P     K          P   QV H   DG H        Q               VS T FNLNV N NNFFA VFT G YY QGDKVLM L I  H AVC  F V R NE  Q CDEN S A I I T A G LL I Y GCK.....
EC_CATII  PW  F               P     K          P   QV H   DG H        Q               VS GFNLNI NDDYFA VFTM  F QEGD VLL SV  H AVC  F RFIN L MCDNL D TG A Q R V AA T L ILK.....
SE_CATII  PW  F               P     K          P   QV H   DG H        Q               VS GFNLNI NDDYF  VFTM  F QEGD VLL SV  H AVC  F RFIN L MCDNL D TG S A Q R V AA T L ILK.....
HI_CATII  PW  F               P     K          P   QV H   DG H        Q               VS GFNLNI NDDYFA VFTM  F QE N VLL SV  H AVC  F RFIN L MCDNL D TG A Q D R V AA T M ILK.....
VS_CATII  PW  F               P     K          P   QV H   DG H        Q               VS GFNLNI NDDYFA VFTM  F QE N VLL SV  H AVC  F RFIN L MCDNL D TG A Q D R V AA T M ILK.....
EC_CATIII  PW  F               P     K          P   QV H   DG H        Q               V  FNLNV N DYFA I TM  Y QEGD LL LSV  H AVC  F V RFIN L ELCNL N DS A FT I A Q RL A R SKLK.....
BC_CATIII  PW  F               P     K          P   QV H   DG H        Q               S TGFNLNI ND DF  I T G YFNE NKV L S   H VC  Y RFIQDL EL N NI A N G LL I C E I V L S AS S SC EWLK..
BA_CATIII  PW  F               P     K          P   QV H   DG H        Q               S TGFNLNI ND DF  I T G YFNE NKIML S   H VC  Y V RFIEDL EL N NI T N G LL I C E V L S S S SC EWLK..
SP_CATIII  PW  F               P     K          P   QV H   DG H        Q               V  TGFNLNI ND Y  IFTLG YFQQ NKILL MSV  H AVC  Y RF NE  EL N EI N Y AT LI D TS F A AS F TWLGEK
CB_CATIII  PW  F               P     K          P   QV H   DG H        Q               V  TGFNLNV NN Y  IFTMG YFEQ NKI  MSI  H AVC  Y I RFINE  EL N QI N Y GT LV N FI S V AL S TWLKHK
EF_CATIII  PW  F               P     K          P   QV H   DG H        Q               S TGFNLNI NN NY  I T G F N GN I L LS   H VC  Y F N  EL D NI T N S LL I A I K S Y L S AGL M SI S RP DWLL..
SA_CATIII  PW  F               P     K          P   QV H   DG H        Q               S TGFNLNI NN NY  I T G F N GN I L LS   H VC  Y F N  EL D NI T N S LL I A I K S Y L S AGL M SI S RP DWLL..
LM_CATIII  PW  F               P     K          P   QV H   DG H        Q               I  FNLNI NN F  I T G FY NKI L S   H AVC  Y V F E  N D NI D SS G SR LL I I SKN Y V L SL MS F IV SV EWI...
CD_CATIII  PW  F               P     K          P   QV H   DG H        Q                GFNLN DY  IFTMG YY E NKI L L I  H AVC  F I RFVNEL EL NI ST D LQKGY LI K D I A C I S........
CT_CATIII  PW  F               P     K          P   QV H   DG H        Q               IS T E DEN  G YF NKVLL SI     Y V FIE L E NI SVSN MVM DSI RISF TKD Y N KLL GY K YI KIK......
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sequesters it through binding by its CAM binding site. This type of mechanism of 
resistance through sequestration is not uncommon and has been observed for other 
antibiotics such as bleomycin and thiocoraline.14-18 Kinetic studies have shown that FA 
competes with CAM for binding to CATI, but not the other CAT types.12 Various bile 
salts and some triphenylmethane dyes also exhibit similar competitive binding to CATI, 
but not to CATII/III.12,19-21 
 
CATI plays an important role in antibiotic resistance of many pathogenic bacteria. In 
addition, CATI has been used as a biochemical and proteomic tool in a number of 
systems22-26 and as a common CAM resistance marker encoded in laboratory plasmids. 
Despite its importance in drug resistance and biotechnology, CATI27 has been much less 
investigated than CATIII. Structural and biochemical studies of CATIII28-34 have been 
mostly used to understand general features of CATI proteins. Despite this progress, 
differences in the substrate selectivity between CATI and CATIII remain unclear in 
absence of analysis of CATI-CAM and CATI-FA structures. 
 
Herein we report crystal structures of CATI alone and in complex with CAM, which 
explain how CATI binds CAM despite differences in its binding site residues from those 
in CATIII. Analysis of these structures along with that of the structure of CATI in 
complex with FA (deposited in the Protein Data Bank (PDB) by Roidis and Kokkinidis; 
accession code: 1Q2335) provides an explanation of the differences in substrate 
preference among CAT types. 
 
5.3. Results 
5.3.1. Overall structure of CATI 
E. coli CATI protein was initially co-crystallized with CAM in the P1 space group (Table 
5.1). Molecular replacement using either a monomer or trimer of apo-CATI (from the 
structure of a serendipitous complex of the nitric oxide synthase oxygenase domain with 
CATI; PDB code: 1NOC36) as a search model did not yield a solution. This complication 
likely arose due to the presence of several copies of the protein molecules within a very 
large unit cell. Further crystallization trials yielded crystals of CATI alone (the apo form) 
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in the P21 space group with a smaller asymmetric unit. These crystals grew under 
conditions similar to those of CATI-CAM crystals. Molecular replacement with a CATI 
trimer from the 1NOC entry as a search model, yielded an apo-CATI structure with three 
CATI trimers in the asymmetric unit (Table 5.1). This three-trimer structure was then 
successfully used as a molecular replacement search model to determine the structure of 
the CATI-CAM complex in the P1 crystal form. The asymmetric unit of the P1 crystal 
form contained six CATI-CAM trimers. The crystal structure of the apo-CATI and that of 
the CATI-CAM complex were refined to 3.2 Å and 2.9 Å resolution, respectively (Table 
5.1).  
 
Table 5.1. X-ray diffraction data collection and refinement statistics for apo-CATI and CATI-CAM structures. 
 Apo-CATI CATI-CAM 
Data collection   
Space group P21 P1 
Number of trimers per asymmetric unit 3 6 
Unit cell dimensions   
     a, b, c (Å) 115.2, 102.7, 114.1 107.5, 114.5, 114.5 
     α, β, γ (°) 90, 119.9, 90 119.9, 97.8, 98.7 
Resolution (Å) 50.0-3.2 (3.3-3.2)a 50.0-2.9 (3.0-2.9)a 
I/s 9.3 (2.1) 14.3 (2.3) 
Completeness (%) 98.4 (86.1) 87.3 (85.0) 
Redundancy 4.3 (3.5) 1.7 (1.7) 
Rmerge 0.15 (0.476) 0.06 (0.38) 
Number of unique reflections 35,818 82,522 
Structure refinement statistics   
Resolution (Å) 40.0-3.2 35.0-2.9 
R (%) 23.8 24.0 
Rfree (%) 30.1 30.9 
Bond length deviation (rmsd) from ideal (Å) 0.009 0.006 
Bond angle deviation (rmsd) from ideal (°) 1.08 0.907 
Ramachadran plot statisticsb   
     % of residues in most allowed regions 84.9 88.7 
     % of residues in additional allowed regions 12.9 10.5 
     % of residues in generously allowed regions 2.3 0.8 
     % of residues in disallowed regions 0 (0 residue) 0 (0 residue) 
a Numbers in parentheses indicate the values in the highest-resolution shell. b Indicates Procheck statistics.37 
 
The structure of CATI in the apo form reported here is very similar to the structure of 
apo-CATI (PDB code: 1NOC) used for the molecular replacement (Ca RMSD = 0.7 Å) 
and to another previously deposited structure of apo-CATI (PDB code: 1PD5; Cα RMSD 
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= 0.7 Å). Furthermore, the structures of apo-CATI are highly similar to the structure of 
CATI in complex with CAM (Cα RMSD ~ 0.4 Å), suggesting that no major protein 
conformational changes occur upon CAM binding. Analogously, no major 
conformational differences were observed for CATIII in the apo and the CAM-bound 
forms.28 The overall fold and the oligomeric organization of CATI (Fig. 5.3A) resemble 
those of the previously characterized CATIII28 variant. Three identical monomers of CATI 
form a trimer with a 3-fold rotational symmetry. The overall trimeric scaffold is formed 
by three 7-stranded β-sheets, each of which is formed by six strands (β6, β5, β7, β9, β10, 
and β2) from one monomer and one strand (β8) from another monomer (Fig. 5.3B). In 
each monomer, this β-sheet is flanked on the outside by 5 α-helices and a small 3-
stranded β-sheet. In the trimeric core, the aliphatic parts of buried Asp157 side-chains (in 
strand β8) of the three monomers come together to form intimate hydrophobic contacts 
with each other while their carboxyl groups are engaged in intricate, asymmetric network 
of hydrogen bonding interactions with the side-chains of Ser155 and Asn159. The 
hydrophobic interactions between the Asp157 residues are likely critical for complex 
stability as this residue is either an Asp or an Asn in most CATI/CATIII proteins. Ser155 
could however be substituted for a Gly (Fig. 5.2). The side-chains of Asp157 residues are 
distorted so that the carboxyl groups form hydrogen bonds with their own backbone 
amide NH moieties justifying a weaker conservation of the Ser155. As the side-chains in 
these β-strands are generally buried away from the solvent, their identities are well 




Fig. 5.3. A. Overall fold and trimeric organization of CAM-bound form. The strands of the β-sheets 
comprising the central scaffold are marked. The CAM molecule and its molecular surface are shown in 
blue. B. A close-up view of the active site at the interface of two monomers in CATI-CAM structure. 
Substrate binding residues of the binding monomer and catalytic monomer are colored in green and 
orange, respectively. A few highly conserved residues involved in catalysis are marked in red. C. A 
representative view of one of the CATI active sites. The violet mesh clearly defining the CAM 
molecule (blue sticks) is Fo-Fc omit electron density generated without the CAM in the model and 
contoured at 3σ. D. A zoomed in view of the active site shown in panel C, depicted in a slightly 
different orientation. E. A schematic view of residues of the CATI active site and their interactions 
with CAM. Hydrogen bonds and hydrophobic contacts are marked by black dashed lines and the grey 
hashed lines, respectively. The color coding is consistent with that of panel B. 
 
 
5.3.2. Chloramphenicol (CAM) interactions in the active site 
Upon trimerization, the active site is formed at the interface of two β-sheets 
predominantly with residues from strands β6, β5, β7, β9, and β8 of one monomer 
(termed as the binding monomer) and strands β2, and β10 of the other (the catalytic 
monomer). Each trimer contains three identical substrate binding sites (Fig. 5.3A). The 
nature of this conserved trimeric assembly strongly suggests that CATI monomers either 




























































































active only in the context of a trimer. Indeed, monomeric mutants of the CATIII, whose 
overall fold is highly similar to that of CATI, were shown to be catalytically inactive.38 
Below, we discuss features of the active site of CATI and highlight its differences from 
that of CATIII that specify the distinct substrate recognition properties of these two 
proteins. 
 
In the structure of CATI-CAM complex, all three active site pockets of the CATI trimer 
are occupied with CAM molecules (Fig. 5.3A), whose positions are clearly defined in the 
electron density map (Figs. 3C and 3D). One of the two monomers forming a binding site 
(called here the binding monomer) provides the majority of the residues (Cys91, Phe102, 
Ser104, Phe134, Phe144, Ser146, Leu158, and Val170) involved in binding of the CAM 
while the other one (called here the catalytic monomer) provides His193, which has been 
demonstrated to be one of the primary conserved catalytic residues7,39,40 (Fig. 5.3B). A 
few other residues from the catalytic monomer (Phe25 and Cys31) also provide an 
important CAM-binding surface in the binding pocket. The disposition of the conserved 
catalytic residues (e.g. His193, Ser146, and Asp197; highlighted in red in Fig. 5.3B) in 
the CATI-CAM structure is highly similar to that observed previously in CATIII-CAM 
complex.41 The position of His193, the likely general base, relative to the bound CAM is 
identical to its counterpart in CATIII (His195). The Nε2 atom of His193 is located 2.7 Å 
away from the 3-hydroxyl of CAM (Fig. 5.3E). The side-chain of His193 is in a distorted 
conformation (His193 χ1 = -150.2° and χ2 = -41.0° with CAM bound and χ1 = -142.0° 
and χ2 = -32.6° with FA bound). This conformation likely ensures that the imidazole ring 
is aligned appropriately for abstracting the 3-hydroxyl proton of CAM, promoting a 
nucleophilic attack by the oxygen on the acetyl group carbonyl of AcCoA,29,30,34 similarly 
to the proposed mechanism of the CATIII variant.40 The imidazole ring of His193 is 
positioned at a proper distance (approximately 3.6 Å) for a face-to-face π-π stacking 
contact with Phe25. This overall structural arrangement of the catalytic monomer for 
proper positioning of His193 at the subunit interface is stabilized by several interactions 
that include a chain of hydrogen bonds between His193, Asp197, Arg18, and the 
backbone carbonyl oxygen of Ala194 (Fig. 5.3E). The conserved Ser146 (another 
catalytically important residue) of CATI is positioned similarly in the active site of all 
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three CATI structures, and likely stabilizes the transition state oxyanion by donating a 
hydrogen bond (possibly water-mediated in CATI), as proposed for Ser148 of CATIII.42 
 
The sequence alignment of CATI and CATIII from E. coli demonstrates that out of the 20 
amino acid residues lining the CAM binding site, 9 are different between the two types 
(Fig. 5.2, blue circles). These differences [Ala24 (CATIII, Phe24), Phe25 (CATIII, Tyr25), 
Ala29 (CATIII, Leu29), Cys91 (CATIII, Gln92), Tyr133 (CATIII, Leu134), Phe144 
(CATIII, Asn146), Phe166 (CATIII, Tyr168), and Val170 (CATIII, Ile172)] are significant 
as they include changes in the size and hydrophobicity of the residues. Remarkably, 
despite these differences, CAM binding affinities for CATI and CATIII appear to be very 
similar.43 Furthermore, the superposition of CATI-CAM and CATIII-CAM structures 
demonstrates that the orientations of the CAM molecule in the active sites of the two 
proteins are nearly identical. The p-NO2 group of CAM is solvent exposed when bound 
in the CATI active site and the aromatic ring rests on the hydrophobic surface provided 
primarily by Leu158 and Val170, as observed in the CATIII-CAM structure. The side-
chains of Leu158, Val160, and Phe166 that line the very bottom of the substrate binding 
pocket (Fig. 5.4C) are positioned through interactions of the trimeric assembly and show 
only minor alterations between CATI and CATIII. The dichloroacetyl moiety of CAM 
closely interacts with Phe134 (Phe135 in CATIII), likely indicating a strong hydrophobic 
interaction. A major difference between the CATI-CAM and CATIII-CAM structures is 
that the residue analogous to Tyr133 of CATI is non-polar (Leu134) in CATIII. Tyr133 
forms a strong hydrogen bond (2.9 Å) with the carbonyl group of CAM. Interestingly, 
this interaction occurs in place of the interaction of that between the hydroxyl of Tyr25 in 
CATIII (Phe25 in CATI) and the carbonyl group of CAM, located at an O-O distance of 
2.8 Å from each other. 
 
5.3.3. Fusidic acid (FA) interactions in the active site 
In the CATI-FA complex (Fig. 5.4A), FA occupies the same binding site as CAM, which 
explains its observed behavior as a competitive inhibitor of CAM acetylation.12 The 
differences between the active site residues of CATI (as described above) and those of 
CATIII while having little effect on CAM binding,41,44 create a unique surface suitable for 
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binding to FA in CATI. In particular, the placement of Ala24 and Ala29 of CATI shapes 
the substrate binding cavity such that the ring D and the 2-methylhex-2-ene “tail” of FA 
can be accommodated. The hydrophobic steroid ring system of FA makes numerous 
hydrophobic contacts with active site residues, including Thr93, Phe102, Phe134, Phe144, 
Ser146, Phe156, Leu158, Val160, Phe166, and Val170 of the binding subunit, as well as 
Ala24, Phe25, Val28, and Ala29 of the catalytic subunit (Figs. 4A and 4C). The hydroxyl 
moiety of ring A of FA closely aligns with the 3-hydroxyl of CAM and forms a very 
strong hydrogen bond the Nε2 atom of His193 at a distance of 2.9 Å (Fig. 5.4C). The 
hydroxyl group of Tyr133 points inward towards the binding pocket forming a hydrogen 
bond with the hydroxyl moiety of ring C, the atoms being separated by a distance of 
about 2.6 Å (Fig. 5.4C), similarly to the interaction between the 3-hydroxyl and Tyr133 
in the CATI-CAM structure (Fig. 5.3E). Residues from both the binding monomer 
(Phe134) and the catalytic monomer (Ala24 and Val28) form a hydrophobic zone near 
the entrance of the binding pocket in CATI that cradle the “tail” section of FA and dictate 
its conformation (Figs. 4A and 4C). 
  
Valuable insight can be gained by comparing this structure with the previously reported 
structures of a CATIII in complex with CAM29 and a quadruple mutant of CATIII in 
complex with FA.43 In the quadruple mutant of CATIII, four catalytic pocket residues 
were mutated (Gln92Cys/Asn146Phe/Tyr168Phe/Ile172Val) to mimic those of CATI. 
This comparison (Fig. 5.4B) indicates a disruption of the FA tail-interacting hydrophobic 
zone in the quadruple mutant of CATIII, in particular due to the Ala24Phe and Val28Arg 
substitutions. The carboxylic acid and acetoxy moieties of ring D are highly solvent 
exposed when bound to both CATI and the CATIII mutant. The acetoxy group of FA 
makes a hydrophobic contact with Phe166 in CATI (Phe168 in CATIII) (Figs. 4C and 4D). 
Despite the same general protein backbone scaffold of CATI and the mutant CATIII 
structures, there are several differences in the FA-protein contacts for the two enzymes. 
Most strikingly, several bulkier residues of CATIII: Phe24 (Ala24 in CATI), Tyr25 (Phe25 
in CATI), Arg28 (Val28 in CATI), and Leu29 (Ala29 in CATI) prevent the FA molecule 
from binding in a position similar to that in CATI. A required shift of the FA molecule 
must not be accommodated due to structural rigidity of wild-type CATIII resulting in the 
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lack of binding to FA. The mutations of the CATIII quadruple mutant apparently relax 
this rigidity, and surprisingly accommodate the FA molecule in a very different position 
from that seen in the CATI-FA structure and in an altered conformation. The hydrophobic 
“tail” of FA now adopts a very different conformation and gets buried in the disordered 
loop region (residues 138-141) of the CATIII mutant. This disorder is very likely due to 
both the Asn146Phe and the Gln92Cys substitutions in the CATIII mutant, which cause 
displacement of the His144 and Thr140 side-chains, respectively, thereby distorting of 
the local backbone. This displacement allows the FA-tail to occupy its altered position in 
CATIII mutant.43 Notably, Tyr25 in the CATIII quadruple mutant structure (positionally 
analogous to Phe25 of CATI) forms hydrogen bond with FA, at a distance of 2.8 Å to the 
hydroxyl on the A-ring (Fig. 5.4D), and stabilize the altered FA orientation. Phe168 and 
Val172 residues in the CATIII quadruple mutant make direct hydrophobic contacts with 
the FA molecule, which explains the contribution of these substitutions to the change in 
binding affinity to FA.43 
 
We observe no major differences in the backbone conformations near the active site of 
CATI in the structures of apo-CATI (PDB code: 3U9B), CATI bound to CAM (PDB 
code: 3U9F), and CATI bound to FA (PDB code: 1Q2335). This strongly suggests that 
CATI has evolved to bind multiple ligands, even as large as an FA molecule, without any 




Fig.5.4. A. Close-up views of interactions of FA with active-site residues of CATI. and B. 
Close-up views of interactions of FA with active-site residues of CATIII (quadruple mutant). 
C. Schematic views of interactions of FA with CATI. D. Schematic views of interactions of 
FA with CATIII (quadruple mutant). The color coding is consistent with that of Fig.5.3. (FA is 




Chloramphenicol acetyltransferase (CAT) is found in many pathogenic bacteria and is 
often the cause of resistance against chloramphenicol (CAM), once a widely used 
antibiotic. Of many known CATs, the type-I appears to be the most prevalent. Recent 
studies have found CATI in many pathogenic bacteria. CATI has a preference for binding 
to a variety of substrates; not only does it inactivate chloramphenicol but it also binds and 










































































































































substrate binding by CATI is important to address the intriguing question of how CAT 
proteins from different classes with similar overall structures display different substrate 
selectivity profiles. In comparison to CATIII that has been studied almost exclusively, 
there are only few mechanistic studies that have been performed on CATI. 
 
The general fold and the trimeric organization of CAT proteins have been observed in 
enzymes of primary metabolic pathways in bacteria and eukaryotes, such as pyruvate 
dehydrogenases45,46 and a-keto acid dehydrogenases.47,48 Therefore, CAT appears to be a 
product of an ancient gene duplication event, which underwent subsequent specialization 
through evolution to serve a protective role against toxic compounds such as CAM. The 
general catalytic mechanism proposed for CAT proteins is based on studies of many such 
proteins. The residue primarily responsible for catalysis of CATI appears to be His193 
(His195 in CATIII).28 This role was proposed based on a previous study in which a mutant 
(His195Tyr) CATIII was shown to be devoid of catalytic activity.49 Another conserved 
residue, Ser146, likely stabilizes the oxyanion formed upon an attack on the AcCoA 
carbonyl carbon by the 3-hydroxyl of CAM. Mutagenesis studies with CATIII confirmed 
that Ser148 (Ser146 in CATI) is crucial for efficient catalysis.42 
 
The CATI protein structure is similar in the apo form and in CAM- and FA-bound states, 
indicating that no major changes in the backbone conformations or in positions of the 
side-chains occur upon ligand binding. It is quite remarkable that such a nearly rigid 
scaffold is evolutionary conserved and yet CATI can bind chemically diverse substrates. 
Analysis of the aligned sequences shows that several residues of CATI are different than 
corresponding residues in CATIII. Our investigation of the CATI structures indicates that 
many of these differences are in residues lining the substrate binding pocket (Fig. 5.2, 
blue circles). The most striking differences are concentrated around a small patch of 
residues (Ala24-Cys31, contributed by the catalytic monomer) that enable the FA 
molecule to be accommodated only in the pocket of CATI. The bulkier residues of CATIII 
at this patch would push the FA towards the opposite side of the pocket and consequently 
disrupt the structure. Interestingly, the flexibility (apparently resulting in the reduced 
rigidity and increased disorder of the backbone) of the quadruple mutant of CATIII helps 
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it accommodate the pushed out FA in a different conformation. The “tail” of FA now 
finds a different hydrophobic pocket to rest in and in turn provides stability to the FA in 
this altered binding pocket. The mutant CATIII shows a 200-fold higher affinity to FA 
than the wild-type CATIII. However, the quadruple mutant of CATIII binds FA with a 
much (4-fold) weaker affinity43 than CATI. In addition, the Km for CAM acetylation by 
the CATIII quadruple mutant was somewhat compromised (with respect to either CATI or 
CATIII) and the value of kcat was between those for CATIII and CATI. With the direct 
structural evidence, it is now clear how the tail of FA nests in a hydrophobic pocket and 
renders CATI more energetically favorable to bind to FA. In CATIII, a similarly 
positioned FA “tail” would get sterically blocked by Phe24 and Arg28, and it is not 
surprising that CATIII does not show affinity towards FA. 
 
Our understanding of CAM’s mechanism of action as well as the mechanisms of 
resistance to it were largely based on biochemical and structural information available on 
CAM binding to CATIII and to the bacterial ribosome.4 The present structural study 
augments this knowledge by filling in the gap in our understanding of the recognition of 
both CAM and FA by CATI. CAM has been largely removed from the clinic in the 
Western world due to its safety concerns, even though cases of extreme toxicity are 
exceedingly rare. CAM has remained a popular drug in underdeveloped areas due to its 
low cost and effectiveness against a variety of pathogens. However, as with other 
antibiotics, development of resistance against CAM is a major obstacle to its power in 
saving lives. The detailed picture of CATI structure is expected to aid in design of 
inhibitors of CAT enzymes that could re-sensitize CAM-resistant strains. In addition, 
structure-guided design of CAM analogs could lead to new antibiotics of this class that 
would be less toxic and more refractory to inactivation by CAT. 
 
5.5. Materials and Methods 
5.5.1. Expression and purification of CATI 
CATI was expressed in BL21 (DE3)/RIL cells (Stratagene), which harbor a plasmid 
containing a constitutively expressed CAM resistance gene camR encoding untagged 
CATI protein. The cells were grown in LB medium (200 rpm, 37 °C) containing CAM 
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(25 µg/mL) until the culture reached the attenuance of 0.4 at 600 nm. The cells were 
harvested after an additional 3 h growth. Pelleted cells (centrifugation at 5,000 g, 10 min, 
4 °C) were resuspended in the lysis buffer [MES pH 6.5 (40 mM), NaCl (200 mM), 
glycerol (5%), β-mercaptoethanol (2 mM), and EDTA (0.1 mM)] and lysed by sonication. 
The lysate was clarified by centrifugation at 35,000 × g for 45 min at 4 °C. We took 
advantage of the thermostability of CAT proteins50 in purifying CATI without an affinity 
tag. The clarified lysate was heated (75 °C, 20 min) and subsequently centrifuged (35,000 
× g, 45 min, 4 °C) to remove unfolded precipitated proteins. The CATI in the soluble 
fraction was further purified by size-exclusion chromatography on an S-200 column (GE 
Healthcare) equilibrated with buffer [Tris pH 8.0 (40 mM) and NaCl (100 mM)]. The 
fractions containing pure CATI, as determined by SDS-PAGE, were concentrated to 5 
mg/mL by using an Amicon Ultra centrifugal filter device (Millipore) and used for 
crystallization. 
 
5.5.2. Crystallization of CATI alone and in complex with CAM 
Crystals of CATI alone and a complex of CATI with CAM (CATI-CAM) were grown by 
vapor diffusion in hanging drops containing 1 µL of protein and 1 µL of the reservoir 
solution [HEPES (100 mM) pH 7.5 (pH of 1 M stock of HEPES acid was adjusted by 
adding NaOH), PEG 4,000 (20% w/v), isopropanol (10% v/v)] or 1 µL of the reservoir 
solution containing CAM (1 mM), respectively. Irregularly shaped crystals, 40-60 mm in 
each of the three dimensions were formed in 7-10 days when incubated at 22 °C against 
the respective reservoir solutions. The crystals were gradually transferred into the 
reservoir solution containing glycerol (15% v/v) and flash frozen in liquid nitrogen. 
 
5.5.3. Data collection and structure determination 
X-ray diffraction data were collected at 100 K at the X25 beamline of the National Light 
Source at the Brookhaven National Laboratory. The data were processed with 
HKL2000.51 The crystals of apo-CATI and CATI-CAM complex were in the P21 and P1 
space groups, respectively. The structures of both apo-CATI and CATI-CAM complex 
were determined by molecular replacement with MOLREP52 as described in Results. The 
locations of the CAM molecules in the active sites of CATI were clearly identified and 
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positioned in the omit Fo-Fc density and then refined. The structures were iteratively 
manually built and refined using programs Coot53 and REFMAC,54 respectively. The data 
collection and refinement statistics are given in Table 5.1. The structures of apo-CATI 
and CATI-CAM complex were deposited in the Protein Data Bank with accession codes 
3U9B and 3U9F, respectively. 
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It has been shown that Eis from Mtb demonstrates unprecedented activity as an AAC, 
performing multiple acetylations of numerous AGs. During my time studying Eis in the 
Garneau-Tsodikova laboratory, we have described several new surprising findings with 
respect to Eis: (1) the multiple acetylations by Eis may occur in a sequential or non-
sequential manner, depending on the AG, (2) Eis acetylates AGs at positions not 
acetylated by other AACs, including the AHB and 3''-position, and (3) Eis is capable of 
acetylating non-AG drugs, such as CAP. Further research towards understanding Eis 
could follow any number of courses, as there is still relatively little known about this 
important protein from Mtb. 
 
First, the structural characteristics that lend Eis its vast substrate promiscuity should be 
investigated, with the aim to understand and overcome the resistance conferred against 
AGs. Further developing our NMR methodology so that we can follow the reaction 
progress of the non-sequentially modified AGs in real time by NMR could provide 
crucial information about Eis’ interaction with the various, diverse scaffolds comprising 
this important family of antibiotics. In the cases of reactions that do not occur 
sequentially, quantitative kinetics experiments to compare the rate of reaction at each 
amine using our current biochemical assays would be impossible. However, NMR 
experiments would allow us to follow the modification of each specific amine in real time. 
These studies of the acetylation of AGs by Eis_Mtb could help in the development of 
novel AG analogs that avoid modification, by providing a type of structure activity 
relationship. This could be aided by expanding our knowledge of the positions acetylated 




We have developed methodology that allows us to utilize the cosubstrate promiscuity of 
AACs to generate libraries of compounds to test the activity of AGs with functionalized 
acyl groups that have been incorporated at specific positions. Extending this methodology 
to the novel positions that may be acetylated by Eis_Mtb would be very useful in 
determining if additional positions may be modified with functionalized acyl groups to 
improve antibacterial activity while avoiding the deactivation by AMEs. Since Eis may 
non-sequentially acetylate multiple positions of a given AG, the investigation of multiply 
acetylated compounds would also be possible, perhaps without reliance on the sequential 
application of multiple AACs. Similarly, the application of an AAC other than Eis that 
may acylate a single position with reliable regio-selectivity followed by acylation by Eis 
using either the same or a different functionalized acyl group would allow us to generate 
extremely diverse libraries of acylated AGs to screen for activity. We have reported that 
Eis_Mtb is, when compared to the AACs used in our previous experiments, not highly 
cosubstrate promiscuous, so, before this strategy may realize its full potential, it will be 
necessary to expand Eis’ cosubstrate promiscuity via site-directed mutagenesis. Studies 
to this affect are currently underway in our laboratory.  
 
There are a number of homologous Eis proteins identified in species of mycobacteria, and 
our laboratory has reported preliminary studies of the Eis from Msm. The systematic 
characterization of these Eis homologs is currently underway in our laboratory. Efforts 
should focus on the identification of Eis enzymes that show increased cosubstrate 
promiscuity for two reasons. First, we could apply them in our efforts to 
chemoenzymatically generate novel AGs for antibacterial activity screening. Second, we 
could use the differences in the binding pockets to identify which amino acid residues 
may be mutated to retain activity while expanding on the cosubstrate promiscuity. 
 
Additional investigations with CAP, including studies of the Eis catalyzed acetylation of 
the β-lysine side chain, could provide valuable information. It was noted, in Chapter 2, 
that previous studies of the Eis proteins from Mtb and Msm have shown that the Eis from 
each strain modifies a different amine on the Lys55 of DUSP16/MPK-7. The activity of 
Eis_Msm towards CAP has not been thoroughly studied, and it would be interesting to 
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see if the terminal amine of the β-lysine side chain is modified or if it is the β-amine that 
is acetylated. Furthermore, since the ability of Eis_Mtb to confer resistance to CAP via 
acetylation has not been conclusively disproved, the synthesis and determination of the 
MIC values of Ac-CAP compounds (separately mono-acetylated at either amine) against 
strains of mycobacteria could provide a more definitive answer. 
 
The synthesis of AGs with functionalized acyl groups, particularly those modified with a 
glycinyl or AHB group, has shown to be a very promising strategy in our ability to 
combat the rapid development of resistance described herein. These problems are in no 
way specific to AGs and CAM and it is certain that as long as antibacterial treatments are 
used, resistance will develop. The screening methodology described above will aid in the 
rapid identification of novel, active compounds; however, once identified, those 
compounds will need to be synthesized on a larger scale for testing against numerous 
bacterial strains. Strategies for the facile protection and deprotection of amines other than 
the 6'- and 1-position on the various AG scaffold should be the primary focus of these 
efforts.  
 
Although CAM is not currently used for the treatment of systemic infections in the 
United States, it remains an important drug in many other countries because it is 
relatively cheap and extremely effective. The need for effective drugs is being amplified 
by the rapid development of resistance, so the development of novel CAM analogs is still 
a worthwhile endeavor. Significant research into CAM analogs was performed in the past, 
yet advances in drug development technology and our increased understanding of 
structure and function of CAM resistance proteins, should allow this process to be more 
expedient and precise than was previously possible. Structure activity relationships could 
now be predicted with some accuracy based on crystallographic data of CAM with its 
ribosomal target as well as with resistance enzymes. Furthermore, understanding of the 
genetic predisposition that leads to CAM toxicity is more easily identified than when 
CAM was withdrawn from many markets, meaning some of the serious toxicity issues 
could likely be avoided ab initio. 
 
